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The endocannabinoid system 
The discovery of the main psychoactive constituent of marijuana, Δ9-
tetrahydrocannabinol (Δ9-THC) led to the identification of the endogenous 
cannabinoid system (Gaoni and Mechoulam, 1964). The main constituents of the 
endocannabinoid system consist in the cannabinoid receptor type 1 and type 2 
(CB1 and CB2, respectively) (Devane et al, 1992; Herkenham et al, 1990; Matsuda 
et al, 1990) and the two major endogenous ligands for these receptors, the N-
arachidonoyl ethanolamine (anandamide, AEA) (Devane et al, 1992) and the 2-
arachidonoyl glycerol (2-AG) (Sugiura et al, 1995). Endocannabinoids are 
synthesized on demand from phospholipid precursors on the postsynaptic 
membrane by Ca2+-dependent and independent mechanisms (Kano et al, 2009). 
This lipophilic molecules are released directly into the synaptic cleft and act in 
retrograde fashion on the presynaptic neuron where the cannabinoid receptors 
are expressed. Activation of the CB1 receptor modulates intracellular transduction 
pathways through activation/inhibition of several ion channels and kinases, thus 
inducing the inhibition of further neurotransmitter release (Kano et al, 2009; Turu 
and Hunyady, 2010). AEA and 2-AG are subsequently taken back into the cell by a 
still poorly defined uptake process mediated by a transporter mechanism (Fu et 
al, 2011; Hillard et al, 1997) and enzymatically degraded by the fatty acid amide 
hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Kano et al, 2009), 
respectively.  
CB receptors couple to Gi/o proteins which function to inhibit adenylyl cyclase 
activity, activate potassium channels and inhibit voltage-gated calcium channels 
(Howlett et al, 2002). CB1 receptors represent the most abundant class of G-
protein-coupled receptors in the central nervous system, but are also present in a 
variety of peripheral tissues (Howlett et al, 2002), while CB2 receptors are mostly 
peripherally located on immunological tissues and, only recently, 
immunohistochemical analyses have revealed the presence of CB2 receptors in 
neuronal and glial cells in diverse rat brain areas, including the cerebellum and 
hippocampus (Onaivi et al, 2006; Van Sickle et al, 2005). Within the limbic system, 
the most prominent expression of the CB1 receptor can be seen in the 
hippocampus, the basolateral complex of the amygdala (BLA), and prefrontal 
cortex (PFC) (Marsicano and Kuner, 2008; McPartland et al, 2007). Only recently, 
CB1 mRNA expression has been clearly detected at low levels in the central 
nucleus of the amygdala (CeA) (Kamprath et al, 2010). Similar to the CB1 receptor, 
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FAAH and MAGL are found in high levels in the BLA, whereas only low levels can 
be found in the CeA (Ramikie and Patel, 2012). Within these limbic regions, CB1 
receptor is expressed at very high levels in cholecystokinin-positive GABAergic 
interneurons (Azad et al, 2008; Marsicano and Lutz, 1999; Morozov et al, 2009) 
and at moderate to low levels in glutamatergic terminals (Kano et al, 2009; 
Kawamura et al, 2006; Monory et al, 2006). However, this receptor has also been 
detected on serotonergic, noradrenergic and dopaminergic terminals (Haring et 
al, 2007; Hermann et al, 2002; Oropeza et al, 2007). CB1 receptors located on 
GABAergic axon terminals are activated by lower concentrations of cannabinoid 
receptor agonists than CB1 receptors located on glutamatergic terminals 
(Hoffman et al, 2007; Ohno-Shosaku et al, 2001). Endocannabinoids and CB1 
receptors have been shown to differentially mediate homeostatic, short- and 
long-term synaptic plasticity processes throughout the brain (Chevaleyre et al, 
2006; Katona and Freund, 2012; Marsicano and Lutz, 2006), thus the cannabinoid 
system has been reported to be crucially involved in learning and memory 
processes (Akirav, 2011; Campolongo et al, 2009; Kano et al, 2009; Marsicano and 
Lafenetre, 2009; Wotjak, 2005).  
Role of the endocannabinoid system in the modulation of emotional memory 
Emotional learning is extremely important for the survival of an individual; indeed 
emotionally arousing events typically leave lasting and vivid memories (McGaugh, 
2000). The most prominent consequence of a stressful experience is a quick 
release of epinephrine from the adrenal medulla that allows the organism to 
liberate energy sources for immediate action. Consequently norepinephrine is 
released in the brain via the stimulation of the vagal nerve and the nucleus tractus 
solitarius (NTS). As part of the response, neurons, including principal cells in the 
amygdala, receive a strong noradrenergic input from the locus coeruleus (LC) 
shortly after stress (Sara, 2009). The same neurons also receive high levels of the 
adrenocortical hormone corticosterone (CORT, in rodents; cortisol in humans) 
which binds with higher affinity to mineralcorticoid receptors (MRs) and lower 
affinity to glucocorticoid receptors (GRs) (Reul and de Kloet, 1985). During stress 
conditions MRs and GRs are occupied and mediate both genomic and rapid non-
genomic actions (Joels and Baram, 2009; Tasker et al, 2006). Although 
noradrenaline and CORT are key elements in the stress response, they accomplish 
their full effect in concert with several other transmitters, thus mediating the 
effect of stress and emotional arousal on memory (Joels et al, 2011; McGaugh and 
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Roozendaal, 2002). In this scenario the endocannabinoid system has emerged as a 
key modulator of stress effects on memory function. Compelling evidence has 
been reported in the literature demonstrating a strong bidirectional interaction 
between endocannabinoids and stress-activated hormones such as 
glucocorticoids and norepinephrine. For instance it has been demonstrated that, 
in the central nervous system, glucocorticoids induce endocannabinoid signaling 
in the hypothalamus (Di et al, 2003). Endocannabinoids, then, act retrogradely to 
inhibit the release of glutamate in the paraventricular nucleus and suppress HPA 
axis activity (Di et al, 2003; Di et al, 2005). Conversely, both stress and 
glucocorticoids significantly alter endocannabinoid content in limbic brain regions 
resulting in opposing actions that can both increase and terminate the stress 
response (Hill and McEwen, 2010a). Furthermore the endocannabinoid system 
mediates stress responses and emotional homeostasis, in part, by targeting 
noradrenergic circuits (Morrish et al, 2009). Early anatomical studies have 
identified moderate CB1 binding and CB1 mRNA in the principal noradrenergic 
nuclei, the LC and the NTS (Derbenev et al, 2004; Herkenham et al, 1991; Jelsing 
et al, 2008; Mailleux and Vanderhaeghen, 1992; Matsuda et al, 1993). The 
existence of CB1 receptors in the LC and NTS suggests that cannabinoids may 
modulate noradrenergic activity. Cannabinoids have been shown to increase 
noradrenergic release in the PFC, (Oropeza et al, 2005). Moreover Muntoni et al. 
(2006) demonstrated that intravenous injection of the cannabinoid agonists 
WIN55,212-2 or Δ9-THC, dose-dependently increases the firing rate of LC 
noradrenergic neurons via the activation of CB1 receptors (Muntoni et al, 2006). 
Given the evidence that CB1 receptors were found to be abundantly expressed 
within the limbic system and to crucially modulate synaptic transmission (Katona 
et al, 2001; Tan et al, 2011) and neuronal firing (Pistis et al, 2004), the 
cannabinoid system has been increasingly emerged as an important modulator of 
different learning and memory processes (Akirav, 2011; Campolongo et al, 2009; 
Kano et al, 2009; Marsicano et al, 2009; Wotjak, 2005).  
The brain regions mainly involved in emotionality are represented by 
subcortical limbic structures, such as the amygdala, hippocampus, ventral 
striatum, and thalamus, as well as cortical structures, including the anterior 
cingulate cortex and medial and orbital regions of the PFC (Price and Drevets, 
2010). In this assembly, the amygdala represents a key region for the association 
between environmental information with emotional significance for fear and 
anxiety responses but also for processing of positive emotions (Aggleton, 1993; 
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Baxter and Murray, 2002; Davis et al, 1994; Pape and Pare, 2010). In particular, 
considerable evidence indicates that emotional memory modulation requires 
activation of the BLA specifically. Lesions of the BLA, but not the CeA, block the 
memory enhancing effects of systemic GR activation on inhibitory avoidance 
retention (Roozendaal and McGaugh, 1996). During emotionally arousing training 
norepinephrine is also released into the amygdala (Galvez et al, 1996; McIntyre et 
al, 2002; Quirarte et al, 1998), whereas attenuation of noradrenergic signaling 
with the β-adrenoceptor antagonists propranolol or atenolol infused into the BLA, 
but not into the CeA, blocked the memory enhancement induced by a 
glucocorticoid administered either systemically or directly into the BLA (Quirarte 
et al, 1997; Roozendaal et al, 2002). Considerable evidence indicates that 
glucocorticoids interact with this training-associated noradrenergic activation 
within the amygdala in enhancing the consolidation of memory of emotionally 
arousing training experiences (Roozendaal et al, 2009). In concert with this 
glucocorticoid-noradrenergic interaction, it has been recently shown that the 
endocannabinoid system plays a crucial role in modulating neural processes 
underlying emotional memory consolidation. It has been reported that the 
cannabinoid receptor antagonist AM251 blocks the ability of systemically injected 
corticosterone (or the synthetic analogue dexamethasone) to enhance memory 
consolidation of an inhibitory avoidance training when directly infused into the 
BLA (Campolongo et al, 2009) or into the hippocampus (de Oliveira Alvares et al, 
2010). These findings provided the first in vivo evidence in mammals of the 
existence of this pathway (Hill et al, 2010b). Besides the enhancing effects of 
glucocorticoids on memory consolidation, many studies demonstrated that such 
hormones typically impairs memory retrieval and working memory during 
emotionally arousing test situations (de Quervain et al, 2009; de Quervain et al, 
1998; Roozendaal, 2000; Roozendaal et al, 2004). Recently, the interaction 
between glucocorticoids and the endocannabinoid system in modulating 
contextual fear memory retrieval has been examined. The cannabinoid antagonist 
AM251 infused into the dorsal hippocampus blocked the impairing effects on 
memory retrieval of systemic administered corticosterone; such impairing effects 
were mediated by elevation of hippocampal 2-AG. Moreover, the β-adrenoceptor 
antagonist propranolol blocked the impairing effect of WIN55,212-2 on memory 
retrieval and, conversely, the CB1 receptor antagonist AM251 infused into 
hippocampus together with an impairing dose of norepinephrine failed to abolish 
the impairing effect of norepinephrine on memory retrieval (Atsak et al, 2012). 
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Collectively, these findings indicate that endocannabinoids interact with 
glucocorticoids and, depending on the availability of arousal-induced activation of 
noradrenergic system, they might differentially modulate memory functions. 
However, despite quite few studies in the literature, there is no consensus 
regarding the direction of endocannabinoid effects on memory; conflicting effects 
of cannabinoid compounds have been reported in many different behavioral 
paradigms and on different memory processes. 
Early studies, examining the effects of systemic pretraining administration of 
the cannabinoid agonists Δ9-THC and WIN55,212-2 on memory acquisition 
reported impairing effects on several behavioral tasks in rodents (Da and 
Takahashi, 2002; Lichtman et al, 1995; Pamplona and Takahashi, 2006b), whereas 
other studies reported that intraperitoneal administration of the cannabinoid 
antagonist rimonabant induces similar effects to those induced by the agonists by 
impairing spatial memory acquisition (Robinson et al, 2008). Similarly, indirect 
cannabinoid receptor agonism impairs memory acquisition in a recognition 
memory task (Campolongo et al, 2012) and in the inhibitory avoidance task 
(Mazzola et al, 2009). Local infusions into distinct brain regions have illustrated 
more clear results in this regard. Pretraining administration of a CB1 receptor 
agonist into the hippocampus has consistently been shown to impair spatial 
learning (Abush and Akirav, 2010; Egashira et al, 2002; Lichtman et al, 1995; 
Wegener et al, 2008), whereas bilateral blockade of BLA CB1 receptor 
transmission has been reported to prevent the acquisition of associative fear 
memory in an olfactory fear conditioning paradigm (Tan et al, 2011).  
Conflicting data have been also reported concerning cannabinoid effect on 
memory consolidation. Systemic posttraining administration of the FAAH inhibitor 
URB597, which increases AEA levels only in those brain regions where it is 
endogenously released, has been shown to impair memory consolidation in an 
object recognition task (Busquets-Garcia et al, 2011). Posttraining intra-
hippocampal administration of the synthetic cannabinoid receptor agonist 
WIN55,212-2 has been reported to impair memory consolidation (Jamali-Raeufy 
et al, 2011; Yim et al, 2008; Zarrindast et al, 2011). However, other authors 
reported enhancing effects of AEA in the hippocampus (De Oliveira Alvares et al, 
2008) and of WIN55,212-2 in the BLA (Campolongo et al, 2009). 
Cannabinoid effects on memory retrieval have been often reported to be 
detrimental when administered either systemically (Mishima et al, 2001; Niyuhire 
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et al, 2007) or in discrete brain areas (Atsak et al, 2012; Piri and Zarrindast, 2011; 
Segev and Akirav, 2011).  
There is a general agreement concerning cannabinoid effects on memory 
extinction where cannabinoids seem to modulate the facilitation of this memory 
process. Using fear conditioning procedure, Marsicano et al. (2002) and 
subsequent investigators demonstrated that inhibition of endocannabinoid 
transmission robustly inhibits fear extinction (Abush et al, 2010; Marsicano et al, 
2002; Pamplona et al, 2006a; Suzuki et al, 2004). Conversely, stimulation of 
endocannabinoid transmission accelerates fear extinction (Barad et al, 2006; 
Chhatwal et al, 2005; Suzuki et al, 2004).  
Although such discrepant findings, collectively, the endocannabinoid system 
appears to be strongly involved in different memory processes by influencing 
multiple brain regions. Differences in handling procedures, experimental 
conditions, behavioral tasks, doses, and the drug administered may account for 
the diversity of findings reported. However, variations in the stressful conditions 
employed in the different studies are implicated as well. The neural processes 
underlying emotional memory formation seems to be differently sensitive to 
cannabinoids depending on the levels of emotional arousal associated to the 
experimental context (see Chapter 5). 
 
Outline 
As mentioned above, a large amount of evidence indicates that the 
endocannabinoid system is crucially involved in the modulation of memory 
consolidation for stressful experiences (Akirav, 2011; Campolongo et al, 2009; 
Kano et al, 2009; Marsicano et al, 2009; Wotjak, 2005). Indeed previous findings 
from our laboratory have demonstrated that CB1 receptor activation within the 
BLA enhances memory consolidation. In particular, the cannabinoid agonist 
WIN55,212-2, bilaterally infused into the BLA immediately after inhibitory 
avoidance training, enhanced memory consolidation. Conversely, the CB1 
receptor antagonist AM251 administered after training into the BLA dose-
dependently impaired 48-h inhibitory avoidance retention (Campolongo et al, 
2009). Based on these previous findings we hypothesized that after an aversive 
experience endocannabinoids might be released within the BLA in order to 
modulate the better storage of emotionally salient events.  
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Chapter 1 explores more in deep the driven hypothesis by investigating whether, 
after experiencing a traumatic event, endocannabinoids are released within the 
BLA and other limbic structures, such as the hippocampus and the medial PFC. 
Further, this chapter examines the effects induced by exogenous augmentation of 
the endocannabinoid system in the same brain regions on memory for 
emotionally salient events. Given the well-established central role of the BLA in 
mediating emotional memory consolidation (McGaugh, 2000), Chapter 2 also 
investigates the role of endocannabinoid system within the BLA in modulating the 
functional interactions with the hippocampus and mPFC during aversive memory 
consolidation. 
In 2003, Patel et al. demonstrated that the intravenous anesthetic agent propofol 
is able to increase AEA brain levels in mice through the inhibition of FAAH (Patel et 
al, 2003). Clinical data have demonstrated that the use of propofol immediately 
after experiencing a traumatic event (i.e. car accidents, myocardial infarctions) 
and during intensive care unit treatment (ICU) is associated with a higher 
incidence of traumatic memories from perioperative awareness and ICU 
treatment as compared to other general anesthetics (Jones et al, 2007). These 
effects could result in stress-related disorders such as posttraumatic stress 
disorder and impaired long-term health-related quality of life outcomes 
(Kapfhammer et al, 2004; Schelling et al, 2003). This evidence together with our 
preliminary results showing that endocannabinoids are released after an aversive 
experience in order to modulate the better storage of emotionally salient events, 
we investigated (Chapter 2) whether propofol administration would modulate 
aversive memory retention of an inhibitory avoidance task, and whether any 
possible effect could be mediated by the indirect activation of the 
endocannabinoid system in rats.  
The complexity of endocannabinoid neuromodulation and the diversity of task-
dependent activation of neuronal circuits makes endocannabinoid effects on 
behavior being strongly dependent on environmental conditions (Zanettini et al, 
2011). It is well established that cannabinoid compounds induce biphasic effects 
on emotionality both in humans (Del Porto and Masur, 1984; Reilly et al, 1998; 
Velez and Ungemack, 1989; Zinberg, 1984) and in rodents (Campos et al, 2010; 
Haller et al, 2009; Sciolino et al, 2011; Zanettini et al, 2011). As described above, 
pharmacological manipulation of the endocannabinoid system has been described 
to induce contradictory effects on memory function. Chapter 3 explores the 
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possibility that cannabinoid effects on memory could be strongly dependent upon 
the arousal state of the animal at the time of testing. In particular, we investigated 
the interaction between cannabinoids and glucocorticoids in the modulation of 
both short- and long-term recognition memory in rats under two experimental 
conditions that differed in the level of novelty-induced emotional arousal at the 
time of encoding. 
Likewise, it has been shown that variation in environmental aversiveness 
differentially influences spatial memory retrieval in rats (Akirav et al, 2004; Salehi 
et al, 2010) and, as described above, that glucocorticoids interact with the 
hippocampal endocannabinoid system in impairing aversive memory retrieval in a 
contextual fear conditioning paradigm (Atsak et al, 2012). Based on these findings, 
Chapter 4 investigates whether the level of stress associated to the experimental 
context could influence endocannabinoid modulation of spatial memory retrieval 
in rats.  
Chapter 5 provides an overview of the existing literature regarding the 
cannabinoid effects on different memory phases, focusing on the interaction 
between the endocannabinoid system and the level of stress associated to the 
experimental context or arising from previous aversive experiences. This chapter 
finalizes providing possible assumptions to explain the opposing effects of 
cannabinoid on cognitive processes reported in the literature. 
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Abstract 
Extensive evidence indicates that the basolateral complex of the amygdala (BLA), 
hippocampus and medial prefrontal cortex (mPFC) modulate the consolidation of 
memory for emotionally arousing experiences. In this study, we first investigated to 
what extent the level of emotional arousal at the time of training would influence 48-h 
memory retention of an inhibitory avoidance task. To this aim three groups of rats were 
trained under different inhibitory avoidance experimental conditions (no, low, high 
footshock) and tested for memory retention 48-h later. Rats trained under the high 
footshock (0.45 mA) condition presented an enhancement of 48-h memory retention. 
We next investigated the role of the endocannabinoid system in the amygdala, 
hippocampus and mPFC in memory consolidation. To examine whether 
endocannabinoids are normally released after arousing inhibitory avoidance training, 
we measured anandamide (AEA) and 2-arachidonoylglycerol (2-AG) endocannabinoid 
levels in these three brain regions of rats 10, 30 or 60 min after training on the different 
experimental conditions considered. We found that rats trained with the high footshock 
had higher levels of AEA in the amygdala, hippocampus and mPFC than rats that were 
only exposed to the inhibitory avoidance apparatus but not shocked. We therefore 
tested whether the AEA hydrolysis inhibitor URB597, which elevates AEA levels, might 
enhance memory consolidation of this training. Immediate posttraining infusions of 
URB597 into the BLA, hippocampus and mPFC enhanced 48-h inhibitory avoidance 
retention performance. Further, separate groups of rats were co-administered with 
URB597 together with a nonimpairing dose of the CB1 receptor antagonist AM251 in 
the three brain regions considered. We found that URB597 memory enhancing effects 
were blocked by the concomitant infusion of AM251, thus demonstrating the 
involvement of CB1 receptors in such memory effects. In the last set of experiments, we 
investigated the role of the BLA in modulating the endocannabinoid response in other 
brain regions. We measured endocannabinoid levels in the hippocampus and mPFC or 
infused URB597 into these two brain regions after inhibitory avoidance training of rats 
with bilateral permanent lesions of the BLA. We found that there was neither an 
increase of endocannabinoid levels nor an URB597-induced enhancement of memory 
consolidation in the lesioned rats. Our findings provide evidence that the 
endocannabinoid system enhances the consolidation of memory of emotionally 
arousing inhibitory avoidance training and, interestingly, that the BLA plays a crucial role 
in modulating the endocannabinoid response during and after aversive experiences.  
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Introduction 
Emotionality plays a key role in learning and memory processes and stressful 
experiences tend to leave lasting and vivid memories (McGaugh, 2000). The 
neurocircuitry controlling emotional behavior is represented by the limbic system; 
it consists of several brain regions functionally interconnected, such as the 
amygdala, the hippocampus, the medial prefrontal cortex (mPFC), the ventral 
striatum, the hypothalamus, the medial thalamus (Price and Drevets, 2010). An 
appropriate emotional response to an aversive event requires fine-tuned 
neurotransmitter release regulation as well as functional neuronal circuits (Gold, 
2004; McEwen, 2012; McGaugh, 2000). In the last decades the endogenous 
cannabinoid system has is emerged as a possible key modulator of such functions. 
It consists of the G-protein coupled cannabinoid 1 and 2 receptors (CB1/2), their 
endogenous ligands so called endocannabinoids, and synthetic and metabolizing 
enzymes (Devane et al, 1988; Herkenham et al, 1991; Herkenham et al, 1990). 
Endocannabinoids are lipidic molecules not stored in vesicles but synthesized on 
demand and released from postsynaptic neurons into the synaptic cleft. They 
travel retrogradely and bind cannabinoid receptors presynaptically located (Kano 
et al, 2009). The most characterized endocannbainoids are N-arachidonoyl 
ethanolamine (anandamide, AEA) (Devane et al, 1992) and 2-arachidonoyl 
glycerol (2-AG) (Sugiura et al, 1995). AEA and 2-AG signaling is mainly deactivated 
by the fatty acid amide hydrolase (FAAH) and the monoacylglycerol lipase (MAGL), 
respectively (Kano et al, 2009). CB1 receptors are abundantly expressed within 
the limbic system (McPartland et al, 2007), particularly in the basolateral complex 
of the amygdala (BLA), hippocampus and mPFC (Herkenham et al, 1991; Tsou et 
al, 1998), where, by regulating synaptic plasticity (Katona and Freund, 2012), play 
a crucial role in the modulation of memory for emotionally arousing experiences 
(Atsak et al, 2012b; Campolongo et al, 2013; Campolongo et al, 2009; Ganon-
Elazar and Akirav, 2009; Marsicano and Lafenetre, 2009; Marsicano et al, 2002; 
Morena and Campolongo, 2013; Tan et al, 2011; Wotjak, 2005).  
It is well known that stress hormones, released after an emotionally arousing 
event, interact with the endocannabinoid system. It has been shown that 
cannabinoids modulate noradrenergic activity (Muntoni et al, 2006; Oropeza et al, 
2005), stimulate glucocorticoid secretion (Hill and McEwen, 2010b; Hill et al, 
2010c; Steiner and Wotjak, 2008) and mediate some of the central effects induced 
by glucocorticoids (Atsak et al, 2012a; Atsak et al, 2012b; Barna et al, 2004; 
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Morena et al, 2013; Weidenfeld et al, 1994)}. On the other hand, both stress and 
glucocorticoids regulate limbic endocannabinoid response, thus demonstrating 
that cannabinoids and glucocorticoids are mutually regulated (Hill et al, 2010b). It 
is well established that stress hormones play an important role in the regulation 
of memory consolidation for emotionally arousing experiences (Roozendaal et al, 
2009a), a cognitive process that require the selective activation of the BLA 
(Roozendaal and McGaugh, 1996; Roozendaal et al, 2006). We and others have 
previously showed that the amygdalar endocannabinoid signaling mediates 
emotional arousal influence on memory modulation (Campolongo et al, 2009; 
Marsicano et al, 2002; Morena et al, 2013). In particular, we previously reported 
that the cannabinoid agonist WIN55,212-2, bilaterally infused into the BLA 
immediately after inhibitory avoidance training, enhanced memory consolidation. 
Conversely, the CB1 receptor antagonist AM251 administered after training into 
the BLA dose-dependently impaired 48-h inhibitory avoidance retention 
(Campolongo et al, 2009). It is well established that the BLA plays an important 
role in integrating stress modulatory influences on memory consolidation of 
different kinds of information through its many efferent projections to other brain 
regions (McGaugh, 2000). The BLA, indeed, projects both directly and indirectly to 
the hippocampus (Petrovich et al, 2001; Pikkarainen et al, 1999), and there is 
considerable evidence that interactions between the BLA and the hippocampus 
regulate emotional-arousal effects on memory consolidation of spatial or 
contextual information (Huff et al, 2006; Roozendaal and McGaugh, 1997; 
Roozendaal et al, 1999). In addition to the hippocampus, the BLA has been 
extensively demonstrated to interact with the mPFC in modulating memory 
acquisition (Laviolette and Grace, 2006; Tan et al, 2011) and consolidation 
(Roozendaal et al, 2009b) for emotionally arousing trainings.  
This evidence prompted us to hypothesize that, after an emotionally arousing 
experience, endocannabinoids might be released within the BLA and other limbic 
regions to modulate the storage of emotionally salient events. Therefore, in the 
present study we first investigated whether endocannabinoid contents in limbic 
areas is modified during early phases of memory consolidation for emotional 
events. To this aim parallel groups of rats were trained in an inhibitory avoidance 
task under three different experimental conditions (i, exposed to the context in 
the absence of any footshock; ii, trained with a 0.35 mA footshock; iii, trained with 
a 0.45 mA footshock). We then evaluated AEA and 2-AG content in the amygdala, 
hippocampus and mPFC 10, 30 or 60 minutes after exposure to the context or 
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training. In a second experiment we used a pharmacological approach to 
investigate whether endogenous released cannabinoids play any role in the 
consolidation of memory for emotionally arousing inhibitory avoidance training. 
Different doses of the FAAH enzyme inhibitor URB597, which increases AEA levels, 
were administered into the BLA, hippocampus or mPFC immediately after an 
aversively motivated inhibitory avoidance training. To investigate whether the 
memory effect of URB597 could be mediated by activation of CB1 receptors, in a 
separate experiment, animals were concurrently infused with URB597 and a non-
impairing dose of the CB1 receptor antagonist AM251 immediately after the 
training trial. Memory retention was tested 48-h after the training trial.  
To explore the hypothesis that the BLA may modulate endocannabinoid 
response to aversive training experiences in the hippocampus and mPFC, in 
another experiment we selectively induced bilateral permanent lesions of the BLA 
and measured endocannabinoid levels in the hippocampus and mPFC in rats 
subjected to an inhibitory avoidance training. Finally, in the last experiment, we 
infused URB597 into the hippocampus or the mPFC immediately after the training 
trial in rats with bilateral permanent lesions of the BLA and tested memory 
retentions 48-h after training and drug administration. 
Thus, the present study has a two-fold interest: (1) to investigate the role of 
the endocannabinoid system within the BLA, hippocampus and mPFC in the 
modulation of memory consolidation for emotionally arousing experiences; (2) to 
examine the role of the BLA in coordinating endocannabinoid response to 
stressful events in the hippocampus and mPFC. 
Materials and Methods 
Animals. Male adult Sprague-Dawley rats (320-370 g at the time of behavioral 
experiments; Charles River Laboratories, Calco, Italy) were individually housed in a 
temperature-controlled (20±1°C) vivarium and maintained under a 12 h light/dark 
cycle (07:00 AM-07:00 PM h lights on). Food and water were available ad libitum. 
Training and testing were performed during the light phase of the cycle between 
10:00 AM to 04:00 PM. All experimental procedures were in compliance with the 
guidelines of the U.S. National Institutes of Health and the Italian Ministry of 
Health (D.L. 116/92), the Declaration of Helsinki, and the Guide for the Care and 
Use of Mammals in Neuroscience and Behavioral Research (National Research 
Council, 2004). 
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Surgery. The rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) 
and given atropine sulfate (0.4 mg/kg, i.p.) to maintain respiration, and were 
subsequently injected with 3 ml of saline (s.c.) to facilitate clearance of these 
drugs and prevent dehydration. The rats were then placed in a stereotaxic frame 
(David Kopf Instruments, Tujunga, CA, USA), and 2 stainless-steel guide cannulae 
(23 gauge) were implanted bilaterally, with the cannula tips 2 mm above the BLA 
[15 mm; coordinates: anteroposterior (AP), -2.8 mm from bregma; mediolateral 
(ML), ±5.0 mm from the midline; dorsoventral (DV), -6.5 mm from skull surface] or 
1.5 mm above the CA1 region of the dorsal hippocampus ⦋11 mm; coordinates: 
AP, -3.4 mm; ML, ±1.8 mm; DV, -2.7 mm⦌ or 1.5 mm above the prelimbic region of 
the mPFC ⦋11 mm; coordinates: AP, +3.7 mm; ML, ±0.7 mm; DV, -2.4 mm⦌ (Atsak 
et al, 2012a; Roozendaal et al, 2009b)according to the atlas of Paxinos and 
Watson (Paxinos and Watson, 2005). The cannulae were affixed to the skull with 2 
anchoring screws and dental cement. Stylets (15- or 11-mm-long 00 insect 
dissection pins) were inserted into each cannula to maintain patency. Other 
groups of rats received bilateral NMDA-induced neurotoxic lesions of the BLA 
(Sigma-Aldrich, Milan, Italy; 1.25 mg per 100 µl of phosphate buffer, pH 7.4) alone 
or in addition to bilateral cannulae in the hippocampus or in the mPFC 
(Roozendaal et al, 2003). The NMDA solution was backfilled into a 10µl Hamilton 
microsyringe (30 gauge needle), driven by an intergrated stereotaxic minipump 
(Stoelting Co., Varese, Italy). The microsyringe needle was inserted into the BLA 
(coordinates: AP, -2.8 mm; ML, ±5.0 mm; DV, -8.5 mm), and NMDA (2.5 µg per 0.2 
µl of phosphate buffer) was infused over a 30 s period. The injection needle was 
retained in place for an additional 3 min to optimize diffusion. Sham operations 
used the same procedure except that the needle was lowered only to the level of 
the caudate/putamen (coordinates: AP, -2.8 mm; ML, ±5.0 mm; DV, -6.5 mm) and 
removed after 3 min without infusion. After surgery, the rats were retained in an 
incubator until recovered from anesthesia and were then returned to their home 
cages. Rats were allowed to recover from surgery for 10 days before training. The 
rats were handled 1 min per day for 3 days before training. 
Inhibitory avoidance apparatus and experimental procedures. For all experiments, 
rats were trained in an inhibitory avoidance apparatus consisting of a trough-
shaped alley (91 cm long, 15 cm deep, 20 cm wide at the top, and 6.4 cm wide at 
the bottom) divided into two compartments, separated by a sliding door that 
opened by retracting into the floor (McGaugh et al, 1988). The starting 
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compartment (31 cm) was made of opaque white plastic and illuminated by a 
lamp; the shock compartment (60 cm) was made of dark, electrifiable metal 
plates and was not illuminated. Training and testing were conducted in a sound- 
and light-attenuated room. For training, the rats were placed in the starting 
compartment of the apparatus, facing away from the door, and were allowed to 
freely explore the apparatus. After the rat stepped completely into the dark 
compartment, the sliding door was closed and a single inescapable footshock 
(0.35-0.6 mA) was delivered. Rats were removed from the shock compartment 15 
s later and returned to their home cages. Retention was tested 48-h after training 
by placing the rat into the starting compartment of the inhibitory avoidance 
apparatus and by measuring the latency to enter the shock compartment with all 
four paws (maximum latency of 600 s). Longer latencies were interpreted as 
indicating better retention. Shock was not administered on the retention test trial. 
Immediately after the training and testing of each animal, the apparatus was 
cleaned with a 70% ethanol solution. In the first experiment non-cannulated rats 
were trained without the exposure to any footshok (No FS), to 0.35 mA (Low FS) 
or to 0.45 mA (High FS) footshocks. Parallel groups of rats were then either tested 
for 48-h retention latencies or sacrified at different time points after the training 
trial (10, 30 or 60 min) for brain tissue dissection. In the other experiments 
cannulated- and BLA-lesioned animals were subjected to the behavioral training 
described above (FS 0.6-0.8 mA). 
Drug treatment. The FAAH inhibitor URB597 was administered into either the BLA 
(3, 10 or 30 ng in 0.2 µl), hippocampus or mPFC (3, 10 or 30 ng in 0.5 µl). Each 
dose was chosen on the basis previous pilot experiments conducted in our 
laboratory. To examine whether the effects of URB597 are mediated via indirect 
anandamide activation of CB1 receptors, in other groups of rats the effective dose 
of URB597 (10 ng in 0.2 µl for BLA, 10 ng in 0.5 µl for Hipp or 30 ng in 0.5 µl for 
mPFC) was infused either alone or concurrently with a non-impairing dose of the 
CB1 receptor antagonist AM251 (0.14 ng in 0.2 µl for BLA, 0.28 ng in 0.5 µl for 
Hipp and mPFC). In a third experiment, bilateral BLA sham or lesioned rats were 
infused with the effective dose of URB597 either into the Hipp (10 ng in 0.5 µl) or 
into the mPFC (30 ng in 0.5 µl). All drugs were dissolved in a vehicle containing 5% 
Polyethylene glycol, 5% Tween80 and 90% saline and administered into the BLA or 
hippocampus or mPFC immediately after inhibitory avoidance training. Bilateral 
infusions of drugs or an equivalent volume of vehicle into these brain regions 
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were given immediately after inhibitory avoidance training by using a 30 gauge 
injection needle connected by polyethylene tubing (PE-20) to a 10 µl Hamilton 
microsyringe driven by a minipump (KD Instruments, Varese, Italy). For BLA 
infusions, the injection needle protruded 2.0 mm beyond the tip of the cannula 
and a 0.2 µl injection volume/hemisphere was infused over a period of 25 s. For 
hippocampus and mPFC infusions, the injection needles protruded 1.5 mm 
beyond the cannula tip and a 0.5 µl injection volume/hemisphere was infused 
over a period of 50 s. The injection needles were retained within the cannulae for 
an additional 20 s after drug infusion to maximize diffusion and to prevent 
backflow of drug into the cannulae. The infusion volumes were chosen on the 
basis of our previous experiments (Malin and McGaugh, 2006; Roozendaal et al, 
1996, 1997). All drugs were purchased from Tocris Bioscience (Milan, Italy) and 
freshly prepared before each experiment. 
Histology. Rats were anesthetized with an overdose of sodium pentobarbital (100 
mg/kg, i.p.) and perfused intracardially with a 0.9% saline solution. The brains 
were then removed and immersed in a 4% formaldehyde solution. At least 48-h 
before sectioning, the brains were transferred to a 20% sucrose solution in saline 
for cryoprotection. Coronal sections of 35 µm were cut on a cryostat, mounted on 
gelatin coated slides, and stained with cresyl violet. The sections were examined 
under a light microscope (Microscope Nikon 801, Florence, Italy) and the location 
of infusion needle tips in the BLA, hippocampus or mPFC as well as the 
determination of the size and location of the lesions of the BLA was made 
according to the standardized atlas plates of Paxinos and Watson (Paxinos et al, 
2005) by an observer blind to drug treatment condition. For all experiments, only 
rats with needle tips within the boundaries of the BLA or hippocampus or mPFC 
were included in the data analysis. Approximately 15% of the animals were 
excluded from analysis because of either cannula misplacement or damage to the 
targeted tissue. For the excitotoxic lesion experiments, approximately 17% of the 
animals with misplaced or absent lesions were excluded from further analysis. 
Endocannabinoid extraction and analysis. AEA and 2-AG endocannabinoid levels in 
the amygdala, hippocampus and mPFC were measured 10, 30 or 60 min after 
training on non-cannulated rats trained under different inhibitory avoidance 
experimental conditions (0.00 mA, 0.35 mA, 0.45 mA). After rapid decapitation, 
the amygdala, hippocampus and mPFC were dissected within 3 min. The brain 
tissue was collected and stored at -80°C. Before the extraction process, tissues 
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were weighted and homogenized in polypropylene tubes (Sarstedt, Numbrecht, 
Germany) and kept in ice water. Five hundred µl of the described homogenized 
tissue solution was transferred to a 2-ml Eppendorf tube, and 20 µl of internal 
standard and 1 ml methyl tertiary butyl ether (Sigma-Aldrich, Milan, Italy) were 
added to extract the endocannabinoids. The mixture was vortexed for 1 min and 
centrifuged at 12,000g for 6 min at 4 °C. The clear supernatant was transferred 
into a clean 5-ml polypropylene tube (Sarstedt, Numbrecht, Germany) and 
evaporated under vacuum at 37°C. The residue of all evaporated samples was 
reconstituted in 100 µl acetonitrile, vortexed for 30 s, and sonicated in 4°C water 
for 15 min. A 20-µl aliquot of the clear solution was used for isotope-dilution 
liquid chromatography-tandem mass spectrometry analysis as described 
previously (Hauer et al, 2010; Schelling et al, 2006). All samples were injected in 
duplicates. 
Statistics. Data were analyzed with one- or two-way ANOVAs. The source of the 
detected significances was determined by Tukey–Kramer post hoc tests. To 
determine whether learning had occurred, paired t tests were used to compare 
the training and retention latencies of the vehicle groups. Unpaired t test was 
used to compare training latencies of sham lesioned and BLA lesioned groups. 
Data are expressed as mean ± SEM. P values of less than 0.05 were considered 
statistically significant. The number of rats per group is indicated in the figure 
legends. 
Results 
Emotionally arousing inhibitory avoidance training increases AEA levels within 
the amygdala, hippocampus and mPFC only under high aversive conditions, 
without altering 2-AG levels 
To investigate whether the level of emotional arousal influenced long-term 
memory retention, parallel groups of rats were trained in an inhibitory avoidance 
task under three different conditions (No FS; Low FS or High FS). Average step-
through latencies for all groups during training, before footshock, were 14.2 ± 1.9 
s. One-way ANOVA for training latencies revealed no significant differences 
between groups (F2,17 = 0.08; P = 0.92; Fig. 1A). As shown in Fig. 1B, different 
levels of footshock intensity progressively increased the memory retention. A one-
way ANOVA for retention latencies revealed a significant footshock condition 
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effect (F2,17 = 20.41; P < 0.0001). Post hoc comparisons indicated that retention 
latencies of rats given the high footshock intensity (0.45 mA) were significantly 
longer than those of both rats only exposed to the context without any footshock 
(P < 0.01) and rats given the low footshock intensity (0.35 mA; P < 0.05). Rats 
given the low footshock intensity had higher retention latencies than rats only 
exposed to the experimental apparatus (P < 0.05).  
Next, we examined whether an emotionally arousing inhibitory avoidance 
training trial affected endocannabinoid AEA and 2-AG tissue levels within the 
amygdala, hippocampus and mPFC. Rats were trained in an inhibitory avoidance 
task under three different conditions (No FS; Low FS or High FS) and sacrified 10, 
30 or 60 min after the training trial for brain dissection and subsequent 
endocannabinoid measurements. As is shown in Fig 2A a two-way ANOVA for AEA 
levels revealed a significant footshock condition effect (F2,50 = 16.92; P < 0.0001), 
but no time point effect (F2,50 = 0.003; P = 0.99) or interaction between both 
factors (F4,50 = 0.40; P = 0.81). Post hoc comparisons indicated that the highest 
footshock intensity significantly increased amygdalar AEA levels 10, 30 and 60 min 
after the training trial as compared to rats only exposed to the experimental 
 
 
 
 
 
 
Figure 1. Effect of emotional arousal on inhibitory avoidance memory retention. (A) Step-through 
latencies on inhibitory avoidance training trial of rats trained under three different conditions (only 
exposed to the context without receiving any footshock, No FS; with a low footshock intensity, Low 
FS; with a high footshock intensity, High FS). (B) Step-through latencies (mean and SEM) on a 48-h 
retention test. The increase of footshock intensity during the training trial enhanced memory 
consolidation of the inhibitory avoidance task. *, P < 0.05, ** P < 0.01 vs No FS group; , P < 0.05 vs 
Low FS group. Results represent mean ± SEM (n = 6-7 per group). 
context (P < 0.05, for 10- and 30-min time points; P < 0.01, for 60-min time point) 
and to rats given the lower footshock intensity (P < 0.05 for 10- and 60-min time 
points; P < 0.01 for 30-min time point). As is shown in Fig 2B a two-way ANOVA 
for AEA levels into the hippocampus revealed a significant footshock condition 
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effect (F2,44 = 14.25; P < 0.0001), no time point effect (F2,44 = 1.27; P = 0.29) and a 
significant interaction between both factors (F4,44 = 2.73; P = 0.041). Post hoc 
comparisons indicated that the highest footshock intensity significantly increased 
hippocampal AEA levels 10 min after the training trial as compared to both rats 
only exposed to the experimental context and rats given the low footshock 
intensity (P < 0.01 for both comparisons). A two-way ANOVA for AEA levels into 
the mPCF revealed a significant footshock condition effect (F2,49 = 5.47; P < 
0.0072), but no time point effect (F2,49 = 2.94; P = 0.062) or an interaction between 
both factors (F4,49 = 1.54; P = 0.20; Fig. 2C). Post hoc comparisons indicated that 
the highest footshock intensity significantly increased AEA levels into the mPFC 60 
min after the training trial as compared to rats only exposed to the experimental  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of the level of emotional arousal of an inhibitory avoidance training trial on 
endocannabinoid AEA and 2-AG levels into the amygdala, hippocampus and mPFC, measured at 
different time points during memory consolidation. The high footshock (High FS) condition induced 
an increase in AEA levels into the amygdala (A) 10, 30 and 60 min after the training, into the 
hippocampus (B) 10 min after the training and into the mPFC (C) 60 min after the training, without 
altering 2-AG content neither into the amygdala (D), nor into the hippocampus (E), nor into the 
mPFC (F). *, P < 0.05, **, P < 0.01 vs the correspondent no footshock (No FS) group; , P < 0.05, 
, P < 0.01 vs the correspondent low footshock (Low FS) group. All results represent mean ± SEM (n 
= 3 - 8 per group). 
0
2
4
6
8
10
2
-A
G
 (
µ
g
/g
 t
is
s
u
e
)
Low FS
No FS
HighFS
10 30 60 min
0
2
4
6
8
10
2
-A
G
 (
µ
g
/g
 t
is
s
u
e
)
Low FS
No FS
HighFS
10 30 60 min
0
5
10
15
20
25
30
*
A
E
A
 (
n
g
/g
 t
is
s
u
e
)
Low FS
No FS
HighFS
10 30 60 min
A
E
A
 (
n
g
/g
 t
is
s
u
e
)
0
5
10
15
20
25
30
**
Low FS
No FS
HighFS
10 30 60 min
A
E
A
 (
n
g
/g
 t
is
s
u
e
)
0
5
10
15
20
25
30
**
* *
Low FS
No FS
HighFS
10 30 60 min
A B C 
F 
10 30 
2
-A
G
 (
µ
g
/g
 t
is
s
u
e
)
0
2
4
6
8
10
60 min
Low FS
No FS
HighFS
D E 
36 
 
context (P < 0.05; Fig. 3B). Inhibitory avoidance training experience did not affect 
2-AG levels neither into the amygdala (Fig. 2D) nor into the hippocampus (Fig. 2E) 
or into the mPFC (Fig. 2F). A two-way ANOVA for 2-AG levels revealed that there 
was neither a footshock condition effect (F2,50 = 2.10; P = 0.13; F2,43 = 2.78; P = 
0.073; F2,46 = 1.69; P = 0.20; for amygdala, hippocampus and mPFC, respectively) 
nor a time point effect (F2,50 = 1.03; P = 0.36; F2,43 =0.34; P = 0.71; F2,46 = 0.39; P = 
0.68; for amygdala, hippocampus and mPFC, respectively), nor an interaction 
between both factors (F4,50 = 1.10; P = 0.37; F4,43 = 0.77; P = 0.55; F4,46 = 0.69; P = 
0.60; for amygdala, hippocampus and mPFC, respectively). Thus, these findings 
indicate that the level of emotional arousal at encoding dose-dependently 
enhanced memory retention and that high arousal training conditions selectively 
increased AEA levels at different time points after the aversive experience within 
the amygdala, hippocampus and the mPFC, without affecting 2-AG levels.  
Posttraining infusions of the FAAH inhibitor URB597 into the BLA, hippocampus 
and mPFC induce enhancement of inhibitory avoidance retention via indirect 
activation of CB1 receptors 
This experiment examined whether posttraining bilateral intra-BLA, intra-
hippocampal or intra-mPFC infusions of the FAAH inhibitor URB597 immediately 
after inhibitory avoidance training modulated memory retention of this trial. 
Average step-through latencies for all groups during trainings, before footshock 
and drug treatment, were 13.8 ± 0.9 s, 14.4 ± 1.2 s and 16.4 ± 1.3 s for BLA, 
hippocampus and mPFC, respectively. One-way ANOVA for training latencies 
revealed no significant differences between groups (F3,46 = 1.31; P = 0.28; F3,32 = 
1.05; P = 0.38; F3,49 = 0.47; P = 0.71; for BLA, hippocampus and mPFC, 
respectively). Forty-eight-hour retention latencies of rats infused with vehicle into 
the BLA, hippocampus or into the mPFC immediately after training were 
significantly longer than their entrance latencies during the training trial (t11 = -
3.63; P = 0.0039; t10 = -2.34; P = 0.042 and t12 = -2.51; P = 0.028, respectively), 
indicating that the rats retaine memory of the shock experience. As shown in Fig. 
3A-B, URB597 infused into the BLA or hippocampus improved 48-h memory 
retention in an inverted U-shape relationship. One-way ANOVAs for retention 
latencies revealed a significant treatment effect (F3,46 = 3.63; P = 0.020; F3,32 = 3.30; 
P = 0.033, for BLA and hippocampus, respectively). Post hoc comparisons 
indicated that retention latencies of rats given posttraining infusions of URB597 
(10 ng) were significantly longer than those of rats given vehicle (P < 0.05, for both 
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comparisons; Fig. 3A-B). Lower or higher doses (3 ng and 30 ng) did not 
significantly affect retention performance. Figure 3C shows that URB597 
enhanced 48-h memory retention when infused into the mPFC. A one-way ANOVA 
for retention latencies revealed a significant treatment effect (F3,49 = 3.67; P = 
0.018). Post hoc comparisons indicated that retention latencies of rats given 
posttraining infusions of URB597 (30 ng) were significantly longer than those of 
rats given vehicle (P < 0.05). Lower doses (3 ng and 10 ng) did not significantly 
affect retention performance. 
Next, we examined whether the memory enhancing effect induced by URB597 
is mediated by the indirect activation of CB1 receptors. To address this question 
rats were concurrently infused into the BLA, hippocampus or mPFC with the 
effective dose of URB597 together with a non-impairing dose of the CB1 
antagonist AM251 immediately after the training trial. Average step-through 
latencies for all groups during trainings, before footshock and drug treatment, 
were 10.0 ± 0.9 s, 12.2 ± 0.8 s and 15.6 ± 1.3 s for BLA, hippocampus and mPFC, 
respectively. Two-way ANOVAs for training latencies revealed no significant 
differences between posttraining drug groups (for all comparisons P > 0.11). 
Forty-eight-hour retention latencies of rats infused with vehicle into the BLA, 
hippocampus or mPFC immediately after training were significantly longer than 
their entrance latencies during the training trial (t9 = -2.89; P = 0.018; t12 = -2.23; P 
= 0.046 and t9 = -2.34; P = 0.044, respectively), indicating that the rats retained 
memory of the shock experience. Fig. 3D shows retention latencies of rats infused 
concurrently with URB597 and AM251 into the BLA immediately after training. A 
two-way ANOVA for memory retention revealed a significant URB597 treatment 
effect (F1,34 = 5.47; P = 0.025), a significant AM251 treatment effect (F1,34 = 4.27; P 
= 0.046) and a significant interaction between both factors (F1,34 = 5.45; P = 0.026). 
Post hoc comparisons indicated that retention latencies of rats given posttraining 
infusions of URB597 (10 ng) were significantly longer than those of rats given 
vehicle (P < 0.05). Retention latencies of rats given a non-impairing dose of 
AM251 (0.14 ng) together with URB597 were significantly shorter than those of 
rats treated with URB597 alone (P < 0.05). Fig. 3E shows retention latencies of rats 
infused concurrently with URB597 and AM251 into the hippocampus immediately 
after training. A two-way ANOVA for memory retention revealed a significant 
URB597 treatment effect (F1,47 = 8.42; P = 0.0056), a significant AM251 treatment 
effect (F1,47 = 11.13; P = 0.0017) and a significant interaction between both factors 
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(F1,47 = 10.74; P = 0.0020). Post hoc comparisons indicated that retention latencies 
of rats given posttraining infusions of URB597 (10 ng) were significantly longer  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effects of intra-BLA, intra-hippocampus or intra-mPFC infusions of the FAAH inhibitor 
URB597, either alone or together with the CB1 antagonist AM251, on 48-h memory retention. 
Immediate posttraining bilateral infusions of URB597 (URB; 3, 10 or 30 ng/0.5 µl) into the BLA (A), 
hippocampus (B) or mPFC (C) enhanced memory consolidation. Immediate posttraining bilateral 
infusions of a non-impairing dose of AM251 (0.14-0.28 ng/0.5 µl) blocked the memory-enhancing 
effects of concurrently administered URB597 (URB; 10 or 30 ng/0.5 µl) into the BLA (D), 
hippocampus (E) or into the mPCF (F). Representative photomicrograph (Microscope Nikon 801, 
original magnification 2X) illustrating placement of cannula and needle tip in the BLA (G), dorsal 
hippocampus (H) and in the mPFC (I). *, P < 0.05, **, P < 0.01 vs the corresponding vehicle (Veh) 
group; , P < 0.05, , P < 0.01 vs the corresponding AM251 group. All results represent mean ± 
SEM (n = 8 - 14 per group). 
than those of rats given vehicle (P < 0.01). Retention latencies of rats given a non-
impairing dose of AM251 (0.28 ng) together with URB597 were significantly 
shorter than those of rats treated with URB597 alone (P < 0.01). Fig. 3F shows 
retention latencies of rats infused concurrently with URB597 and AM251 into the 
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mPFC immediately after training. A two-way ANOVA for memory retention 
revealed a significant URB597 treatment effect (F1,38 = 5.58; P = 0.023), no 
significant AM251 treatment effect (F1,38 = 3.87; P = 0.056) and a significant 
interaction between both factors (F1,38 = 4.41; P = 0.042). Post hoc comparisons 
indicated that retention latencies of rats given posttraining infusions of URB597 
(30 ng) were significantly longer than those of rats given vehicle (P < 0.05). 
Retention latencies of rats given a non-impairing dose of AM251 (0.28 ng) 
together with URB597 were significantly shorter than those of rats treated with 
URB597 alone (P < 0.05). These results indicated that the memory enhancement 
induced by URB597 is mediated by an indirect activation of CB1 receptors into the 
BLA, hippocampus and mPFC.  
Bilateral permanent lesions of the BLA block the training-induced increase of 
AEA levels within the hippocampus and the mPFC  
The present study evaluated whether the BLA modulates endocannabinoid 
response to aversive training experiences in the hippocampus and mPFC. To 
explore this possibility, we selectively induced bilateral permanent lesions of the 
BLA and measured AEA and 2-AG endocannabinoid levels in the hippocampus and 
mPFC in rats subjected to an inhibitory avoidance training. Rats were trained 
under the 0.45 mA FS condition and sacrified 10 or 60 min later for hippocampus 
and mPCF dissection, respectively (in the previous experiments we found that AEA 
levels increased 10 and 60 min after training in the hippocampus and mPFC, 
respectively; see Fig. 2B-C). Fig 4A-B show the effects induced by BLA lesions on 
hippocampal and mPFC AEA levels. One-way ANOVAs for AEA levels into the 
hippocampus or into the mPFC revealed a significant experimental condition 
effect (F2,14 = 25,04; P < 0.0001; F2,16 = 5,58; P < 0.015 for hippocampus and mPFC, 
respectively). Post hoc comparisons indicated that bilateral BLA permanent lesions 
significantly abolished the increase in AEA levels seen in sham lesioned controls (P 
< 0.01; P < 0.05 for hippocampus and mPFC, respectively). Bilateral BLA lesions did 
not affect 2-AG levels neither into the hippocampus nor into the mPFC of rats 
subjected to the inhibitory avoidance training (F2,14 = 0.16; P < 0.85; F2,16 = 0.14; P 
< 0.87, respectively; data not shown). Thus, these findings indicate that bilateral 
lesions of BLA blocked the training-induced increase of AEA levels without 
affecting 2-AG levels.  
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Bilateral permanent lesions of the BLA block the memory enhancing effects 
induced by posttraining URB597 infusions in the hippocampus or in the mPFC 
The present experiments evaluated the BLA modulates the memory effect 
induced by intra-hippocampus or intra-mPFC infusions of URB597. The first 
experiment examined the effects of URB597 infusions into the hippocampus of 
rats with bilateral BLA lesions. Average step-through latencies of rats with sham 
or BLA lesions to enter the shock compartment on the training trial, before 
footshock exposure, were not statistically different (12.1 ± 1.3 s for sham-lesioned 
rats, 10.2 ± 1.0 s for BLA lesioned rats; t48 = 1.17; P = 0.25). Two-way ANOVA for 
training latencies revealed no significant BLA lesion effect (F1,46 = 1.46; P = 0.23), 
no differences between posttraining intra-hippocampal drug infusions (F1,46 = 
0.28; P = 0.60) or an interaction between both factors (F1,46 = 0.68; P = 0.41). 
Forty-eight-hour retention latencies of sham lesioned rats infused with vehicle 
into the hippocampus were significantly longer than their entrance latencies 
during the training trial (t13 = -2.26; P = 0.041), indicating that rats retained 
memory for the task. As shown in Fig. 4C bilateral BLA lesions blocked the 
memory enhancing effect induced by URB597 infused into the hippocampus 
immediately after the training trial. Two-way ANOVA for retention latencies 
revealed a significant BLA lesion effect (F1,46 = 12.10; P = 0.0011), a significant 
URB597 treatment effect (F1,46 = 4.12; P = 0.048) and a significant interaction 
between these two factors (F1,46 = 4.84; P = 0.033). Post-training infusions of 
URB597 (10 ng) into the hippocampus of sham lesioned rats enhanced 48-h 
retention of rats relative to their corresponding group (P < 0.05). BLA lesions 
alone, while not impairing retention memory, blocked the memory enhancing 
effect of URB597 infused into the hippocampus (P < 0.01). The second experiment 
examined the effects of URB597 infusions into the mPFC of rats with bilateral BLA 
lesions. Latencies of rats with sham lesions or BLA lesions to enter the shock 
compartment on the training trial, before footshock exposure, did not differ (15.4 
± 2.0 s for sham lesioned rats, 12.1 ± 1.5 s for BLA lesioned rats; t43 = 1.35; P = 
0.18). Two-way ANOVA for training latencies revealed no significant BLA lesion 
effect (F1,41 = 1.99; P = 0.17), no differences between posttraining intra-mPFC drug 
infusions (F1,41 = 1.04; P = 0.31) or an interaction between both factors (F1,41 = 0.46; 
P = 0.50). Forty-eight-hour retention latencies of sham lesioned rats infused with 
vehicle into the mPFC were significantly longer than their entrance latencies 
during the training trial (t10 = -2.68; P = 0.023), indicating that rats retained memory  
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Figure 4. Role of the BLA in modulating endocannabinoid response to an emotionally arousing 
inhibitory avoidance training in the hippocampus and the mPFC. Bilateral permanent lesions of the 
BLA blocked the training-induced increase of AEA levels into the hippocampus (A) and mPFC (B), 10 
and 60 min after the training trial, respectively. *, P < 0.05, **, P < 0.01 vs the corresponding sham 
lesioned group only exposed to the experimental context (Sham les No FS); , P < 0.05, , P < 
0.01 vs the corresponding BLA lesioned group trained under the high footshock condition (Sham les 
High FS). Results represent mean ± SEM (n = 4 - 7 per group). Bilateral lesions of the BLA blocked the 
memory enhancing effects induced by URB597 infused into the hippocampus (10 ng/0.5 µl; C) or 
into the mPFC (30 ng/0.5 µl; D). *, P < 0.05 vs the corresponding vehicle group (Veh); , P < 0.01 
vs the corresponding BLA lesioned group (BLA les). Results represent mean ± SEM (n = 10 - 14 per 
group).  
for the task. Fig. 4D shows that bilateral BLA lesions blocked the memory 
enhancing effect induced by URB597 infusions into the mPFC. Two-way ANOVA 
for retention latencies revealed a significant BLA lesion effect (F1,41 = 11.80; P = 
0.0014), a significant URB597 treatment effect (F1,41 = 6.26; P = 0.016) and a 
significant interaction between these two factors (F1,41 = 4.91; P = 0.032). Post hoc 
comparisons indicated that posttraining infusions of URB597 (30 ng) into the 
mPFC of sham lesioned rats enhanced 48-h retention of rats as compared to their 
corresponding vehicle control group (P < 0.05). Importantly, BLA lesions alone did 
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not impair retention latencies but blocked the memory enhancing effect of 
URB597 infused into the mPFC (P < 0.01). Thus, our findings indicated that the BLA 
is critically involved in mediating endocannabinoid enhancing effects in the 
hippocampus and mPFC on memory consolidation for the inhibitory avoidance 
training. 
Discussion 
The present findings demonstrate that the endogenous cannabinoid AEA crucially 
modulates the consolidation of memory for aversive experiences within the BLA, 
hippocampus and mPFC, three brain regions importantly involved in emotional 
memory processes (Price et al, 2010). Most importantly, our findings indicate that 
the BLA plays a crucial role in the coordination of the hippocampal and prefrontal 
cortex endocannabinoid response after a stressful event, shedding light on the 
dynamic interplay occurring among these three brain regions.  
Here we show that rats trained under higher arousal conditions retain better 
memories of the event than rats trained to mild footshock intensities. 
Interestingly, this effect is paralleled by an increase of AEA levels in the BLA, 
hippocampus and mPFC, while 2-AG levels are unaffected. The increase in AEA 
content shows a temporal-dependent response during the early phases of 
memory consolidation, with permanent increase of AEA in the BLA (from 10 to 60 
min after training) and an activation of the endocannabinoid tone only 10 min 
after training in the hippocampus and 60 min after training in the mPFC. 
Interestingly, the exogenous activation of the endocannabinoid tone induced by 
bilateral posttraining infusions of the FAAH inhibitor URB597 into all the three 
considered brain regions induced an enhancement of 48-h inhibitory avoidance 
retention performance. This memory enhancing effect is mediated by indirect 
activation of CB1 receptors since the concurrent administration of a nonimpairing 
dose of the CB1 receptor antagonist AM251 is able to block such effect.  
It is well known that CB1 receptors, highly expressed throughout the limbic 
system (Herkenham et al, 1991; McPartland et al, 2007; Tsou et al, 1998), 
modulate neuronal signaling and synaptic plasticity (Chevaleyre et al, 2006; 
Katona et al, 2012; Marsicano and Lutz, 2006), thus, regulating emotional 
behavior and memory processes related to emotionally arousing events (Atsak et 
al, 2012b; Campolongo et al, 2009; Ganon-Elazar et al, 2009; Marsicano et al, 
2009; Marsicano et al, 2002; Tan et al, 2011; Wotjak, 2005). Unfortunately, with 
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regard to cannabinoid effects on memory consolidation a large number of studies 
report contradictive findings. Some authors showed that posttraining intra-
hippocampal administration of cannabinoid agonists impair memory consolidation 
in several behavioral tasks (e.g. step-down inhibitory avoidance, step-through 
inhibitory avoidance, Morris water maze) (Jamali-Raeufy et al, 2011; Yim et al, 
2008; Zarrindast et al, 2011) while other studies reported enhancing effects when 
cannabinoid agonists were infused either into the hippocampus (De Oliveira 
Alvares et al, 2008) or into the BLA (Campolongo et al, 2009). In addition to 
differences in dose, route of administration and timing of exposure, cannabinoid 
effects on memory function are strikingly dependent on the level of emotional 
arousal induced by the environmental context and by the stressfulness of the 
experimental condition employed in the different studies (Campolongo et al, 
2013; Campolongo et al, 2012; Morena et al, 2013)}. In support of this view in the 
present study we demonstrated that only under high (and not low) aversive 
conditions (i.e. augmented footshock intensity) AEA is released within the three 
key brain regions involved in memory processes for emotional events. Our 
findings indicate that the pavlovian association between a physical stress (i.e. 0.45 
mA footshock intensity) and the dark compartment of the inhibitory avoidance 
apparatus induces a selective release of the endocannabinoid AEA in the BLA, 
hippocampus and mPFC, brain areas crucially involved in the memory modulation 
of the aversive experience. This increase in the endocannabinoid response was 
not detectable when animals were subjected to milder foot-shock intensities, still 
able to induce a memory of the event but less stronger in term of emotional 
arousal. The present finding is in line with the result of de Oliveira Alvares and co-
workers (2010) reporting that immediate posttraining infusion of the cannabinoid 
antagonist AM251 into the dorsal hippocampus impaired 24-h memory retention 
of a contextual fear conditioning paradigm only when conducted under high 
arousal conditions (i.e. high footshock intensity) (de Oliveira Alvares et al, 2010). 
Similarly, Bucherelli and coworkers (2006) reported that the blockade of the 
endogenous cannabinoid neurotransmission in the amygdala obtained by local 
infusions of the CB1 receptor antagonist AM251 impaired memory consolidation 
of a contextual fear conditioning (Bucherelli et al, 2006).  
We then pharmacologically tested whether an exogenous amplification of the 
endocannabinoid neurotransmission in the three brain areas objective of the 
study could modulate memory consolidation for inhibitory avoidance training. Our 
results showed that the FAAH inhibitor URB597, which increases endogenous 
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levels of AEA, enhanced 48-h memory retention when infused into the BLA, 
hippocampus or mPFC. Interestingly, the URB597 memory enhancing effect was 
blocked by a concurrent infusion of AM251, demonstrating a CB1-mediated effect 
in all the three brain areas. Our results are consistent with previous findings 
demonstrating that intra-hippocampal administration of AEA or the cannabinoid 
antagonist AM251 enhanced or impaired, respectively, memory consolidation of a 
step-down inhibitory avoidance task (de Oliveira Alvares et al, 2005; De Oliveira 
Alvares et al, 2008). To our knowledge only one very recent evidence has been 
recently reported in the literature concerning cannabinoid effects on memory 
consolidation when directly infused into the mPFC. Kuhnert et al. (2013) 
demonstrated that intra-mPFC infusions of AM251 impaired memory 
consolidation of an aversively motivated behavioral task (Kuhnert et al, 2013), 
again corroborating the accordance with the present findings. 
As highlightened above, we have previously demonstrated that 
endocannabinoid effects on cognitive functions are strictly dependent on the 
aversiveness of the environmental condition and on the level of emotional arousal 
at the time of testing. This prompted us to hypothesize that the interaction with 
stress hormones is of crucial importance in determining the modulatory effects of 
cannabinoid compounds on memory processes. The amygdala represents a key 
region for the association between environmental information with emotional 
significance for the processing of both negative and positive emotions (Aggleton, 
1993; Baxter and Murray, 2002; Davis et al, 1994; Pape and Pare, 2010). It is well 
established that emotionally arousing training experiences increase BLA neuronal 
activity (Pelletier et al, 2005) and the selective activation of the BLA is of crucial 
importance for enabling emotional arousal influence on memory modulation. 
Indeed, lesions of the BLA block the memory enhancing effects of an inhibitory 
avoidance training induced by a systemic administration of the synthetic 
glucocorticoid dexamethasone (Roozendaal et al, 1996). Corroborating and 
extending these findings, we demonstrated that bilateral lesions of the BLA block 
URB597 hippocampal and mPFC memory enhancing effects. In a previous paper 
we have shown that administration of the CB1 receptor antagonist AM251 in the 
BLA blocks the ability of systemically administered corticosterone to facilitate 
memory consolidation of inhibitory avoidance training (Campolongo et al, 2009). 
These findings indicated, for the first time in vivo, that glucocorticoids recruit 
endocannabinoid signaling in the BLA to modulate aversive memory consolidation 
(Hill et al, 2010a; Hill et al, 2010b). Within the BLA, CB1 receptors are abundantly 
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expressed in GABAergic interneurons (Katona et al, 2001) where they have 
consistently been shown to suppress the release of GABA (Katona et al, 2001; 
Katona et al, 1999; Ohno-Shosaku et al, 2001). It has been reported that inhibition 
of GABAergic activity within the BLA enhances memory consolidation by 
increasing the release of norepinephrine (Hatfield et al, 1999). In view of this 
evidence, we previously proposed a model: After experiencing an emotionally 
arousing event, corticosterone, released from the adrenal gland, binds to a 
membrane bound receptor in the BLA to stimulate the synthesis of 
endocannabinoids; once in the synaptic cleft, endocannabinoids may inhibit GABA 
release by presynaptic terminals, thus leading to the disinhibition of 
norepinephrine release and increased noradrenergic activation of postsynaptic β-
adrenoceptors, increasing the consolidation of aversive memories (Atsak et al, 
2012b; Campolongo et al, 2009; Hill and McEwen, 2009; Morena et al, 2013). Our 
present findings add to this model by demonstrating for the first time the increase 
of AEA during early phases of memory consolidation. Thus, after a stressful event 
there is an endogenous release of AEA mediated by a non-genomic effect of 
corticosterone and AEA mediates the enhancement of memory consolidation for 
aversive experiences via the activation of CB1 receptors. However, the BLA is 
thought not as a locus for memory storage; presumably, following its activation, 
this brain area modulates memory consolidation by coordinating the activation of 
other brain regions (Packard and Wingard, 2004). There are two different ways by 
which the BLA may influence the activation of other brain areas. First, the BLA 
may exert this modulatory influences indirectly by increasing autonomic and 
humoral stress responses (Roozendaal, 2002; Roozendaal et al, 1992). Accordingly 
with this assumption, de Oliveira Alvares and coworkers demonstrated that 
blockade of endocannabinoids action by intra-hippocampal infusion of the CB1 
receptor antagonist AM251 impaired memory consolidation in rats that had 
received dexamethasone immediately before training, thus demonstrating that 
blockade of hippocampal endocannabinoid transmission abolishes glucocorticoid 
effects on memory consolidation (de Oliveira Alvares et al, 2010). We can 
speculate that, as a consequence, stress hormones may interact with the 
increased levels of AEA into the hippocampus or the mPFC, thus  enhancing 
memory consolidation. The second hypothesis with regard to BLA modulation of 
other brain areas in the regulation of memory consolidation, is that the BLA might 
modulate cognitive functions through either direct or indirect neural connections 
to various limbic structures (Krettek and Price, 1978; Pape et al, 2010; Petrovich et 
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al, 2001; Pikkarainen et al, 1999). In the present study we show for the first time 
that the enhancement of memory consolidation requires a release of amygdalar 
endocannabinoids and, most importantly, that a functional BLA is required to 
enable hippocampal and mPFC endocannabinoid effects on memory 
consolidation. This demonstrates a critical role for BLA CB1 neurotransmission in 
modulating projection neurons to other brain regions during the processing of 
emotionally salient information., There is considerable evidence corroborating our 
findings which demonstrates that interactions between the BLA and the 
hippocampus regulate emotional-arousal effects on memory consolidation of 
spatial or contextual information (Huff et al, 2006; Roozendaal et al, 1997; 
Roozendaal et al, 1999). For instance, pharmacological inactivation of the BLA 
impaired memory consolidation and decreased ARC mRNA and protein levels in 
the dorsal hippocampus (McIntyre et al, 2005). Other studies, indicated that an 
intact and functional BLA is required to enable memory modulation that is 
initiated by a manipulation of hippocampal activity. In particular, posttraining 
hippocampal infusions of a glucocorticoid receptor agonist enhanced memory 
consolidation of inhibitory avoidance training but, most importantly, inactivation 
of the BLA blocked this effect (Roozendaal et al, 1997; Roozendaal et al, 1999). In 
addition to the hippocampus, it has been extensively demonstrated that the BLA 
interacts with the mPFC in modulating memory acquisition (Laviolette et al, 2006; 
Tan et al, 2011) and consolidation (Roozendaal et al, 2009b) for emotionally 
arousing training experiences. Tan and coworkers (2011) demonstrated that the 
modulation of cannabinoid transmission specifically within the BLA strongly 
influences: i) neuronal firing frequency and burst activity in mPFC neuronal 
subpopulations, ii) the encoding of emotionally salient associative memories via 
functional connectivity with the mPFC (Tan et al, 2011). It has been  demonstrated 
that glucocorticoid receptor agonist infusion into the mPFC after inhibitory 
avoidance training enhanced memory consolidation and induced a rapid increase 
in BLA levels of phosphorylated extracellular signal-regulated kinase 1/2 (pErk1/2) 
and vice versa, suggesting a bidirectional interaction between the BLA and the 
mPFC in the regulation of memory consolidation (Roozendaal et al, 2009b).  
In addition to the evidence already present in the literature, our results further 
indicate that depending on the brain region considered, AEA increases with 
distinct temporal windows during early phases of memory consolidation. It is 
likely that the activation of the BLA drives the endocannabinoid response into the 
other two brain regions considered with a time-dependent fashion. Such evidence 
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was confirmed by the finding that permanent lesions of the BLA blocked the 
training-induced increase of AEA levels both into the hippocampus and the mPFC. 
Moreover, bilateral posttraining infusions of URB597 into the hippocampus or 
into the mPFC did not enhance memory retention in rats with permanent lesions 
of the BLA, thus confirming that the BLA is crucially involved in coordinating 
endocannabinoid response to an aversive event in the hippocampus and mPFC. It 
has been proposed that the initiation of a strong emotional experience activates 
memory-related neuroplasticity in the hippocampus and amygdala and 
suppresses PFC functioning (Diamond et al, 2007). Such model suggests a rapid 
activation of the BLA (from seconds to hours) and hippocampus (from seconds to 
minutes) after a stressful experience, followed by an inhibitory phase. Conversely, 
stress induces an inhibition of the functioning of the mPFC and the recovery from 
its suppression of functioning depends on the nature and intensity of the stressor. 
According with this model we found a rapid increase of AEA levels within the BLA 
(from 10 to 60 minutes after the FS) and the hippocampus (10 minutes after the 
FS). Such rapid increase of amygdalar AEA levels, may represent one of the most 
rapid action of its activation. The subsequent stimulation of BLA CB1 receptors 
may decrease feedforward inhibition via inhibitory interneurons, thereby 
increasing the activity of BLA projection neurons (Pistis et al, 2004). The 
emotionally arousal-induced activation of the BLA may serve as a marker warning 
the hippocampus to process and stabilize important events to be remembered. 
On the other hand, basal mPFC activity is known to provide inhibitory influence on 
BLA activity (Likhtik et al, 2005; Quirk and Gehlert, 2003a; Quirk et al, 2003b), 
whereas stress and glucocorticoids suppress mPFC functioning. As a consequence 
the BLA greater activation during emotionally arousing situations (Amat et al, 
2005; Davidson, 2002) may then enhance the consolidation of different kinds of 
information via its projections to other brain regions.  
Taken together our findings suggest that as a response to stress 
endocannabinoids are released within three important limbic regions where they 
modulate the consolidation of memory for emotionally arousing events. 
Immediately after an aversive experience, it occurs a temporal interplay between 
the BLA, hippocampus and the mPFC modulated by the endocannabinoid system. 
In this scenario it is plausible to hypothesize that the endocannabinoid system, 
particularly AEA within the BLA, drives the disinhibition of neuronal projections to 
the hippocampus first and subsequently to the mPFC with the final result of a 
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coordination of memory processes underlying the consolidation of emotionally 
arousing experiences.  
These finding have important clinical implications. Understanding the neural 
underpinnings of the temporal interactions between limbic regions after 
experiencing a stressful event will shed light on the neural mechanism involved in 
psychiatric disorders such as the post-traumatic stress disorder (PTSD), thus 
leading to new therapeutic opportunities. 
  
49 
 
References 
Aggleton JP (1993). The contribution of the amygdala to normal and abnormal emotional 
states. Trends Neurosci 16(8): 328-333. 
 
Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF (2005). Medial prefrontal 
cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. 
Nat Neurosci 8(3): 365-371. 
 
Atsak P, Hauer D, Campolongo P, Schelling G, McGaugh JL, Roozendaal B (2012a). 
Glucocorticoids interact with the hippocampal endocannabinoid system in impairing 
retrieval of contextual fear memory. Proc Natl Acad Sci U S A 109(9): 3504-3509. 
 
Atsak P, Roozendaal B, Campolongo P (2012b). Role of the endocannabinoid system in 
regulating glucocorticoid effects on memory for emotional experiences. Neuroscience 204: 
104-116. 
 
Barna I, Zelena D, Arszovszki AC, Ledent C (2004). The role of endogenous cannabinoids in 
the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 
receptor knockout mice. Life Sci 75(24): 2959-2970. 
 
Baxter MG, Murray EA (2002). The amygdala and reward. Nat Rev Neurosci 3(7): 563-573. 
 
Bucherelli C, Baldi E, Mariottini C, Passani MB, Blandina P (2006). Aversive memory 
reactivation engages in the amygdala only some neurotransmitters involved in 
consolidation. Learn Mem 13(4): 426-430. 
 
Campolongo P, Morena M, Scaccianoce S, Trezza V, Chiarotti F, Schelling G, et al (2013). 
Novelty-Induced Emotional Arousal Modulates Cannabinoid Effects on Recognition 
Memory and Adrenocortical Activity. Neuropsychopharmacology 38: 1276-1286. 
 
Campolongo P, Ratano P, Manduca A, Scattoni ML, Palmery M, Trezza V, et al (2012). The 
endocannabinoid transport inhibitor AM404 differentially modulates recognition memory 
in rats depending on environmental aversiveness. Front Behav Neurosci 6: 11. 
 
Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL, et al (2009). 
Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and 
enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A 106(12): 4888-
4893. 
 
Chevaleyre V, Takahashi KA, Castillo PE (2006). Endocannabinoid-mediated synaptic 
plasticity in the CNS. Annu Rev Neurosci 29: 37-76. 
 
Davidson RJ (2002). Anxiety and affective style: role of prefrontal cortex and amygdala. 
Biol Psychiatry 51(1): 68-80. 
50 
 
 
Davis M, Rainnie D, Cassell M (1994). Neurotransmission in the rat amygdala related to 
fear and anxiety. Trends Neurosci 17(5): 208-214. 
 
de Oliveira Alvares L, de Oliveira LF, Camboim C, Diehl F, Genro BP, Lanziotti VB, et al 
(2005). Amnestic effect of intrahippocampal AM251, a CB1-selective blocker, in the 
inhibitory avoidance, but not in the open field habituation task, in rats. Neurobiol Learn 
Mem 83(2): 119-124. 
 
de Oliveira Alvares L, Engelke DS, Diehl F, Scheffer-Teixeira R, Haubrich J, de Freitas Cassini 
L, et al (2010). Stress response recruits the hippocampal endocannabinoid system for the 
modulation of fear memory. Learn Mem 17(4): 202-209. 
 
De Oliveira Alvares L, Genro BP, Diehl F, Quillfeldt JA (2008). Differential role of the 
hippocampal endocannabinoid system in the memory consolidation and retrieval 
mechanisms. Neurobiol Learn Mem 90(1): 1-9. 
 
Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC (1988). Determination 
and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5): 605-613. 
 
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al (1992). Isolation 
and structure of a brain constituent that binds to the cannabinoid receptor. Science 
258(5090): 1946-1949. 
 
Diamond DM, Campbell AM, Park CR, Halonen J, Zoladz PR (2007). The temporal dynamics 
model of emotional memory processing: a synthesis on the neurobiological basis of stress-
induced amnesia, flashbulb and traumatic memories, and the Yerkes-Dodson law. Neural 
Plast 2007: 60803. 
 
Ganon-Elazar E, Akirav I (2009). Cannabinoid receptor activation in the basolateral 
amygdala blocks the effects of stress on the conditioning and extinction of inhibitory 
avoidance. J Neurosci 29(36): 11078-11088. 
 
Gold PE (2004). Coordination of multiple memory systems. Neurobiol Learn Mem 82(3): 
230-242. 
 
Hatfield T, Spanis C, McGaugh JL (1999). Response of amygdalar norepinephrine to 
footshock and GABAergic drugs using in vivo microdialysis and HPLC. Brain Res 835(2): 
340-345. 
 
Hauer D, Ratano P, Morena M, Scaccianoce S, Briegel I, Palmery M, et al (2010). Propofol 
enhances memory formation via an interaction with the endocannabinoid system. 
Anesthesiology 114(6): 1380-1388. 
 
51 
 
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). 
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in 
vitro autoradiographic study. J Neurosci 11(2): 563-583. 
 
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al (1990). 
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87(5): 1932-1936. 
 
Hill MN, Karatsoreos IN, Hillard CJ, McEwen BS (2010a). Rapid elevations in limbic 
endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology 
35(9): 1333-1338. 
 
Hill MN, McEwen BS (2009). Endocannabinoids: The silent partner of glucocorticoids in the 
synapse. Proc Natl Acad Sci U S A 106(12): 4579-4580. 
 
Hill MN, McEwen BS (2010b). Involvement of the endocannabinoid system in the 
neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol 
Psychiatry 34(5): 791-797. 
 
Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS (2010c). Functional 
interactions between stress and the endocannabinoid system: from synaptic signaling to 
behavioral output. J Neurosci 30(45): 14980-14986. 
 
Huff NC, Frank M, Wright-Hardesty K, Sprunger D, Matus-Amat P, Higgins E, et al (2006). 
Amygdala regulation of immediate-early gene expression in the hippocampus induced by 
contextual fear conditioning. J Neurosci 26(5): 1616-1623. 
 
Jamali-Raeufy N, Nasehi M, Zarrindast MR (2011). Influence of N-methyl D-aspartate 
receptor mechanism on WIN55,212-2-induced amnesia in rat dorsal hippocampus. Behav 
Pharmacol 22(7): 645-654. 
 
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009). 
Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1): 309-380. 
 
Katona I, Freund TF (2012). Multiple functions of endocannabinoid signaling in the brain. 
Annu Rev Neurosci 35: 529-558. 
 
Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, et al (2001). Distribution of CB1 
cannabinoid receptors in the amygdala and their role in the control of GABAergic 
transmission. J Neurosci 21(23): 9506-9518. 
 
Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al (1999). Presynaptically located 
CB1 cannabinoid receptors regulate GABA release from axon terminals of specific 
hippocampal interneurons. J Neurosci 19(11): 4544-4558. 
 
Krettek JE, Price JL (1978). Amygdaloid projections to subcortical structures within the 
basal forebrain and brainstem in the rat and cat. J Comp Neurol 178(2): 225-254. 
52 
 
 
Kuhnert S, Meyer C, Koch M (2013). Involvement of cannabinoid receptors in the 
amygdala and prefrontal cortex of rats in fear learning, consolidation, retrieval and 
extinction. Behav Brain Res 250: 274-284. 
 
Laviolette SR, Grace AA (2006). The roles of cannabinoid and dopamine receptor systems 
in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol 
Life Sci 63(14): 1597-1613. 
 
Likhtik E, Pelletier JG, Paz R, Pare D (2005). Prefrontal control of the amygdala. J Neurosci 
25(32): 7429-7437. 
 
Malin EL, McGaugh JL (2006). Differential involvement of the hippocampus, anterior 
cingulate cortex, and basolateral amygdala in memory for context and footshock. Proc 
Natl Acad Sci U S A 103(6): 1959-1963. 
 
Marsicano G, Lafenetre P (2009). Roles of the endocannabinoid system in learning and 
memory. Curr Top Behav Neurosci 1: 201-230. 
 
Marsicano G, Lutz B (2006). Neuromodulatory functions of the endocannabinoid system. J 
Endocrinol Invest 29(3 Suppl): 27-46. 
 
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al (2002). The 
endogenous cannabinoid system controls extinction of aversive memories. Nature 
418(6897): 530-534. 
 
McEwen BS (2012). Brain on stress: how the social environment gets under the skin. Proc 
Natl Acad Sci U S A 109 Suppl 2: 17180-17185. 
 
McGaugh JL (2000). Memory--a century of consolidation. Science 287(5451): 248-251. 
 
McGaugh JL, Introini-Collison IB, Nagahara AH (1988). Memory-enhancing effects of 
posttraining naloxone: involvement of beta-noradrenergic influences in the amygdaloid 
complex. Brain Res 446(1): 37-49. 
 
McIntyre CK, Miyashita T, Setlow B, Marjon KD, Steward O, Guzowski JF, et al (2005). 
Memory-influencing intra-basolateral amygdala drug infusions modulate expression of Arc 
protein in the hippocampus. Proc Natl Acad Sci U S A 102(30): 10718-10723. 
 
McPartland JM, Glass M, Pertwee RG (2007). Meta-analysis of cannabinoid ligand binding 
affinity and receptor distribution: interspecies differences. Br J Pharmacol 152(5): 583-
593. 
 
Morena M, Campolongo P (2013). The endocannabinoid system: An emotional buffer in 
the modulation of memory function. Neurobiol Learn Mem. 
 
53 
 
Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, Pistis M (2006). Cannabinoids modulate 
spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic 
neurons. Eur J Neurosci 23(9): 2385-2394. 
 
Ohno-Shosaku T, Maejima T, Kano M (2001). Endogenous cannabinoids mediate 
retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. 
Neuron 29(3): 729-738. 
 
Oropeza VC, Page ME, Van Bockstaele EJ (2005). Systemic administration of WIN 55,212-2 
increases norepinephrine release in the rat frontal cortex. Brain Res 1046(1-2): 45-54. 
 
Packard MG, Wingard JC (2004). Amygdala and "emotional" modulation of the relative use 
of multiple memory systems. Neurobiol Learn Mem 82(3): 243-252. 
 
Pape HC, Pare D (2010). Plastic synaptic networks of the amygdala for the acquisition, 
expression, and extinction of conditioned fear. Physiol Rev 90(2): 419-463. 
 
Paxinos G, Watson C (2005). The rat brain in stereotaxic coordinates 
4edn. San Diego: Academic. 
 
Pelletier JG, Likhtik E, Filali M, Pare D (2005). Lasting increases in basolateral amygdala 
activity after emotional arousal: implications for facilitated consolidation of emotional 
memories. Learn Mem 12(2): 96-102. 
 
Petrovich GD, Canteras NS, Swanson LW (2001). Combinatorial amygdalar inputs to 
hippocampal domains and hypothalamic behavior systems. Brain Res Brain Res Rev 38(1-
2): 247-289. 
 
Pikkarainen M, Ronkko S, Savander V, Insausti R, Pitkanen A (1999). Projections from the 
lateral, basal, and accessory basal nuclei of the amygdala to the hippocampal formation in 
rat. J Comp Neurol 403(2): 229-260. 
 
Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL (2004). Cannabinoids modulate 
neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated 
actions. Neuropharmacology 46(1): 115-125. 
 
Price JL, Drevets WC (2010). Neurocircuitry of mood disorders. Neuropsychopharmacology 
35(1): 192-216. 
 
Quirk GJ, Gehlert DR (2003a). Inhibition of the amygdala: key to pathological states? Ann N 
Y Acad Sci 985: 263-272. 
 
Quirk GJ, Likhtik E, Pelletier JG, Pare D (2003b). Stimulation of medial prefrontal cortex 
decreases the responsiveness of central amygdala output neurons. J Neurosci 23(25): 
8800-8807. 
 
54 
 
Roozendaal B (2002). Stress and memory: opposing effects of glucocorticoids on memory 
consolidation and memory retrieval. Neurobiol Learn Mem 78(3): 578-595. 
 
Roozendaal B, Griffith QK, Buranday J, De Quervain DJ, McGaugh JL (2003). The 
hippocampus mediates glucocorticoid-induced impairment of spatial memory retrieval: 
dependence on the basolateral amygdala. Proc Natl Acad Sci U S A 100(3): 1328-1333. 
 
Roozendaal B, Koolhaas JM, Bohus B (1992). Central amygdaloid involvement in 
neuroendocrine correlates of conditioned stress responses. J Neuroendocrinol 4(4): 483-
489. 
 
Roozendaal B, McEwen BS, Chattarji S (2009a). Stress, memory and the amygdala. Nat Rev 
Neurosci 10(6): 423-433. 
 
Roozendaal B, McGaugh JL (1996). Amygdaloid nuclei lesions differentially affect 
glucocorticoid-induced memory enhancement in an inhibitory avoidance task. Neurobiol 
Learn Mem 65(1): 1-8. 
 
Roozendaal B, McGaugh JL (1997). Basolateral amygdala lesions block the memory-
enhancing effect of glucocorticoid administration in the dorsal hippocampus of rats. Eur J 
Neurosci 9(1): 76-83. 
 
Roozendaal B, McReynolds JR, Van der Zee EA, Lee S, McGaugh JL, McIntyre CK (2009b). 
Glucocorticoid effects on memory consolidation depend on functional interactions 
between the medial prefrontal cortex and basolateral amygdala. J Neurosci 29(45): 14299-
14308. 
 
Roozendaal B, Nguyen BT, Power AE, McGaugh JL (1999). Basolateral amygdala 
noradrenergic influence enables enhancement of memory consolidation induced by 
hippocampal glucocorticoid receptor activation. Proc Natl Acad Sci U S A 96(20): 11642-
11647. 
 
Roozendaal B, Okuda S, Van der Zee EA, McGaugh JL (2006). Glucocorticoid enhancement 
of memory requires arousal-induced noradrenergic activation in the basolateral amygdala. 
Proc Natl Acad Sci U S A 103(17): 6741-6746. 
 
Schelling G, Hauer D, Azad SC, Schmoelz M, Chouker A, Schmidt M, et al (2006). Effects of 
general anesthesia on anandamide blood levels in humans. Anesthesiology 104(2): 273-
277. 
 
Steiner MA, Wotjak CT (2008). Role of the endocannabinoid system in regulation of the 
hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 170: 397-432. 
 
Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al (1995). 2-
Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. 
Biochem Biophys Res Commun 215(1): 89-97. 
55 
 
 
Tan H, Lauzon NM, Bishop SF, Chi N, Bechard M, Laviolette SR (2011). Cannabinoid 
transmission in the basolateral amygdala modulates fear memory formation via functional 
inputs to the prelimbic cortex. J Neurosci 31(14): 5300-5312. 
 
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical 
distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 
83(2): 393-411. 
 
Weidenfeld J, Feldman S, Mechoulam R (1994). Effect of the brain constituent 
anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in 
the rat. Neuroendocrinology 59(2): 110-112. 
 
Wotjak CT (2005). Role of endogenous cannabinoids in cognition and emotionality. Mini 
Rev Med Chem 5(7): 659-670. 
 
Yim TT, Hong NS, Ejaredar M, McKenna JE, McDonald RJ (2008). Post-training CB1 
cannabinoid receptor agonist activation disrupts long-term consolidation of spatial 
memories in the hippocampus. Neuroscience 151(4): 929-936. 
 
Zarrindast MR, Navaeian M, Nasehi M (2011). Influence of three-day morphine-treatment 
upon impairment of memory consolidation induced by cannabinoid infused into the dorsal 
hippocampus in rats. Neurosci Res 69(1): 51-59. 
 
  
56 
 
 
CHAPTER 2 
 
PROPOFOL ENHANCES MEMORY FORMATION VIA AN 
INTERACTION WITH THE ENDOCANNABINOID SYSTEM 
Daniela Hauer1, Patrizia Ratano2, Maria Morena2, Sergio Scaccianoce2, Isabel 
Briegel1, Maura Palmery2, Vincenzo Cuomo2, Benno Roozendaal3, Gustav 
Schelling1, Patrizia Campolongo2 
1
Department of Anaesthesiology, Ludwig-Maximilians University, Munich, Germany. 
2
Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; 
3
Department of Neuroscience, Section Anatomy, University Medical Center Groningen, 
University of Groningen, Groningen, The Netherlands  
 
 
 
 
 
Anesthesiology 2011; 114: 1380-8 
 
 
  
57 
 
Abstract 
Background: Propofol is associated with postoperative mood alterations and 
induces a higher incidence of dreaming compared with other general anesthetics. 
These effects might be mediated by propofol’s inhibitory action on fatty acid 
amide hydrolase, the enzyme that degrades the endocannabinoid anandamide. 
Because propofol is also associated with a higher incidence of traumatic 
memories from perioperative awareness and intensive care unit treatment and 
the endocannabinoid system is involved in regulating memory consolidation of 
emotional experiences, the authors investigated whether propofol, at anesthetic 
doses, modulates memory consolidation via an activation of the endocannabinoid 
system.  
Methods: Male Sprague-Dawley rats were trained on an inhibitory avoidance task 
in which they received an inescapable foot shock upon entering the dark 
compartment of the apparatus. Drugs were administered intraperitoneally 
immediately or 30, 90, or 180 min after training. On the retention test 48 h later, 
the latency to reenter the dark compartment was recorded and taken as a 
measure of memory retention. 
Results: The anesthetic doses of propofol administered after training significantly 
increased latencies of 48-h inhibitory avoidance performance (483.4 ± 181.3, 
432.89 ± 214.06, 300 and 350 mg/kg, respectively; mean ± SD) compared with the 
corresponding vehicle group (325.33 ± 221.22, mean ± SD), which is indicative of 
stronger memory consolidation in propofol treated rats. Administration of a 
nonimpairing dose of the cannabinoid receptor antagonist rimonabant blocked 
the memory enhancement induced by propofol (123.39 ± 133.10, mean ± SD). 
Delayed administration of propofol 90 and 180 min after training or immediate 
posttraining administration of the benzodiazepine midazolam or the barbiturate 
pentobarbital did not significantly alter retention. 
Conclusions: These findings indicate that propofol, in contrast to other commonly 
used sedatives, enhances emotional memory consolidation when administered 
immediately after a stressful event by enhancing endocannabinoid signaling. 
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Introduction 
Propofol is a commonly used agent for general anesthesia and for sedation in 
patients undergoing intensive care treatment (ICU). It is known to reduce 
postoperative nausea and vomiting (Apfel et al, 2004) and is associated with 
postoperative mood alterations and a higher incidence of dreaming compared 
with other general anesthetics. However, the use of propofol for general 
anesthesia or for sedation of critically ill patients in the ICU is not universally 
successful with respect to preventing traumatic memories from perioperative 
awareness and ICU treatment (Jones et al, 2007). There is extensive evidence that 
the occurrence of traumatic experiences associated with perioperative awareness 
or ICU treatment could result in stress-related disorders such as posttraumatic 
stress disorder and impaired long-term health-related quality of life outcomes 
(Kapfhammer et al, 2004; Schelling et al, 2003). One clinical study, investigating 
propofol’s effects on memory, reported that propofol inhibits conscious memory 
processing in human subjects soon after memory encoding and that it impairs the 
encoding of material into long-term memory (Veselis et al, 2009). In another 
study, propofol administration to rats induced amnesia of training on an inhibitory 
avoidance task (Alkire et al, 2001). However, in both studies propofol was 
administered before learning, thus revealing propofol’s effect on the encoding of 
new information. No studies are available regarding propofol’s effects on the 
consolidation of traumatic memories. However, because patients often have 
experienced stressful events, such as preoperative fear and anxiety, car accidents, 
myocardial infarctions, or acute respiratory distress shortly before induction of 
general anesthesia or sedation with propofol, it is crucial to investigate the effects 
of propofol administered shortly after the acquisition of new information, a time 
window when the memory trace is consolidated into stable long-term memory.  
Propofol inhibits the enzyme fatty acid amide hydrolase, which is known to 
degrade endocannabinoids, especially anandamide (Patel et al, 2003). Like 
propofol, the endocannabinoid system recently has been shown to be crucially 
involved in mood control in animals (Bortolato et al, 2006; Gobbi et al, 2005) and 
the regulation of nausea and vomiting in humans during stress (Chouker et al, 
2010). Thus, some of the mentioned propofol effects could be attributable to an 
activation of the endocannabinoid system (Di Marzo, 2003). Propofol 
administration to mice has been shown to increase endocannabinoid content 
within the brain, an effect that could not be detected with other sedative agents, 
such as midazolam or thiopental (Patel et al, 2003). In addition, endocannabinoid 
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plasma concentrations increased moderately in patients undergoing propofol 
anesthesia but decreased in patients undergoing general anesthesia with a 
volatile agent such as sevoflurane (Schelling et al, 2006) or isoflurane (Weis et al, 
2010). The endocannabinoid system consists of endocannabinoid ligands, the 
endogenous cannabinoid receptors 1 and 2 (CB1 and CB2), and enzymes involved 
in the synthesis and metabolism of endocannabinoids (De Petrocellis and Di 
Marzo, 2009). Endocannabinoids (i.e., anandamide and 2-arachidonoylglycerol) 
are synthesized on demand through cleavage of membrane precursors and serve 
as retrograde messengers at central synapses (Hashimotodani et al, 2007). They 
bind to CB1 receptors on axon terminals to regulate ion channel activity and 
neurotransmitter release (Piomelli, 2003) and are degraded intracellularly by 
specific enzymes: anandamide is mainly degraded by fatty acid amide hydrolase 
and 2-arachidonoylglycerol by monoacylglycerol lipase (Petrosino and Di Marzo, 
2010). CB1 receptors are highly expressed in several brain regions and in lower 
densities outside the brain (Matsuda et al, 1990; Munro et al, 1993). In contrast, 
CB2 receptors have a more restricted distribution and are found mainly on 
immune cells and in low numbers in the brainstem (Van Sickle et al, 2005) and 
some other brain regions (Gong et al, 2006). Both CB1 and CB2 receptors primarily 
signal through inhibitory G proteins (Howlett et al, 2002).  
Recent evidence indicates an important role for endocannabinoids and CB1 
receptor activation in enhancing the memory consolidation of emotionally 
arousing experiences (Campolongo et al, 2009b; Graham et al, 2009). Moreover, it 
recently has been shown that the fatty acid amide hydrolase inhibitor URB597 
enhances memory acquisition and consolidation in rats (Mazzola et al, 2009). 
These findings suggest that propofol might modulate memory consolidation of 
emotionally arousing experiences via an interaction with the endocannabinoid 
system. To investigate this issue, in a first experiment, anesthetic doses of 
propofol were administered to rats by intraperitoneal injection, immediately and 
30, 90, and 180 min after aversively motivated inhibitory avoidance training, a 
widely used animal model to assess drug effects on emotional memory 
consolidation. In a second experiment, we evaluated whether the propofol effect 
on the consolidation of inhibitory avoidance memory is specific for this anesthetic 
by administering anesthetic doses of the benzodiazepine midazolam or the 
barbiturate pentobarbital immediately after inhibitory avoidance training. In the 
last experiment, we investigated whether the memory-enhancing effect of 
propofol depends on concurrent CB1 activity by administering a nonimpairing 
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dose of the CB1 receptor antagonist rimonabant 30 min before propofol injection; 
we also studied whether propofol administration modulates endocannabinoid 
release in rats. 
Materials and Methods 
Animals 
Male adult Sprague-Dawley rats (350–450 g at the time of training; Charles River 
Laboratories, Calco, Italy) were housed individually and maintained in a 
temperature-controlled environment (20° ± 1°C) under a 24-h light-dark cycle 
(7:00 AM to 7:00 PM lights on) with unlimited access to food and water. All 
procedures involving animal care or treatments were approved by the Italian 
Ministry of Health (Rome, Italy) and performed in compliance with the guidelines 
of the US National Institutes of Health and the Italian Ministry of Health (D.L. 
116/92), the Declaration of Helsinki, and the Guide for the Care and Use of 
Mammals in Neuroscience and Behavioral Research (National Research Council 
2004). 
Drug treatment 
2,6-Diisopropyl phenol (propofol, 250, 300, or 350 mg/kg), purchased from Sigma-
Aldrich (Milan, Italy), was dissolved in a vehicle containing 100% sesame oil. 
Midazolam (30, 50, or 70 mg/kg; Ratiopharm, Ulm, Germany) was dissolved in 
saline, and pentobarbital (60, 70, or 80 mg/kg; Sigma-Aldrich, St. Louis, MO) was 
dissolved in a vehicle containing 40% propylene glycol (1,2-propanediol), 10% 
ethanol, and 50% distilled water. Drug solutions were freshly prepared before 
each experiment and administered by intraperitoneal injection in a volume of 1 
ml/kg immediately after the training trial. To control for time specificity, propofol 
was administered to different groups of rats either 30, 90, or 180 min after the 
training trial. To assess whether CB1 receptors are involved in mediating the 
propofol effect on memory consolidation, the CB1 receptor antagonist 
rimonabant (1 mg/kg; donated by the National Institute of Mental Health, 
Chemical Synthesis and Drug Supply Program, Bethesda, MD) was dissolved in a 
vehicle containing 5% polyethylene glycol, 5% TWEEN 80, and 90% saline 
(Bortolato et al, 2006) and administered immediately after training, whereas 
propofol was given 30 min later.  
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Behavioral studies 
Inhibitory Avoidance Apparatus and Procedures. Rats were trained and tested 
in an inhibitory avoidance apparatus consisting of a trough-shaped alley (91 cm 
long, 15 cm deep, 20 cm wide at the top, and 6.4 cm wide at the bottom) divided 
into two compartments, separated by a sliding door that opened by retracting 
into the floor. The starting compartment (31 cm long) was made of opaque white 
plastic and illuminated by a lamp; the shock compartment (60 cm long) was made 
of two dark, electrifiable metal plates and was not illuminated (McGaugh et al, 
1988). Training and testing were performed during the light phase, between 10:00 
AM and 2:00 PM, and were conducted in dim light conditions in a sound-
attenuated room. Animals were handled 1 min each for 2 days before the training 
day.  
For training, the rats were placed into the starting compartment of the 
apparatus, facing away from the door, and were permitted to explore the 
apparatus. After the rats stepped completely into the dark compartment, the 
sliding door was closed and a single, inescapable foot shock (0.35 mA) was 
delivered for 1 s. The animals were removed from the shock compartment 15 s 
after termination of the foot shock. Retention was tested 48 h later. On the 
retention test trial, the rats were placed into the starting compartment, and the 
latency to reenter the shock compartment with all four paws (maximum latency 
of 600 s) was recorded and used as a measure of retention. Longer latencies were 
interpreted as indicating better retention (Dawson and McGaugh, 1971). 
Immediately after the training and testing of each animal, the apparatus was 
cleaned with a 70% ethanol solution.  
To be included in the test phase, rats they had to reach a minimum criterion on 
the training test (before treatment), which is 60 s maximum to step in the dark 
compartment of the maze.  
All the analyses were performed by the same observer, who was unaware of 
animal treatment. 
Sleeping Time. Sleeping parameters were determined in different groups of 
rats. To determine sleeping onset and recovery, immediately after anesthetic 
administration each rat was placed on its back once every 30 s until it was unable 
to right itself within 30 s. Sleeping onset was defined as the interval between 
anesthetic injection and the time the rat was unable to turn itself upright at least 
twice within 1 min. Then each rat was left undisturbed on its back until it 
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spontaneously regained its righting reflexes, defined as having at least three paws 
under its body. Complete recovery of the righting reflex was defined as the rat 
being able to turn itself upright. The time between loss and recovery of righting 
reflex for each rat was defined as sleeping time (cutoff=180 min) (Cagiano et al, 
2002). All of the analyses were performed by the same observer, who was 
unaware of animal treatment.  
Endocannabinoid Measurement 
In accordance with Patel’s protocol in mice (Patel et al, 2003), rats were 
treated with propofol (300 mg/kg, intraperitoneally) or with its vehicle and killed 8 
or 40 min after administration.  
Brain and plasma samples were subjected to a lipid extraction process, and the 
endocannabinoid content of the lipid extracts was determined using isotope-
dilution liquid chromatography-mass spectrometry as described previously 
(Schelling et al, 2006). The brain tissue was collected and stored at -80°C. Before 
the extraction process, tissues were weighted and homogenized in polypropylene 
tubes (Sarstedt, Numbrecht, Germany) and kept in ice water. Five hundred µl of 
the described homogenized tissue solution was transferred to a 2-ml Eppendorf 
tube, and 20 µl of internal standard and 1 ml methyl tertiary butyl ether (Sigma-
Aldrich, Italy) were added to extract the endocannabinoids. The mixture was 
vortexed for 1 min and centrifuged at 12,000g for 6 min. The clear supernatant 
was transferred into a clean 5-ml polypropylene tube (Sarstedt) and evaporated 
under vacuum at 37°C. The residue of all evaporated samples was reconstituted in 
100 µl acetonitrile, vortexed for 30 s, and sonicated in 4°C water for 15 min. A 20-
µl aliquot of the clear solution was used for liquid chromatography-tandem mass 
spectrometry analysis. All samples were injected in duplicates.  
Statistical Analysis 
The training and retention latencies of rats were analyzed with one-way 
ANOVA. Time-dependent effects of propofol, the interactions between propofol 
and rimonabant, and propofol effects on endocannabinoid concentrations were 
analyzed with two-way ANOVAs. The source of the detected significances was 
determined by Tukey–Kramer post hoc tests. To determine whether learning had 
occurred, paired t tests were used to compare the training and retention latencies 
of the vehicle groups. Sleeping parameters were analyzed with Kruskal-Wallis one-
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way ANOVA on ranks or Mann–Whitney U test because of their nonnormal 
distribution. StatView software (SAS Institute, Cary, NC) was used to conduct 
statistical analyses. Normal data are expressed as mean ± SD; nonparametric data 
are expressed as median and percentiles. Two-tailed testing was used for all the 
analyses. P values of < 0.05 were considered statistically significant. The number 
of rats per group is indicated in the figures and tables. 
Results 
Posttraining administration of propofol enhances 48-h inhibitory avoidance 
retention performance  
This experiment examined whether immediate posttraining administration of 
propofol would enhance 48-h retention performance of inhibitory avoidance 
training. Average step-through latencies for all groups during training (i.e., before 
foot shock and drug treatment) were 17.6 ± 13.7 s (mean ± SD). One-way ANOVA 
for training latencies revealed no significant differences between groups (F3,46 = 
0.93, P = 0.43). The 48-h retention latencies of rats given vehicle immediately 
after training were significantly longer than their entrance latencies during the 
 
 
 
 
 
 
training trial (t = -5.59, P = 0.0002), indicating that the rats retained memory of 
the shock experience. As shown in figure 1, propofol induced dose-dependent 
retention enhancement. One-way ANOVA for 48-h retention latencies revealed a 
significant treatment effect (F3,43 = 7.82, P = 0.0003). Post hoc analysis indicated 
that rats treated with the higher doses of propofol (300 or 350 mg/kg) had 
significantly longer retention than did those treated with vehicle or with 250 
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Fig. 1. Effects of posttraining administration of 
propofol on retention of an inhibitory avoidance 
response. Step-through latencies (mean ± SD) 
on a 48-h retention test. Immediate 
posttraining administration of propofol (300 
mg/kg) enhanced memory retention. * P < 0.05; 
** P < 0.01 versus vehicle; # P < 0.05; ## P < 
0.01 versus 250 mg/kg propofol (n = 12, vehicle; 
n = 13, 250 and 300 mg/kg propofol; n = 9, 350 
mg/kg propofol). 
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mg/kg propofol (P < 0.01 and P < 0.05 for 300 and 350 mg/kg, respectively). The 
lower dose of propofol (250 mg/kg), which did not induce anesthesia, did not 
induce retention enhancement. Three of 12 rats given 350 mg/kg propofol died of 
respiratory depression.  
Propofol administered immediately or 30 min (but not 90 or 180 min) after the 
training enhanced 48-h inhibitory avoidance retention performance 
To examine whether propofol influences the consolidation phase of memory 
processing, rats were treated with propofol (300 mg/kg) immediately or 30, 90, or 
180 min after training. Average step-through latencies for all groups during 
training, before foot shock and drug treatment, were 16.6 ± 13.0 s (mean ± SD). 
Two-way ANOVA for training latencies revealed no significant differences 
between groups (main effect of treatment F1,78 = 0.77, P = 0.38; main effect of 
time of administration F3,78 = 2.0, P = 0.12; interaction F3,78 = 1.54, P = 0.21). Two-
way ANOVA for 48-h retention latencies revealed a significant main effect of 
propofol (F1,78 = 17.64, P < 0.0001) as well as a significant main effect of time of 
administration (F3,78 = 3.76, P = 0.014). Moreover, there was a statistically 
significant interaction effect between treatment and time of administration (F3,78 = 
4.76, P = 0.0042). As shown in figure 2, post hoc analysis indicated that rats 
treated with propofol either immediately or 30 min after training had significantly 
longer retention latencies than did those given vehicle (P < 0.01). Retention 
latencies of rats injected with propofol immediately or 30 min posttraining were 
significantly longer than were those of rats given propofol 180 min after the 
training (P < 0.01). 
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Fig. 2. Effects of immediate and delayed 
posttraining administration of propofol on 
retention of an inhibitory avoidance response. 
Step-through latencies (mean ± SD) on a 48-h 
retention test. Rats injected with propofol 
immediately or 30 min posttraining showed 
retention latencies longer than those of rats 
injected with vehicle at the corresponding time 
point and with propofol 180 min after training. 
** P < 0.01 versus the corresponding vehicle 
group; ## P < 0.01 versus rats injected with 
propofol 180 min after training (n = 10, vehicle 
30 min and 300 mg/kg propofol 90 min; n = 11, 
all other groups). 
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Posttraining administration of midazolam or pentobarbital does not enhance 48-
h inhibitory avoidance retention performance 
To determine whether the propofol effect on inhibitory avoidance memory 
enhancement is specific for this anesthetic, rats were treated with anesthetic 
doses of midazolam (30, 50, or 70 mg/kg, intraperitoneally) or pentobarbital (60, 
70, or 80 mg/kg, intraperitoneally) immediately after inhibitory avoidance 
training. For midazolam, average stepthrough latencies for all groups during 
training, before foot shock and drug treatment, were 17.7 ± 13.9 s (mean ± SD). 
One-way ANOVA for training latencies revealed no significant differences between 
groups (F3,34 = 0.17, P = 0.92). As shown in figure 3A, one-way ANOVA for 48-h 
retention latencies indicated that midazolam did not significantly enhance 
retention latencies (F3,34 = 0.09, P = 0.97). For pentobarbital, average step-through 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Effects of posttraining administration of midazolam or pentobarbital on retention of an 
inhibitory avoidance response. Step-through latencies (mean ± SD) on a 48-h retention test. 
Immediate posttraining administration of midazolam (A) or pentobarbital (B) did not enhance 
memory consolidation (n = 9, 30 mg/kg midazolam and 70 or 80 mg/kg pentobarbital; n = 10 vehicle, 
50 or 70 mg/kg midazolam and 60 mg/kg pentobarbital). 
 
latencies for both groups during training, before foot shock and drug treatment, 
were 17.2 ± 14.2 s (mean ± SD). One-way ANOVA for training latencies revealed 
no significant differences between groups (F3,34 = 0.34, P = 0.79). As shown in 
figure 3B, one-way ANOVA for 48-h retention latencies indicated that 
pentobarbital did not significantly enhance retention latencies (F3,34 = 0.21, P = 
0.89).  
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The CB1 antagonist rimonabant blocks the memory enhancing effect induced by 
propofol 
This experiment examined whether the memory-enhancing effect of propofol 
depends on a concurrent activation of CB1 receptors. To address this issue, we 
investigated whether the CB1 receptor antagonist rimonabant (1 mg/kg) 
administered intraperitoneally immediately after inhibitory avoidance training 
would block the retention enhancement induced by propofol given 30 min later. 
Average step-through latencies for all groups during training, before foot shock 
and drug treatment, were 15.2 ± 11.8 s. The 48-h retention latencies of rats given 
vehicle after training were significantly longer than their entrance latencies during 
the training trial (P = 0.0001). As shown in figure 4, posttraining administration of 
rimonabant blocked the retention enhancement induced by propofol (300 
mg/kg). Two-way ANOVA for 8-h retention latencies revealed a significant 
rimonabant plus propofol interaction effect (F1,27 = 11.70, P = 0.002). Post hoc 
comparison revealed that retention latencies of rats given propofol alone were 
significantly longer than were those of vehicle-treated rats (P < 0.01). Most 
importantly, retention latencies of rats given an otherwise nonimpairing dose of 
rimonabant together with propofol were significantly shorter than those of rats 
treated with propofol alone (P < 0.01). 
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Fig. 4. Effects of the CB1 antagonist rimonabant 
on the memory-enhancing effects induced by 
propofol. Stepthrough latencies (mean ± SD) on 
a 48-h retention test. Immediate posttraining 
administration of the cannabinoid receptor 
antagonist rimonabant (1 mg/kg) blocked the 
memory-enhancing effects of propofol (300 
mg/kg). ** P < 0.01 versus the corresponding 
vehicle group; ## P < 0.01 versus the 
corresponding propofol group (n = 7, 1 mg/kg 
rimonabant + vehicle propofol; n = 8, all other 
groups). 
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Sleeping time 
 
Table 1 shows the effects of propofol, midazolam, and pentobarbital on sleeping 
parameters. Kruskal-Wallis ANOVA revealed no statistically significant effect on 
sleeping onset (H6 = 10.27, P = 0.11).  
However, Kruskal-Wallis ANOVA revealed a statistically significant effect for 
sleeping time (H6 = 19.64, P = 0.002). Post hoc comparisons (Mann–Whitney U test 
with Bonferroni correction) revealed that rats given 50 mg/kg midazolam slept for 
a shorter amount of time than did rats given 70 or 80 mg/kg pentobarbital or 
those given 350 mg/kg propofol. None of the rats treated with the lower doses of 
midazolam (30 mg/kg) or propofol (250 mg/kg) lost righting reflex.  
Table 2 shows the effects of rimonabant on propofol in inducing anesthesia. 
Mann–Whitney U test showed no difference between rats pretreated with 
rimonabant compared with rats pretreated with vehicle on sleeping onset or time 
induced by propofol (U = 5.0, P = 0.11; U = 11.000, P = 0.75, respectively), 
indicating that the anesthetic effect of propofol is independent from the indirect 
activation of the endocannabinoid system.  
Table 1. Sleeping parameters of propofol-, midazolam-, and pentobarbital-treated rats 
Treatment, mg/kg 
 
Prop 
300 
(n = 6) 
Prop 
350 
(n = 5) 
Mid 50 
(n = 6) 
Mid 70 
(n = 6) 
Pento 60 
(n = 6) 
Pento 70 
(n = 5) 
Pento 80 
(n = 6) 
Onset time(min) 
Median 
 
12.0 20.0 11.0 10.5 4.0 4.0 14.0 
25
th
 
Percentile 
6.3 9.3 6.0 9.0 3.0 3.0 9.0 
75
th
 
Percentile 
13.8 20.3 24.0 15.0 13.0 7.5 24.0 
Sleep time (min) 
Median 
 
180 180 86.5* 113 113 144 165 
25
th
 
Percentile 
31.8 180 50.0 97.0 92.0 135 150 
75
th
 
Percentile 
180 180 102 158 163 180 180 
Prop, propofol; Mid, midazolam; Pento, pentobarbital.* P < 0.05 vs. 350 mg/kg propofol and 70 or 
80 mg/kg pentobarbital. 
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Table 2. Sleeping parameters of rats treated with propofol alone or together with 
rimonabant 
Treatment 
Onset Sleeping (min) Sleep Time (min) 
Median 
25th 
Percentile 
75th 
Percentile 
Median 
25th 
Percentile 
75th 
Percentile 
Vehicle 
rimonabant + 
propofol (n = 5) 
16.0 11.0 17.0 180 142 180 
Rimonabant + 
propofol 
(n = 5) 
11.0 9.0 13.5 180 134 180 
 
Endocannabinoid measurement 
Two-way ANOVA for propofol effects on endocannabinoid content revealed a 
statistically significant interaction between treatment and time of administration  
Table 3. Endocannabinoid Concentrations 
Treatment 
Anandamide 2-Arachidonoylglycerol 
Brain (ng/g 
Tissue) 
Plasma (ng/ml) 
Brain (µg/g 
Tissue) 
Plasma (ng/ml) 
Vehicle (8 min, n = 6) 13.8 ± 7.1 0.9 ± 0.3 28.4 ± 27.1 0.3 ± 0.1 
Propofol (8 min, n = 6) 50.7 ± 38.8* 0.9 ± 0.2 29.1 ± 19.9 0.3 ± 0.1 
Vehicle (40 min, n = 5) 33.7 ± 29.2 1.1 ± 0.5 45.9 ± 41.7 0.4 ± 0.2 
Propofol (40 min, n = 6) 16.3 ± 6.5 1.1 ± 0.5 46.3 ± 36.3 0.4 ± 0.2 
* P < 0.05 versus vehicle-treated rats (8 min). 
(F1,19 = 7.1, P = 0.015). Post hoc comparisons revealed that propofol increases 
anandamide concentrations in rat brains 8 min after administration (P < 0.05, 
table 3). 
Discussion 
The current findings indicate that propofol, at anesthetic doses, enhances 
memory consolidation of inhibitory avoidance training in rats when administered 
immediately after the training experience. This memory enhancement is blocked 
by coadministration of the CB1 cannabinoid receptor antagonist rimonabant, 
suggesting that the enhancing effect of propofol on memory consolidation 
depends on an indirect activation of CB1 receptors. In contrast, midazolam and 
pentobarbital, two anesthetics that do not increase endocannabinoid signaling 
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(Patel et al, 2003), did not enhance the consolidation of memory of inhibitory 
avoidance training.  
The current findings may appear at odds with preclinical and clinical findings 
indicating that propofol induces amnesia. For example, Veselis et al. (Veselis et al, 
2009) reported that propofol inhibits conscious memory processes in human 
subjects soon after memory encoding and that it impairs the acquisition or 
encoding of material into long-term memory. In addition, propofol has been 
reported to induce amnesia of training in rats on the same inhibitory avoidance 
task used in the current study (Alkire et al, 2001). However, a critical difference 
between these investigations and the current study is that in the human studies, 
memory function was assessed shortly after drug administration, whereas in the 
preclinical study, rats were given the drug before training. Therefore, acute 
pharmacologic effects could have influenced directly both the acquisition and 
retention of the training. In contrast, in our study the drug was administered after 
the training and was not present during the acquisition phase. Thus, the 
enhancing effects of propofol on retention performance in our study are likely 
mediated by specific influences on the consolidation of memory of the training 
experience (McGaugh and Roozendaal, 2009). The use of posttraining drug 
manipulation is a widely accepted method for effectively dissociating memory 
processes from secondary behavioral effects of nonassociative nature, such as 
those related to sensory sensitivity (Cahill et al, 2001). Because retention testing 
took place 48 h after training and drug treatment, these findings further exclude 
residual pharmacologic effects as having a direct influence on behavior during 
retention testing. Moreover, the effect of posttraining propofol administration on 
retention enhancement was time dependent: propofol administration 
immediately or 30 min after inhibitory avoidance training resulted in memory 
enhancement, whereas administration of propofol 90 or 180 min after training 
was ineffective. Together these findings provide evidence that propofol enhances 
time-dependent processes underlying the consolidation of memory for 
emotionally arousing experiences. The posttraining drug administration protocol 
used in the current article has a translational value to humans. Acute sedation or 
even the induction of anesthesia immediately after a traumatic experience (e.g., 
in the consolidation phase of a traumatic memory) is a common clinical scenario 
in emergency medicine and in the ICU.  
Our findings demonstrate that propofol is able to enhance memory 
consolidation when administered immediately after the exposure to a traumatic 
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event and that this effect on memory depends on an indirect activation of the 
endocannabinoid system. In accordance with the behavioral data, we also found 
that propofol administration increases anandamide concentrations in the rat 
brain 8 min after injection, whereas anandamide plasma concentrations remain 
unaffected. Our data are in accordance with preclinical and clinical evidence. Patel 
et al. (Patel et al, 2003) demonstrated increased concentrations of anandamide in 
the mouse brain after systemic administration of propofol in contrast to the 
administration of benzodiazepines, barbiturates, or volatile anesthetics; the effect 
of propofol on anandamide concentrations is mediated by an inhibition of fatty 
acid amide hydrolase, the major degradation enzyme of anandamide (Patel et al, 
2003). In humans undergoing general anesthesia, plasma concentrations of the 
endocannabinoid anandamide remained unchanged during propofol anesthesia 
but were significantly reduced during anesthesia with volatile agents (Schelling et 
al, 2006; Weis et al, 2010).  
The basolateral complex of the amygdala (BLA) appears to be a critical site for 
mediating drug effects on memory performance, including those of propofol. One 
study reported that permanent neurotoxic lesions of the BLA produced with N-
methyl-D-aspartate blocked the amnestic effect of pretraining propofol 
administration of rats trained on an inhibitory avoidance task (Alkire et al, 2001). 
We recently have shown that the endocannabinoid system in the BLA is involved 
in the enhanced consolidation of inhibitory avoidance memory and that CB1 
activity within the BLA is essential for mediating glucocorticoid effects on long-
term memory (Campolongo et al, 2009a; Campolongo et al, 2009b). Based on 
these findings, a new model has emerged (Hill and McEwen, 2009; Hill et al, 
2010). In this model, stress-induced glucocorticoids bind to membrane-bound 
receptors in the BLA that activate a G-protein signaling cascade that induces 
endocannabinoid synthesis. The ensuing release of endocannabinoid ligands could 
diffuse to local γ-aminobutyric acid–mediated (GABAergic) terminals and inhibit γ-
aminobutyric acid release onto noradrenergic terminals in the BLA. The end result 
of this process is an increased norepinephrine release within the BLA and 
subsequently an enhancement of emotional memory consolidation. Many 
sedative and anamnestic effects of general anesthetics, including those of 
propofol, crucially depend on γ-aminobutyric acid release. The current findings 
demonstrate that the enhancing effects of propofol on memory consolidation 
depend on concomitant CB1 receptor activity, so we hypothesize that the 
anamnestic effects of propofol are mediated by an endocannabinoid-induced 
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inhibition of γ-aminobutyric acid release, resulting in a more pronounced memory 
consolidation during stressful conditions when glucocorticoid signaling is high 
(Roozendaal et al, 2006).  
The pharmacokinetic properties of midazolam, pentobarbital, and propofol 
differ to a large extent, but all three drugs share the pharmacodynamic capability 
to potentiate γ-aminobutyric acid neurotransmission (Goodman and Gilman's, 
2008). Our results showing that rats treated with midazolam (50 mg/kg) slept less 
than did rats treated with propofol (350 mg/kg) or pentobarbital (70 or 80 mg/kg) 
are in accordance with clinical evidence showing that midazolam has a shorter 
half-life than propofol and barbiturates (Goodman and Gilman's, 2008). However, 
neither rats treated with the higher dose of midazolam nor the ones treated with 
pentobarbital showed differences in the sleeping parameters compared with 
those treated with propofol. Although propofol enhances memory consolidation 
through an activation of the endocannabinoid system, the anesthetic effect of 
propofol does not depend on this activation. The CB1 receptor antagonist 
rimonabant blocks the propofol-enhancing effect on memory consolidation but 
does not influence propofol’s effects on sleeping. On the whole, these data 
suggest that, unlike midazolam and pentobarbital, propofol induces selective 
effects on memory consolidation, which are linked to the activation of the 
endocannabinoid system and not related to the potentiation of GABAergic 
neurotransmission.  
These findings, together with the results showing that midazolam and 
pentobarbital, at anesthetic doses, did not influence memory consolidation 
strongly corroborate the hypothesis that propofol’s effects on memory 
consolidation are not attributable to a general nonspecific anesthetic effect.  
In summary, our study demonstrates that propofol enhances memory 
consolidation via an endocannabinoid-mediated mechanism. These effects are 
markedly different from those of other direct GABAergic agents such as 
midazolam or pentobarbital. These findings from animal experiments suggest that 
propofol should be used with caution in individuals during the aftermath of an 
acute traumatic event and may help to explain the increased incidence of aversive 
memories from intraoperative awareness seen in patients undergoing total 
intravenous anesthesia with propofol (Errando et al, 2008). Likewise, the findings 
suggest that pharmacologic manipulation of endocannabinoid signaling could be a 
useful intervention aimed at blocking memory consolidation immediately after a 
traumatic event. 
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Abstract 
Although it is well established that cannabinoid drugs can influence cognitive 
performance, the findings describing both enhancing and impairing effects have 
been ambiguous. Here, we investigated the effects of posttraining systemic 
administration of the synthetic cannabinoid agonist WIN55,212-2 (0.1, 0.3, or 1.0 
mg/kg) on short- and long-term retention of object recognition memory under 
two conditions that differed in their training-associated arousal level. In male 
Sprague-Dawley rats that were not previously habituated to the experimental 
context, WIN55,212-2 administered immediately after a 3-min training trial, 
biphasically impaired retention performance at a 1-h interval. In contrast, 
WIN55,212-2 enhanced 1-h retention of rats that had received extensive prior 
habituation to the experimental context. Interestingly, immediate posttraining 
administration of WIN55,212-2 to non-habituated rats, in doses that impaired 1-h 
retention, enhanced object recognition performance at a 24-h interval. 
Posttraining WIN55,212-2 administration to habituated rats did not significantly 
affect 24-h retention. In light of intimate interactions between cannabinoids and 
the hypothalamic–pituitary–adrenal axis, we further investigated whether 
cannabinoid administration might differently influence training-induced 
glucocorticoid activity in rats in these two habituation conditions. WIN55,212-2 
administered after object recognition training elevated plasma corticosterone 
levels in non-habituated rats whereas it decreased corticosterone levels in 
habituated rats. Most importantly, following pretreatment with the 
corticosterone-synthesis inhibitor metyrapone, WIN55,212-2 effects on 1- and 24-
h retention of non-habituated rats became similar to those seen in the low-
aroused habituated animals, indicating that cannabinoid-induced regulation of 
adrenocortical activity contributes to the environmentally sensitive effects of 
systemically administered cannabinoids on short- and long-term retention of 
object recognition memory. 
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Introduction 
Extensive evidence indicates that cannabinoids, either administered 
exogenously or released from endogenous sites, have pronounced effects on 
learning and memory (Marsicano and Lafenetre, 2009; Wilson and Nicoll, 2001). 
The cannabinoid system consists of two types of G-proteincoupled receptors (CB1 
and CB2 receptors), endogenous ligands, and enzymes involved in their synthesis 
and inactivation (Piomelli, 2003). Endogenous ligands for cannabinoid receptors, 
that is, endocannabinoids, are synthesized on demand in an activity-dependent 
manner and released from postsynaptic neurons. They travel backward across the 
synapse to activate presynaptic CB1 receptors and modulate presynaptic 
functions (Piomelli, 2003). Cannabinoid signaling is crucial for certain forms of 
short- and long-term plasticity at both excitatory and inhibitory synapses 
(Deadwyler et al, 2007) and thereby contributes to various aspects of brain 
function, including learning and memory (Marsicano et al, 2009). However, 
evidence indicates that the mnemonic consequence of cannabis exposure in 
humans does not always correspond to the effects observed in laboratory animals 
administered with cannabinoid compounds systemically or into discrete brain 
regions. For example, although it is well appreciated that cannabis use can impair 
short-term memory and executive function in humans (Pattij et al, 2008), not all 
preclinical studies, using WIN55,212-2 or other synthetic cannabinoid agonists, 
were able to confirm these findings (Baek et al, 2009; Clarke et al, 2008; Kosiorek 
et al, 2003; Schneider et al, 2008; Suenaga and Ichitani, 2008). Cannabinoid 
effects on long-term memory in humans did not receive much attention and 
findings of preclinical studies are not unequivocal, independent of the 
pharmacodynamic properties of the drug used. Whereas some animal studies 
indicate that systemic or intracranial administration of cannabinoid agonists 
impairs the encoding and consolidation of long-term memory processing (Barros 
et al, 2004; Robinson et al, 2008), enhancing effects are reported as well (De 
Oliveira Alvares et al, 2008). Although such discrepancies are not unusual in 
memory research, the factors contributing to these conflicting findings are yet 
poorly understood.  
Emerging evidence indicates that cannabinoid drugs can induce distinct and 
even opposite effects on anxiety and several other behaviors, depending on the 
aversiveness of the environmental context (Campolongo et al, 2012; Carlin et al, 
1972; Haller et al, 2009; Szuster et al, 1988; Zanettini et al, 2011). Based on these 
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findings, we hypothesized that the level of emotional arousal that is associated 
with a training experience might also be a primary factor in determining the 
outcome of cannabinoid administration on learning and memory. Therefore, in 
the present study we investigated the effects of cannabinoid administration on 
both short- and long-term object recognition memory under two experimental 
conditions that differed with respect to their training-associated arousal level. By 
employing a previously described procedure (Okuda et al, 2004), one group of rats 
was not habituated to the training context, whereas the other group was 
extensively habituated to the experimental apparatus to decrease its novelty-
induced stress response during the training trial. The cannabinoid receptor 
agonist WIN55,212-2 was administered intraperitoneally to either extensively 
habituated or not previously habituated rats immediately after the object 
recognition training trial. In the first experiment, retention was tested 1 h after 
the training trial to assess possible cannabinoid effects on short-term cognitive 
performance. In the second experiment, we investigated cannabinoid effects on 
long-term object recognition memory by assessing retention 24 h after the 
training trial and drug treatment.  
In addition to direct actions in the brain, cannabinoids are crucially involved in 
regulating hypothalamic–pituitary–adrenocortical (HPA) axis activity (Atsak et al, 
2012b; Campolongo et al, 2009b; Di et al, 2003; Hill et al, 2010b), shaping the 
corticosterone response to stressful stimulation. As it is well established that 
glucocorticoids hormones are potent modulators of learning and memory 
(Campolongo and Roozendaal, 2011; Okuda et al, 2004; Roozendaal, 2002; 
Roozendaal et al, 2006b; Schwabe et al, 2012), we next investigated whether the 
neuroendocrine consequence of cannabinoid administration on plasma 
corticosterone levels contributes to the environmentally sensitive effects of 
systemically administered WIN55,212-2 on object recognition memory. We first 
investigated whether WIN55,212-2 administration after object recognition 
training differentially affected the release of endogenous corticosterone in rats in 
the two habituation conditions. Further, to assess whether this cannabinoid-
induced shaping of the corticosterone response plays a role in regulating the 
memory modulatory influence of WIN55,212-2, we examined whether 
pharmacological suppression of corticosterone synthesis with metyrapone altered 
the effects of WIN55,212-2 administration on both short- and long-term retention 
of object recognition memory. 
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Materials and methods 
Animals. Male adult Sprague–Dawley rats (350–450 g at the time of training, 
Charles River Laboratories, Italy) were kept individually in an air-conditioned 
colony room (temperature: 21 ± 1 °C; relative humidity: 60 ± 10%; lights on from 
0700 to 1900 hours). Pellet food and water were available ad libitum. Training and 
testing were performed during the light phase of the cycle between 1000 and 
1400 hours. All procedures involving animal care and treatments were in 
accordance with the guidelines released by the Italian Ministry of Health (D.L. 
116/92) and the European Communities Council Directive of 24 November 1986 
(86/ 609/EEC).  
Drug Treatment. The cannabinoid receptor agonist WIN55,212-2 (R(+)-[2,3-
dihydro-5-methyl-3-[(morpholinyl) methyl] pyrolol [1,2,3-de]-1,4-benzoxazin-yl]-
(1-naphthalenyl) methanone mesylate; 0.1, 0.3, and 1.0 mg/kg; Sigma-Aldrich) 
was administered intraperitoneally in a volume of 1.0 ml/kg immediately after the 
training trial. Prior findings indicate that WIN55,212-2, after intraperitoneal 
administration, crosses the blood–brain barrier (Saghafi et al, 2011). For 
adrenocortical suppression, the 11β-hydroxylase inhibitor metyrapone (2-methyl-
1,2-di-3-pyridyl-1-propanone; 35 mg/kg; Sigma-Aldrich) was injected in a volume 
of 2.0 ml/kg 40 min before the training trial. Metyrapone is a selective inhibitor of 
glucocorticoid synthesis in animals and humans (Schimmer and Parker, 2001). It 
blocks the conversion of the corticosterone precursor deoxycorticosterone in the 
adrenal cortex, thereby preventing the release of endogenous corticosterone into 
the bloodstream (Strashimirov and Bohus, 1966). All drugs were dissolved in 5% 
polyethylene glycol, 5% Tween-80, and 90% saline. The vehicle solution contained 
5% polyethylene glycol and 5% Tween-80 in saline only.  
Object Recognition Task. The experimental apparatus was a gray open-field box 
(in cm, 40 wide x 40 deep x 40 high) with the floor covered with sawdust, 
positioned in a dimly illuminated room. The objects to be discriminated were 
transparent glass vials (5.5 cm diameter and 5 cm height) and white glass light 
bulbs (6 cm diameter and 11 cm length). All rats were handled twice per day for 1 
min each for 7 days preceding the training day. The rats were divided into two 
groups. One group of rats was not habituated to the experimental apparatus 
(WITHOUT-habituation condition), whereas the other group was extensively 
habituated to the experimental context (WITH-habituation condition) to decrease 
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their novelty stress to the apparatus during the training trial. During habituation, 
the rats were allowed to explore the apparatus in the absence of objects twice per 
day for 3 min each for 7 days (Okuda et al, 2004). On the training trial, each rat 
was individually placed in the experimental apparatus at the opposite end from 
the objects. The rat was allowed to explore two identical objects (A1 and A2) for 3 
min, then was removed from the apparatus and, after drug treatment, returned 
to its home cage. To avoid the presence of olfactory trails, sawdust was stirred 
and the objects were cleaned with 70% ethanol after each trial. Rat’s behavior 
was recorded by using a video camera positioned above the experimental 
apparatus. Exploration of an object was defined as pointing the nose to the object 
at a distance of < 1 cm and/or touching it with the nose. Turning around or sitting 
on an object was not considered as exploration. The time spent exploring the two 
objects was taken as a measure of object exploration, and exploratory behavior of 
the experimental apparatus was analyzed by the total number of rearings and 
crossings. For crossings, the floor of the apparatus was divided into four imaginary 
squares and the total number of crossings between squares was determined. 
Retention was tested either 1 or 24 h after the training trial. On the retention test 
trial, one copy of the familiar object (A3) and a new object (B) were placed in the 
same location as stimuli during the training trial. All combinations and locations of 
objects were used to reduce potential biases due to preference for particular 
locations or objects. Each rat was placed in the apparatus for 3 min, and its 
behavior was recorded. Videos were analyzed by a trained observer who was 
unaware of treatment condition. The time spent exploring each object and the 
total time spent exploring both objects were recorded. To analyze cognitive 
performance, a discrimination index was calculated as the difference in time 
exploring the novel and the familiar object, expressed as the percentage ratio of 
the total time spent exploring both objects.  
Plasma Corticosterone Levels. Corticosterone levels were determined in parallel 
groups of rats in the WITHOUT-habituation and WITH-habituation condition and 
in rats that were handled (twice per day for 7 days) but not trained. For the last 
experiment, the corticosterone-synthesis inhibitor metyrapone was injected 40 
min prior to the training trial. As novelty stimulation triggers an HPA-axis response 
that leads to a corticosterone plasma peak at 15–30 min and returns to baseline 
by 60–90 min (Grota et al, 1997), rats were killed 30 min after training and 
WIN55,212-2 administration. Trunk blood was collected after decapitation and 
82 
 
samples were centrifuged at 1900 g for 20 min at 4 1C. Plasma was stored at -80 
°C and analyzed for corticosterone using ELISA kits (Assay designs, Ann Arbor, MI, 
USA; IDS, Boldon, Tyne and Wear, UK) according to the manufacturer’s 
instructions. 
Statistics. All data are expressed as mean ± SEM. Data were analyzed by one- 
or two-way ANOVA, followed by Tukey’s post hoc comparison tests or paired or 
unpaired Student’s t-tests, when appropriate. One-sample t-tests were used to 
determine whether the discrimination index was different from zero. A probability 
level of o0.05 was accepted as statistically significant. Fourteen rats were 
removed from statistical analyses because they showed a total exploration time of 
o10 s on either training or testing. Prior findings indicate that such rats do not 
adequately acquire the task (Okuda et al, 2004). 
Results 
Posttraining WIN55,212-2 induces opposite effects on 1-h retention of object 
recognition memory of rats in the WITHOUT-habituation and WITH-habituation 
condition 
This experiment investigated whether immediate posttraining injection of the 
cannabinoid receptor agonist WIN55,212-2 altered short-term performance on an 
object recognition task and whether this WIN55,212-2 effect was influenced by 
prior habituation to the experimental context.  
Training trial. Two-way ANOVA for total exploration time of the two identical 
objects on the training trial revealed a significant habituation condition effect 
(F1,88 = 11.46, P = 0.001), but no differences between posttraining drug groups or 
an interaction between habituation condition and later drug treatment. Rats in 
the WITHOUT-habituation condition showed significantly less total exploration of 
the two objects than rats in the WITH-habituation condition (t94 = -3.37, P = 0.001; 
Figure 1a). In contrast, examination of rats’ exploratory behavior of the training 
apparatus during the training trial indicated that the rats in the WITHOUT-
habituation condition explored the experimental apparatus more than the rats in 
the WITH-habituation condition. Figure 1b and c shows that the number of 
crossings and rearings were significantly higher in rats in the WITHOUT-
habituation condition than that in rats in the WITH-habituation condition (t94 = 
4.33, P < 0.0001 for crossings, t94 = 3.36, P = 0.001 for rearings).  
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Figure 1. Behavioral effects during object recognition training in rats in the WITHOUT-habituation 
and WITH-habituation conditions. Rats in the WITHOUT-habituation (WITHOUT) condition spent 
significantly less time exploring the two identical objects during the training trial as compared with 
rats in the WITH-habituation (WITH) condition (A). Conversely, rats in the WITHOUT-habituation 
condition showed a higher number of crossings (B) and rearings (C) during training as compared with 
rats in the WITH-habituation condition. **P < 0.01 vs the WITH-habituation group. Data are 
expressed as mean ± SEM (n = 48 per group). 
Retention trial. One-sample t-tests revealed that the discrimination index of 
vehicle-treated rats was significantly different from zero in both the WITHOUT-
habituation (t11 = 4.27, P = 0.001) and WITH-habituation condition (t11 = 2.15, P = 
0.05), indicating that rats in both conditions discriminated the novel object at the 
1-h retention interval. As shown in Figure 2, WIN55,212-2 administered 
immediately after the 3-min training trial, induced opposite effects on 1-h retention 
 
 
 
 
 
 
Figure 2. Effect of posttraining administration of WIN55,212-2 on 1-h retention of rats in the 
WITHOUT- and WITH-habituation conditions. Posttraining administration of WIN55,212-2 (WIN, 0.3 
mg/kg, i.p.) impaired 1-h retention of object recognition memory of rats in the WITHOUT 
habituation condition (A) but enhanced 1-h retention of rats in the WITH habituation condition (B). 
*P < 0.05 vs the corresponding vehicle control group. Data are expressed as mean ± SEM (n = 12 per 
group). 
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performance of rats in the WITHOUT habituation and WITH-habituation 
conditions. Two-way ANOVA for discrimination index revealed no main effect of 
either drug treatment or habituation condition, but revealed a statistically 
significant interaction between these two factors (F3,88 = 8.60, P < 0.0001). Post 
hoc analysis indicated that the 0.3 mg/kg dose of WIN55,212-2, but not lower or 
higher doses, significantly decreased the discrimination index of rats in the 
WITHOUT-habituation condition (P < 0.05; Figure 2a). In contrast, the same dose 
of WIN55,212-2 increased the discrimination index of rats in the WITH-
habituation condition (P < 0.05; Figure 2b). Two-way ANOVA for total exploration 
time of the two objects during the retention trial revealed no statistically 
significant effects of habituation condition, drug treatment or of the interaction 
between these two factors. Rats’ exploratory behavior of the apparatus during 
the test trial also did not differ between rats in the WITHOUT-habituation and 
WITH-habituation condition (Table 1). 
 
 Total object 
exploration time 
(s) 
Number of crossings Number of rearings 
WITHOUT 
Vehicle 28.2 ± 3.3 14.0 ± 1.3 17.5 ± 2.2 
WIN 0.1 21.3 ± 2.0 13.5 ± 1.2 15.5 ± 2.0 
WIN 0.3 23.2 ± 1.8 11.0 ± 1.5 15.9 ± 3.2 
WIN 1.0 22.8 ± 3.7 13.4 ± 2.4 14.9 ± 3.0 
WITH 
Vehicle 25.9 ± 3.3 15.0 ± 1.9 15.9 ± 1.5 
WIN 0.1 25.2 ± 3.3 14.6 ± 1.5 19.9 ± 3.2 
WIN 0.3 30.8 ± 4.0 14.3 ± 1.7 15.3 ± 1.7 
WIN 1.0 30.9 ± 3.9 12.6 ± 1.5 15.1 ± 2.2 
 
 
Posttraining WIN55,212-2 enhances 24-h retention of object recognition 
memory of rats in the WITHOUT-habituation but not in the WITH-habituation 
condition  
This experiment examined, in separate groups of rats, whether immediate 
posttraining injection of WIN55,212-2 influenced long-term performance on an 
Table 1. Exploratory behavior of rats in the WITHOUT- and WITH-habituation conditions at the 
1-h retention test 
Total time spent exploring the two objects (in seconds) and the number of crossings and rearings 
of all groups in the WITHOUT- and WITH-habituation conditions. Results are expressed as 
mean±SEM (n = 12 per group). 
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object recognition task and whether this WIN55,212-2 effect was also influenced 
by prior habituation to the experimental context. 
Training trial. The pattern of effects on the training trial was highly comparable 
to that observed in the first experiment. Two-way ANOVA for total exploration 
time of the two objects on the training trial revealed a significant habituation 
condition effect (F1,88 = 4.04, P = 0.05), but no differences between posttraining 
drug groups or an interaction between habituation condition and posttraining 
drug treatment. Rats in the WITHOUT-habituation condition explored the two 
objects significantly less (23.7 ± 1.3 s) than did rats in the WITH-habituation 
condition (28.2 ± 1.9 s) (t94 = -2.05, P < 0.05). Also, as found in the first 
experiment, rats in the WITHOUT-habituation condition showed significantly 
more exploration of the experimental apparatus than did rats in the WITH-
habituation condition, as indicated by a higher number of crossings (t94 = 2.89, P = 
0.005) and rearings (t94 = 2.92, P = 0.004). 
Retention trial. As expected, after a 3-min training trial, rats of both vehicle 
groups did not express long-term retention of the familiar object: One-sample t-
tests revealed no preference for the novel object in vehicle-treated rats in either 
the WITHOUT-habituation or WITH-habituation condition. As shown in Figure 3, 
posttraining WIN55,212-2 induced different effects on object recognition memory 
of rats in the WITHOUT-habituation and WITH-habituation groups at the 24-h 
retention interval. Two-way ANOVA for discrimination index indicated no main  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of posttraining administration of WIN55,212-2 on 24-h retention of rats in the 
WITHOUT- and WITH-habituation conditions. Posttraining administration of WIN55,212-2 (WIN, 0.3 
mg/kg, i.p.) enhanced 24-h retention of object recognition memory of rats in the WITHOUT-
habituation condition (A) and did not significantly affect 24-h retention of rats in the WITH-
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habituation condition (B). *P < 0.05 vs the corresponding vehicle control group. Data are expressed 
as mean ± SEM (n = 10–14 per group). 
effect of either drug treatment or habituation condition, but revealed a 
statistically significant drug treatment x habituation condition interaction (F3,88 = 
5.65, P = 0.001). WIN55,212-2 improved 24-h retention of rats in the WITHOUT-
habituation condition in an inverted U-shape relationship (F3,49 = 3.81, P = 0.02; 
Figure 3a), without significantly affecting 24-h retention of rats in the WITH-
habituation condition (F3,39 = 2.49, P = 0.07 Figure 3b). Post hoc analysis indicated 
that the 0.3 mg/kg dose of WIN55,212-2, but not lower or higher doses, 
administered to rats in the WITHOUT-habituation condition increased the 
discrimination index as compared with vehicle controls (P < 0.05). Two-way 
ANOVA for total exploration time of the two objects during the retention trial 
revealed a significant habituation condition effect (F1,88 = 6.67, P = 0.01), but no 
drug treatment effect or interaction between both factors (Table 2). Comparable 
to the findings of the first experiment, rats’ exploratory behavior of the 
experimental apparatus during the retention test trial did not differ between rats 
in the WITHOUT-habituation and the WITH-habituation conditions (Table 2). 
 
 
 Total object 
exploration time 
(s) 
Number of crossings 
Number of 
rearings 
WITHOUT 
Vehicle 18.0 ± 1.7 13.2 ± 1.4 12.3 ± 1.2 
WIN 0.1 19.9 ± 2.1 13.4 ± 1.2 12.2 ± 0.9 
WIN 0.3 15.5 ± 0.7 13.8 ± 1.6 14.3 ± 1.1 
WIN 1.0 22.6 ± 2.3 10.5 ± 0.9 11.8 ± 1.2 
WITH 
Vehicle 25.0 ± 3.8 13.9± 1.9 12.9 ± 1.2 
WIN 0.1 18.8 ± 1.7 11.0 ± 1.1 11.1 ± 1.5 
WIN 0.3 26.0 ± 3.9 12.9 ± 2.6 13.3 ± 2.6 
WIN 1.0 24.1 ± 2.3 10.3 ± 1.1 12.3 ± 2.2 
 
 
Posttraining WIN55,212-2 induces opposite effects on plasma corticosterone 
levels in rats in the WITHOUT-habituation and WITH-habituation condition 
Table 2. Exploratory behavior of rats in the WITHOUT- and WITH-habituation conditions at the 
24-h retention test 
Total time spent exploring the two objects (in seconds) and the number of crossings and 
rearings of all groups in the WITHOUT- and WITH-habituation conditions. Results are expressed 
as mean ± SEM (n = 10–14 per group). Results are expressed as mean ± SEM (n = 12 per group). 
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Figure 4 shows plasma corticosterone levels of parallel groups of trained rats in 
the WITHOUT-habituation or WITH-habituation condition, as assessed 30 min 
after  
 
 
 
 
 
 
 
 
Figure 4. Effect of object recognition training and posttraining administration of WIN55,212-2 on 
plasma corticosterone levels in rats in the WITHOUT- and WITH-habituation conditions. Plasma 
corticosterone levels in rats in the WITHOUT-habituation condition treated with vehicle posttraining 
were significantly higher than those in vehicle-injected rats in the WITH-habituation condition, as 
assessed 30 min after training; *P < 0.05 vs vehicle-treated rats in the WITH-habituation condition. 
Further, plasma corticosterone levels in vehicle-treated trained rats in both the WITHOUT- and 
WITH-habituation conditions were significantly higher than those in non-trained vehicle-treated 
rats; P < 0.01 vs vehicle-treated not exposed rats. WIN55-212,2 (WIN, 1 mg/kg, i.p.) 
administered immediately after object recognition training increased plasma corticosterone levels in 
rats in the WITHOUT-habituation condition; ##P < 0.01 vs the corresponding vehicle-treated control 
group. In contrast, WIN55,212-2 (0.3 mg/kg, i.p.) decreased plasma corticosterone levels in 
habituated rats; #P < 0.05 vs the corresponding vehicle-treated control group. Data are expressed as 
mean ± SEM (n = 4–7 per group). 
the training trial and WIN55,212-2 injection. Another group of rats was 
administered WIN55,212-2, but was only handled and not trained (home cage). 
Concerning plasma corticosterone levels in rats treated with vehicle only, one-way 
ANOVA revealed a significant habituation condition effect (F2,14 = 30.75, P < 
0.0001). Post hoc comparison tests showed that plasma corticosterone levels in 
rats in the WITHOUT-habituation condition treated with vehicle were significantly 
higher than those in vehicle-injected rats in the WITH-habituation condition (P < 
0.05), supporting the view that the habituation procedure efficiently suppressed 
the level of emotional arousal during the training trial. Further, plasma 
corticosterone levels in vehicle-treated trained rats in both the WITHOUT- and 
WITH-habituation conditions were significantly higher than those in non-trained 
vehicle-treated rats (P < 0.01 for both comparisons). 
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WIN55,212-2 induced opposite effects on plasma corticosterone levels in rats 
after object recognition training, depending on the level of emotional arousal at 
the time of drug administration. Two-way ANOVA revealed a significant 
habituation condition effect (F2,56 = 41.19, P < 0.0001), drug treatment effect (F3,56 
= 9.58, P < 0.0001) and interaction between both factors (F6,56 = 4.78, P = 0.0005). 
Post hoc analysis indicated that the 1.0 mg/kg dose of WIN55,212-2 elevated 
plasma corticosterone levels in rats in the WITHOUT-habituation condition (P < 
0.01). In contrast, the 0.3 mg/kg dose of WIN55,212-2, but not any of the other 
doses, decreased plasma corticosterone levels when administered to rats in the 
WITH-habituation condition (P < 0.05). WIN55,212-2 administration did not 
significantly alter plasma corticosterone levels in non-trained control rats.  
Adrenocortical suppression in rats in the without-habituation condition modifies 
the effect of posttraining WIN55,212-2 on short- and long-term object 
recognition memory 
The findings described above indicate that WIN55,212-2 administered to rats in 
the two habituation conditions not only induces opposite effects on short- and 
long-term retention of object recognition memory but also on plasma 
corticosterone levels. To determine whether the WIN55,212-2 effect on the 
corticosterone response contributes to how WIN55,212-2 influences object 
recognition memory, in the last experiment we investigated whether 
pharmacological suppression of adrenocortical activity with metyrapone (35 
mg/kg, i.p.), administered to non-habituated rats 40 min prior to the training trial, 
altered the effects of posttraining WIN55,212-2 administration on short- and long-
term object recognition memory.  
Training trial. Two-way ANOVA for total exploration time of the two identical 
objects on the training trial revealed no significant metyrapone effect, no 
difference between posttraining WIN55,212-2 treatment groups or interaction 
between these two parameters. Two-way ANOVAs for the number of crossings 
and rearings on the training trial also did not reveal any significant metyrapone or 
later WIN55,212-2 treatment effect.  
One-hour retention. As shown in Figure 5a, pretreatment of rats in the 
WITHOUT-habituation condition with metyrapone transformed the effect of 
posttraining WIN55,212-2 administration on 1-h retention performance into that 
of rats in the WITH-habituation condition. Two-way ANOVA for discrimination 
index indicated no main effect of metyrapone or WIN55,212-2 treatment, but 
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revealed a significant metyrapone x WIN55,212-2 interaction effect (F1,35 = 11.83, 
P = 0.02). Comparable to the findings shown in Figure 2a, WIN55,212-2 (0.3 
mg/kg) administered alone to non-habituated rats immediately after the training  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of pretreatment with metyrapone on the effect of posttraining administration of 
WIN55,212-2 on 1- and 24-h retention of rats in the WITHOUT-habituation condition. Metyrapone 
(Mety, 35 mg/kg, i.p.) administered to rats in the WITHOUT-habituation condition 40 min before 
object recognition training reverted the impairing effect of posttraining WIN55,212-2 (WIN, 0.3 
mg/kg, i.p.) on 1-h retention (A) and the enhancing effect of WIN55,212-2 (0.3 mg/kg, i.p.) on 24-h 
retention (B). Both 1- and 24-h retention performance became very similar to those observed in low-
aroused rats in the WITH-habituation condition (see Figures 2B and 3B). *P < 0.05; **P < 0.01 vs the 
corresponding vehicle group, ##P < 0.01 vs the WIN55,212-2 alone group. Data are expressed as 
mean ± SEM (n = 9–12 per group). 
 
trial significantly decreased the discrimination index relative to that of vehicle-
treated rats (P < 0.05). However, in non-habituated rats pretreated with 
metyrapone, the same dose of WIN55,212-2 significantly increased the 
discrimination index (P < 0.05 vs vehicle) and thus highly resembled the 
WIN55,212-2 effect on 1-h retention as described above for rats in the WITH-
habituation condition (see, Figure 2b). Metyrapone pretreatment by itself did not 
significantly alter the discrimination index. Total exploration time of the two 
objects and rats’ exploratory behavior of the apparatus on the 1-h retention test 
did not differ between drug treatment groups (Table 3).  
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Total time spent exploring the two objects (in seconds) and the number of crossings and rearings of 
rats in the WITHOUT-habituation condition administered metyrapone (Mety, mg/kg, i.p.) 40 min 
prior to training and WIN55,212-2 (WIN, mg/kg, i.p.) immediately posttraining. Results are expressed 
as mean ± SEM (n = 10–12 per group). 
 
Twenty-four-hour retention. As shown in Figure 5b, pretreatment of non-
habituated rats with metyrapone also transformed the effect of posttraining 
WIN55,212-2 on 24-h retention performance into that of rats in the WITH-
habituation condition. Two-way ANOVA for discrimination index indicated no 
main effect of either metyrapone or WIN55,212-2 treatment, but revealed a 
significant metyrapone_WIN55,212-2 interaction effect (F1,40 = 4.94, P = 0.03). 
Comparable to the findings shown in Figure 3a, WIN55,212-2 (0.3 mg/kg)  
administration alone significantly increased the discrimination index of rats in 
the WITHOUT-habituation condition (P < 0.01). However, in rats pretreated with 
metyrapone, posttraining WIN55,212-2 administration did not significantly alter 
retention performance on the 24-h test trial, thus resembling the findings 
described above for rats in the WITH-habituation condition (see, Figure 3b). 
Metyrapone pretreatment alone did not significantly alter the discrimination 
index. Total exploration time of the two objects during the 24-h retention trial and 
rats’ exploratory behavior of the apparatus did not differ between drug treatment 
groups (Table 3).  
Plasma corticosterone levels. Table 4 shows the effect of metyrapone 
pretreatment and posttraining WIN55,212-2 administration on plasma 
corticosterone levels in rats in the WITHOUT-habituation condition, as assessed 
30 min after object recognition training and WIN55,212-2 administration. Rats 
treated with metyrapone 40 min prior to the training trial had significantly lower 
 
Treatment 
Total object 
exploration 
time (s) 
Number of 
crossings 
Number of 
rearings 
1-h Retention trial   
 Vehicle Vehicle 24.9 ± 2.3 12.7 ± 1.5 15.9 ± 3.0 
 Vehicle WIN 0.3 23.1 ±1.8 11.6 ± 1.5 14.9 ± 3.6 
 Mety 35 Vehicle 19.3 ± 2.2 11.9 ± 1.8 17.4 ± 2.8 
 Mety 35 WIN 0.3 21.4 ± 3.0 11.1 ±2.3 13.5 ± 3.0 
24-h Retention trial   
 Vehicle Vehicle 21.3 ± 3.5 14.5 ± 1.5 8.3 ± 0.9 
 Vehicle WIN 0.3 16.5 ± 0.8 15.5 ± 0.8 12.1 ± 1.2 
 Mety 35 Vehicle 25.4 ± 3.0 15.3 ± 2.3 12.1 ± 1.9 
 Mety 35 WIN 0.3 20.3 ± 3.1 14.2 ± 2.4 11.6 ± 2.5 
Table 3. Exploratory behavior of rats in the WITHOUTH-habituation condition injected with 
metyrapone and WIN55,212-2 at the 1- and 24-h retention tests 
91 
 
plasma corticosterone levels than rats administered vehicle before training (t8 = 
3.44, P = 0.009). In rats pretreated with metyrapone, posttraining WIN55,212-2 
administration did not significantly elevate plasma corticosterone levels.  
 
 
 
Mety WIN Cort, ng/ml 
Vehicle Vehicle 245.3 ± 12.7 
Mety 35 Vehicle 158.1 ± 22.0** 
Mety 35 WIN 0.1 190.0 ± 47.8 
Mety 35 WIN 0.3 222.8 ± 40.4 
Mety 35 WIN 1.0 180.1 ± 20.3 
 
 
 
 
Discussion  
Using a previously described habituation procedure, we show that the 
synthetic cannabinoid agonist WIN55,212-2 interacts with training-associated 
emotional arousal in influencing both short- and long-term object recognition 
memory. Furthermore, our findings indicate that the cannabinoid system shapes 
the response of the HPA-axis to emotional arousal and that this neuroendocrine 
action is importantly involved in determining how WIN55,212-2 might affect 
object recognition memory. WIN55,212-2, administered systemically immediately 
after object recognition training, biphasically impaired retention at a 1-h interval 
in rats that were not habituated to the experimental context. In contrast, the 
same dose of WIN55,212-2 enhanced 1-h retention of rats that had reduced 
novelty-induced emotional arousal because of extensive prior habituation to the 
experimental context. Additionally, immediate posttraining administration of 
WIN55,212-2 to non-habituated rats, in a dose that impaired 1-h retention, 
enhanced object recognition performance at a 24-h interval. Posttraining 
WIN55,212-2 administration did not significantly affect 24-h retention of 
Table 4. Plasma corticosterone levels in rats in the WITHOUT-habituation 
condition injected with Metyrapone and WIN55,212-2 at the 1- and 24-h 
retention tests 
Plasma corticosterone (Cort) levels (mean ± SEM) in ng/ml in rats in the 
WITHOUT-habituation condition as assessed 30 min after the training trial. 
Metyrapone (Mety, mg/kg, i.p.), injected 40 min prior to training, reduced 
training-induced plasma corticosterone levels and prevented the increase in 
corticosterone plasma levels induced by posttraining WIN55,212-2 (WIN, mg/kg, 
i.p.) administration. **P < 0.01 vs the vehicle control group (n = 4–5 per group). 
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habituated rats. This habituation procedure also produced opposite cannabinoid 
effects on training-induced HPA-axis activity. WIN55,212-2 administration after 
object recognition training elevated plasma corticosterone levels in rats that were 
not previously habituated to the experimental context, but decreased levels in 
habituated rats. Most importantly, as non-habituated rats administered the 
corticosterone-synthesis inhibitor metyrapone prior to training and WIN55,212-2 
injection performed equally to extensively habituated rats on short- and long-
term retention tests, these findings indicate that cannabinoid-induced regulation 
of adrenocortical activity contributes to the environmentally sensitive effects of 
systemically administered cannabinoids on short- and long-term retention of 
object recognition memory. Table 5 summarizes our findings of WIN55,212-2 on 
both short- and long-term recognition memory and on adrenocortical activity.  
Table 5. Schematic representation of the effects of posttraining WIN55,212-2 on recognition 
memory 
Habituation condition Treatment 
Short-term memory 
effects 
Long-term memory 
effects 
WITHOUT WIN impairing enhancing 
WITH WIN enhancing --- 
WITHOUT WIN + Mety enhancing --- 
Schematic representation of the effects of posttraining WIN55,212-2 (WIN, 0.3 mg/kg, i.p.) either 
alone or together with the corticosterone-synthesis inhibitor metyrapone (Mety, 35 mg/kg, i.p.) on 
1- and 24-h retention performance in rats in the WITHOUT-habituation and WITH-habituation 
conditions. 
Clinical evidence indicates that cannabis use, either chronic consumption or acute 
intoxication, can impair both short-term memory and executive function (Pattij et 
al, 2008). Although some preclinical studies were able to confirm these findings 
(Baek et al, 2009; Kosiorek et al, 2003), the literature appears highly ambiguous 
(Clarke et al, 2008; Suenaga et al, 2008). In a previous study, we demonstrated 
that pretraining enhancement of endocannabinoid tone biphasically modified 
short-term retention of a recognition task in a spatial open field, and that this 
effect was likely influenced by the emotional state of the rat during the training 
trial (Campolongo et al, 2012). Here, we employed posttraining drug 
administration in order to more properly investigate the cognitive processes 
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involved and found that the level of emotional arousal at encoding influenced the 
outcome of later administration of the cannabinoid agonist WIN55,212-2 on both 
short- and long-term retention of object recognition memory. As vehicle-control 
rats in both habituation conditions showed a similar preference for the novel 
object at the 1-h retention interval, it is unlikely that any difference in acquisition 
(ie, total exploration of the objects during the training trial) between the two 
groups underlies the differential effects. It seems most likely that a difference in 
the arousal level induced by the habituation procedure was critical. The finding 
that non-habituated rats displayed significantly higher levels of locomotion and 
rearing behavior during the training trial than habituated rats is consistent with 
previous evidence that exposure of rats to novel contexts induces changes in 
behavioral responses, including hyperlocomotion and increased rearing behavior 
(Okuda et al, 2004; van den Buuse et al, 2001). Novelty-induced arousal also 
activates stress hormone systems, including glucocorticoids (Emmert and Herman, 
1999; Handa et al, 1994) and epinephrine (Feenstra et al, 2000; McQuade et al, 
1999). Corroborating previous findings by Okuda et al (2004), we found that non-
habituated rats had a significantly more pronounced training-induced increase in 
plasma corticosterone levels than habituated rats. Although these behavioral and 
endocrine measures clearly indicate that our habituation procedure efficiently 
reduced the level of emotional arousal during the training session, we cannot 
exclude the possibility that it is the stress history and not the level of emotional 
arousal per se that may be influencing cannabinoid effects on memory. Repeated 
exposure to the testing arena might be mildly stressful to the animals. Prior 
evidence indicated that a history of repeated (restraint) stress reduces CB1 
receptor function on GABAergic terminals within several brain regions involved in 
learning and memory (Hu et al, 2011; Patel et al, 2009). As such, the divergent 
effects of WIN55,212-2 on short-term retention of rats in the WITHOUT-
habituation and WITH-habituation groups may be due to a different ability of CB1 
receptor activation to suppress GABAergic inhibitory control because of the stress 
history of the animals and not the immediate levels of arousal during the training 
session. In both scenarios, however, our findings show that the cannabinoid 
system exerts an environmentally sensitive modulation of short-term memory. As 
WIN55,212-2 levels are probably still elevated at the time of the 1-h retention 
test, it is most likely that WIN55,212-2 affected short-term retention performance 
via direct influences on the retrieval of memory processing (Atsak et al, 2012a).  
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Whereas clinical studies mainly focused on the potentially disruptive effects of 
cannabinoid drugs on short-term cognitive performance, findings of animal 
experiments provide extensive evidence that cannabinoid treatments also 
influence long-term memory. However, findings of these experiments have been 
conflicting as well. Some studies reported that cannabinoid agonists impair the 
consolidation of long-term memory of training on several tasks (Barros et al, 2004; 
Robinson et al, 2008), whereas others found enhancing effects (De Oliveira 
Alvares et al, 2008). Differences in dosage or drug administration regimen (eg, 
pretraining vs posttraining administration) could have contributed to these 
opposite findings. Here we show that, similar to WIN55,212-2 effects on short-
term memory, the level of emotional arousal at encoding, or alternatively the 
stress history of the animals, is another important factor modulating cannabinoid 
effect on long-term memory. WIN55,212-2 enhanced 24-h retention of rats that 
were not previously habituated to the experimental context, but failed to 
significantly alter performance of well-habituated rats. As WIN55,212-2 was 
administered immediately after the training trial, the effect of WIN55,212-2 on 
long-term retention is likely mediated by a selective influence on the 
consolidation of memory (McGaugh and Roozendaal, 2002). Moreover, because 
retention testing took place 24 h after the training and drug treatment, it is 
unlikely that the effects are mediated by any residual pharmacological effects on 
directly influencing behavior during retention testing (Cahill et al, 2001).  
Clinical evidence supports the view that cannabis consumption can induce 
opposite effects on a variety of behaviors and subjective feelings in different 
individuals or even in the same subject (Green et al, 2003). Apart from genetic 
vulnerability (Xian et al, 2008), environmental factors such as stress-induced 
alterations could contribute to these differential effects (Viveros et al, 2012; Xian 
et al, 2008). Preclinical models have confirmed opposite effects of cannabinoid 
drugs on motor activity (Rodriguez de Fonseca et al, 1998), positive incentive 
and/or motivational processes (Chaperon and Thiebot, 1999), anxiety (Haller et al, 
2009) and fear-related behaviors (Moreira and Wotjak, 2011). Although 
differences in dose, route of administration, and timing of exposure are typically 
listed as being responsible for the opposite behavioral effects, recent findings 
indicate that variations in the stressfulness of the experimental conditions 
employed in the different studies are implicated as well. The general assumption 
that enhancement of cannabinoid levels via an inhibition of the anandamide-
degrading enzyme fatty acid amide hydrolase (FAAH) results in anxiolytic- and 
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antidepressant-like effects in rodents (Gobbi et al, 2005; Kathuria et al, 2003) has 
recently been revisited. Haller et al (2009) found robust anxiolytic-like effects of 
the FAAH inhibitor URB597 when rats were tested without prior habituation to 
the experimental room. However, URB597 administration did not induce any 
anxiolytic-like effect in rats that were habituated to the testing environment. 
Similarly, both low and high doses of delta-9-tetrahydrocannabinol, the main 
psychoactive constituent of cannabis preparations, exerted anxiolytic-like effects 
in non-stressed animals (Fokos and Panagis, 2010). In stressed animals, however, 
only the higher dose of delta-9-tetrahydrocannabinol induced an anxiolytic-like 
response whereas the lower dose induced an anxiogenic effect. Our present 
findings are thus very reminiscent of these other behaviors and indicate that the 
level of emotional arousal that is associated with the training procedure is also a 
key regulator of cannabinoid effects on both short- and long-term recognition 
memory.  
Considering the extensive evidence indicating a close relationship between the 
cannabinoid system and HPA-axis activity (Armario, 2010; Barna et al, 2004), we 
explored the possibility that the divergent effects of systemic WIN55,212-2 
administration on object recognition memory might be related to differential 
effects of WIN55,212-2 on training-induced glucocorticoid levels in rats in these 
two habituation conditions. Our findings indicate that WIN55,212-2 
administration produced opposite effects on training-induced plasma 
corticosterone levels in habituated vs non-habituated rats. Generally, these 
findings are thus consistent with the evidence that the cannabinoid system is an 
important regulator of HPA-axis activity and consequently of the release of 
glucocorticoid hormones (Cota et al, 2007; Ganon-Elazar and Akirav, 2009). Our 
finding that WIN55,212-2 induced opposite effects on HPA-axis activity in rats in 
the two habituation conditions has a twofold interest. First, these findings might 
help to reconcile earlier observations that cannabinoid administration can both 
activate and inhibit the HPA-axis (Cota et al, 2007; Ganon-Elazar et al, 2009). 
Second, as extensive evidence indicates that glucocorticoid hormones influence 
both short- and long-term memory of emotionally arousing experiences 
(Roozendaal et al, 2009; Schwabe et al, 2012), these findings suggest the 
intriguing possibility that this arousal-dependent influence of WIN55,212-2 on the 
HPAaxis might contribute to the observed opposite effects of WIN55,212-2 on 
both short- and long-term memory. Highly comparable to our present findings 
with WIN55,212-2, it has been previously reported that corticosterone 
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administration after object recognition training impaired short-term performance 
in emotionally aroused non-habituated rats (Okuda et al, 2004; Roozendaal et al, 
2006b). Moreover, corticosterone enhanced 24-h retention performance of rats 
that were not previously habituated to the experimental context. Corticosterone 
administration to well-habituated rats failed to affect either short- or long-term 
object recognition performance. Even though the dose of WIN55,212-2 that 
affected memory function in the non-habituated rats did not overlap entirely with 
its efficacious dose on corticosterone levels, our assumption was confirmed by the 
finding that adrenocortical suppression with the corticosterone-synthesis inhibitor 
metyrapone in non-habituated rats altered the effect of posttraining WIN55,212-2 
administration on both short- and long-term recognition memory in such a way 
that performance became similar to that seen in habituated animals. Thus, these 
findings provide strong support for the view that a WIN55,212-2-induced 
potentiation of glucocorticoid secretion plays an important role in determining 
the pattern of cannabinoid effects on memory in these animals.  
Previously, we showed that the cannabinoid and glucocorticoid effects on 
memory might converge within the basolateral amygdala (BLA). The possible 
interaction of these two systems was originally investigated for memory 
consolidation of inhibitory avoidance training (Campolongo et al, 2009b) but 
similar mechanisms might exist in other brain regions for regulating other 
memory functions (Atsak et al, 2012a). Extensive evidence indicates that the BLA 
preferentially modulates memory of emotionally arousing training experiences 
(McGaugh, 2000) and that arousal-induced activation of noradrenergic signaling 
plays an important role herein (Quirarte et al, 1997; Roozendaal, 2002; 
Roozendaal et al, 2004; Roozendaal et al, 2006a). In prior studies, we showed that 
training-induced noradrenergic activity within the BLA is required for enabling the 
modulatory influence of glucocorticoids on memory (Quirarte et al, 1997). As 
habituation to the object recognition apparatus is known to attenuate training-
induced increases in noradrenergic activity (Roozendaal et al, 2006b), we 
previously hypothesized that glucocorticoids might not modulate memory of 
object recognition training in habituated rats because of inadequate levels of 
arousal-induced norepinephrine. In support of this interpretation, we found that 
stimulating noradrenergic activity with the α2-adrenoceptor antagonist yohimbine 
was sufficient to enable glucocorticoid-induced memory enhancement in 
habituated rats (Roozendaal et al, 2006b). Recent findings indicate that the 
endocannabinoid system within the BLA might be importantly involved in 
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regulating glucocorticoid effects on memory (Campolongo et al, 2009b). 
Systemically administered corticosterone rapidly elevates endocannabinoid levels 
in the amygdala (Hill et al, 2010a), whereas a blockade of CB1 receptor activity in 
the BLA prevents corticosterone-induced memory enhancement (Campolongo et 
al, 2009b). On the basis of these findings, we previously proposed a model in 
which glucocorticoids bind to a membrane-bound receptor in the BLA that 
activates a G-protein signaling cascade to stimulate the synthesis of 
endocannabinoids. The ensuing release of endocannabinoid ligands could diffuse 
to local GABAergic terminals and inhibit GABA release onto noradrenergic 
terminals in the BLA (Campolongo et al, 2009a; Hill and McEwen, 2009). 
Importantly, as recent findings indicate that the β-adrenoceptor antagonist 
propranolol infused into the BLA also prevented the memory-enhancing effect of 
WIN55,212-2 (Hauer et al, 2010), it is thus possible that, comparable to the effects 
of glucocorticoids, cannabinoid effects on memory are also dependent on the 
availability of sufficient levels of arousal-induced noradrenergic activity within the 
BLA. On top of this direct interaction of WIN55,212-2 with arousal-induced 
noradrenergic mechanisms within the brain, the opposite effects of WIN55,212-2 
on circulating corticosterone levels might add to the environmentally sensitive 
effects of cannabinoids on both short- and long-term recognition memory. 
In summary, we provide evidence that cannabinoid effects on short- and long-
term retention of recognition memory depend on the level of novelty-induced 
emotional arousal. These cannabinoid effects likely involve, at least in part, 
peripheral actions on modulating HPA-axis activity. These findings shed light on 
the contrasting effects of cannabinoid drugs on memory processing, thus 
providing new evidence that cannabinoid compounds can be either beneficial or 
detrimental to memory processes depending on the affective state of the 
individual at the time of drug consumption. 
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Abstract 
Compelling evidence indicates that cannabinoid drugs often induce biphasic 
effects on cognitive and emotional behavior depending on the aversiveness of the 
environmental context and the level of emotional arousal. It has been shown that 
variation in environmental aversiveness differentially influences spatial memory 
retrieval in rats and that glucocorticoids interact with the endocannabinoid 
system in impairing contextual aversive memory retrieval. Based on these 
findings, we investigated the role of the hippocampal endocannabinoid system on 
spatial memory retrieval in rats under two experimental conditions that differed 
with respect to their training- and test-associated arousal levels. To this aim male 
adult Sprague Dawley rats were trained in a Morris Water Maze task at two 
different water temperatures (19° C and 25° C) in order to elicit different levels of 
emotional arousal. First, we examined the arousal effects on spatial memory in 
vehicle treated rats and found that they showed a better retention and retrieval 
of the behavioral task. In a second set of experiments, 60 min before the retrieval 
trial the cannabinoid agonist WIN55,212-2 was bilaterally infused into the 
hippocampus. We found that WIN55,212-2 impaired memory retrieval only in rats 
trained under the high arousing condition (19° C) and such effect was blocked by a 
concurrent infusion with a nonimpairing dose of the cannabinoid type 1 receptor 
(CB1) antagonist AM251. In a third set of experiments, by employing the same 
experimental protocol, we examined whether the endogenous cannabinoid 
anandamide (AEA) and/or 2-arachidonoylglycerol (2-AG) could modulate spatial 
memory retrieval as well. To this aim the AEA hydrolysis inhibitor URB597 or the 
2-AG hydrolysis inhibitor JZL184 were infused bilaterally into the hippocampus 60 
min before the retrieval trial. We found that URB597 did not alter spatial memory 
retrieval performances in any of the two experimental conditions. Interestingly, 
highly comparable with WIN55,212-2 effects, JZL184 impaired spatial memory 
retrieval only in rats trained at the lower, high-arousing, temperature via an 
interaction with CB1 receptors. Consistently, in the high aroused rats, we found 
an increase in hippocampal 2-AG levels, but not AEA, after the training and probe 
trials, and alterations in CB1 affinity and in the activity of the main 2-AG 
degradative enzyme after the probe. The present findings indicate that the 
hippocampal endocannabinoid system plays a key role in mediating emotional 
arousal effects on spatial memory retrieval, shedding light on the neurobiological 
mechanism involved in the differential impact of stress on memory processes.  
106 
 
Introduction  
Growing evidence demonstrates that the endocannabinoid system is crucially 
involved in the modulation of cognitive functions (Akirav, 2011; Campolongo et 
al, 2009b; Kano et al, 2009; Marsicano and Lafenetre, 2009; Wotjak, 2005). The 
main constituents of the endocannabinoid system are the cannabinoid receptor 
type 1 and type 2 (CB1 and CB2, respectively) (Devane et al, 1992; Herkenham 
et al, 1990; Matsuda et al, 1990) and the two major endogenous ligands for 
these receptors, the N-arachidonoyl ethanolamine (anandamide, AEA) (Devane 
et al, 1992) and the 2-arachidonoyl glycerol (2-AG) (Sugiura et al, 1995). In 
contrast to other classical neurotransmitters, AEA and 2-AG are not stored in 
vesicles at the presynapse, but are synthesised on demand and use a retrograde 
signaling by traveling from post- to presynaptic neurons where the cannabinoid 
receptors are expressed (Kano et al, 2009). Endocannabinoids bind to G protein-
coupled CB1 receptors at presynaptic sites to regulate ion channel activity and 
neurotransmitter release (Kano et al, 2009). AEA and 2-AG are subsequently 
taken back into the cell by a still poorly defined uptake process mediated by a 
transporter mechanism (Fu et al, 2011; Hillard et al, 1997) and enzymatically 
degraded by the fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase 
(MAGL) (Kano et al, 2009). CB1 receptors are highly expressed within cortico-
limbic brain areas such as the basolateral complex of the amygdala (BLA), 
hippocampus and the prefrontal cortex (PFC) (Herkenham et al, 1991; Tsou et al, 
1998) where they crucially modulate learning and memory processes for 
emotionally arousing experiences (Akirav, 2011; Campolongo et al, 2009b; Kano 
et al, 2009; Marsicano et al, 2009; Wotjak, 2005). Although there is a large 
number of contradictory reports in the literature regarding cannabinoid effects 
with respect to different memory phases (Morena and Campolongo, 2013) and 
the literature related to cannabinoid effects on retrieval is fairly limited, it 
seems that no controversy exists in this regard. Detrimental effects of 
cannabinoid receptor agonism on memory retrieval have been reported when 
administered either systemically (Mishima et al, 2001; Niyuhire et al, 2007) or in 
discrete brain areas such as the hippocampus (Atsak et al, 2012; Piri and 
Zarrindast, 2011; Segev and Akirav, 2011) and the BLA (Segev et al, 2011), at 
least under the experimental conditions investigated thus far. We recently 
reported that cannabinoid effects on memory retrieval are strictly related to the 
aversiveness of the environmental conditions and on the level of stress at the 
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time of drug injection, in such a way that systemic injections of the CB1 receptor 
agonist WIN55,212-2 induces opposing results on short-term object recognition 
memory retrieval depending on the level of context-induced emotional arousal 
(Campolongo et al, 2013). It has been previously reported that the 
endocannabinoid system within the BLA (Campolongo et al, 2009b) and 
hippocampus (de Oliveira Alvares et al, 2010) is crucially involved in mediating 
glucocorticoid impairing effects on memory consolidation. Furthermore, we 
recently showed that glucocorticoids interact with endocannabinoids in 
impairing contextual aversive memory retrieval (Atsak et al, 2012). It is well 
established that glucocorticoids have multiple effects on the different memory 
phases (Lupien and McEwen, 1997). The effects of stress and glucocorticoids on 
memory follow an inverted U-shaped dose-response relationship: extreme low 
and high levels may impair consolidation, but intermediate doses enhance 
memory (Mendl, 1999; Sandi and Pinelo-Nava, 2007; Yerkes, 1908). Likewise, it 
has been shown that variation in environmental aversiveness differentially 
influences spatial memory processes in rats (Akirav et al, 2004; Salehi et al, 
2010). Salehi and coworkers (2010) induced different levels of stress in rats 
trained in a radial arm water maze task using three water temperatures (25°C, 
19°C, and 16°C), which elicited increased plasma corticosterone levels: An 
inverted-U shape effect was found, with animals trained at 19°C showing a 
better memory retention than animals trained at either higher (16°C) or lower 
(25°C) stress conditions (Salehi et al, 2010). Once memories are consolidated, 
the efficacy or accuracy of the information retrieved remains vulnerable to 
glucocorticoids at the time of recall. Indeed stress or exogenous glucocorticoid 
administration typically impair memory of contextual/spatial information in rats 
and declarative information in human subject (de Quervain et al, 2009; de 
Quervain et al, 1998; de Quervain et al, 2000; Roozendaal et al, 2004a; 
Roozendaal et al, 2003; Roozendaal et al, 2004b). We recently demonstrated 
that glucocorticoids impair contextual fear memory retrieval by interacting with 
the endocannabinoid 2-AG within the hippocampus (Atsak et al, 2012), a brain 
region importantly implicated in the processing of spatial and contextual 
information (Meck et al, 1984; Morris et al, 1982; Moser et al, 1993). Based on 
the evidence summarized above, we investigated the role of the hippocampal 
endocannabinoid system on spatial memory retrieval in rats under two 
experimental conditions that differed with respect to their environment-
induced stress level. Rats were divided into two main groups (high aroused and 
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low aroused) and trained in a Morris water maze task under two different water 
temperatures (19°C and 25°C) in order to elicit different levels of stress. In the 
first set of experiments we pharmacologically modulated the hippocampal 
endocannabinoid system to evaluate its putative role in the modulation of spatial 
memory retrieval under the two different stressful conditions. We next 
investigated whether there could be any alteration of endocannabinoid release in 
response to different stressful conditions with the final aim to evaluate how such 
alteration might underlie differential cannabinoid drug effects on spatial memory 
retrieval. Therefore, in the second part of this study hippocampal AEA and 2-AG 
levels were measured after training and probe trials in high aroused, low aroused 
and naïve (home-cage) rats. We further analyzed whether such changes could be 
related to any alteration of the cannabinoid hydrolytic enzymatic machinery or to 
the hippocampal CB1 receptor functionality.  
Materials and Methods 
Animals. Male adult Sprague-Dawley rats (320-370 g at the time of behavioral 
experiments; Charles River Laboratories, Calco, Italy) were individually housed in a 
temperature-controlled (20±1°C) vivarium and maintained under a 12 h light/dark 
cycle (07:00 AM-07:00 PM lights on). Food and water were available ad libitum. 
Training and testing were performed during the light phase of the cycle between 
10:00 AM to 04:00 PM. All experimental procedures were in compliance with the 
guidelines of the U.S. National Institutes of Health and the Italian Ministry of 
Health (D.L. 116/92) and the European Communities Council Directive of 24 
November 1986 (86/609/EEC). 
Surgery. The rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) 
and given atropine sulfate (0.4 mg/kg, i.p.) to maintain respiration, and were 
subsequently injected with 3 mL of saline (s.c.) to facilitate clearance of these 
drugs and prevent dehydration. The rats were then placed in a stereotaxic frame 
(David Kopf Instruments, Tujunga, CA, USA), and 2 stainless-steel guide cannulae 
(23 gauge) were implanted bilaterally, with the cannula tips 1.5 mm above the 
CA1 region of the dorsal hippocampus ⦋11 mm; coordinates: AP, -3.4 mm; ML, 
±1.8 mm; DV, -2.7 mm⦌ according to the atlas of Paxinos and Watson (Paxinos and 
Watson, 2005). The cannulae were affixed to the skull with 2 anchoring screws 
and dental cement. Stylets (11-mm-long 00 insect dissection pins) were inserted 
into each cannula to maintain patency. After surgery, the rats were retained in an 
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incubator until recovered from anesthesia and were then returned to their home 
cages. Rats were allowed to recover from surgery for 10 days before training. The 
rats were handled 1 min per day for 3 days before training. 
Water maze task and experimental procedures. The experimental apparatus was a 
circular, black galvanized tank, 1.83 m in diameter and 0.6 m in height, filled with 
water to a depth of 20 cm. The maze was located in a room containing many 
salient, visual, extra-maze cues. A rectangular hidden platform (20 cm x 25 cm) 
was placed at a fixed location 25 cm away from the edge of the pool and 2.5 cm 
below the water. We used a slightly modified procedure of one previously 
described (Campolongo et al, 2009a). On each day of training, the rats were 
carried from the vivarium to the laboratory, and training began 120 min later. For 
spatial training, the rats were given four trials on each daily session for 2 
consecutive days. This relatively small number of trials was chosen such that 
retention performance of control animals was moderate and drug administration 
could either enhance or impair performance. Before the first training trial, the rat 
was placed directly on the submerged platform for 15 sec. On each of the trials 
the rat was placed into the tank at one of the four designated starting points and 
allowed to find and escape onto the platform. If an animal failed to find the 
platform within 60 sec, it was manually guided to the platform. After mounting 
the platform, the rat was allowed to remain there for 10 sec and then it was 
placed into a holding cage for 25 sec until the start of the next trial. The time each 
rat spent to reach the platform was recorded as the escape latency. Retention of 
the spatial training was assessed 24 hr after the last training session with a 60 sec 
free-swim probe trial using a new starting position. The probe trial was 
videotaped and an automated tracking system (Panlab S.L.U., Varese, Italy) 
analyzed the swim path of each subject and calculated several corresponding 
dependent measures such as time spent in the quadrant containing the platform 
during training (target quadrant), time spent in the quadrant opposite to the 
target quadrant (opposite quadrant), initial latency to cross the platform location, 
number of crossings through the platform location, and total swim distance. The 
target and opposite quadrants were equidistant from the starting position used 
on the probe trial. In order to induce different experimental conditions with 
respect to their context-associated stress intensity, separate groups of animals 
were trained and tested at different water temperatures (25°C or 19°C) which 
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were previously shown to be appropriate temperatures to elicit different stress 
levels in rats (Akirav et al, 2004). 
Drug treatment. The CB1 agonist WIN55,212-2 (10 or 30 ng in 0.5 µl), the FAAH 
inhibitor URB597 (10 or 30 ng in 0.5 µl) or the MAGL inhibitor JZL184 (0.1 or 1 µg 
in 0.5 µl) were administered into the hippocampus. To examine whether the 
effects of WIN55,212-2 and JZL184 were mediated via a selective activation of 
CB1 receptors, in other groups of rats the effective dose of WIN55,212-2 (10 ng in 
0.5 µl) or JZL184 (1 µg in 0.5 µl) was infused either alone or concurrently with a 
non-impairing dose of the CB1 receptor antagonist AM251 (0.28 ng in 0.5 µl). Each 
dose was chosen on the basis previous pilot experiments conducted in our 
laboratory. All drugs were dissolved in a vehicle containing 5% Polyethylene 
glycol, 5% Tween80 and 90% saline and administered in the hippocampus 60 min 
before the probe trial in order to test animals for spatial memory retrieval. 
Bilateral infusions of drugs or an equivalent volume of vehicle into this brain 
region were given 60 min before the probe trial by using a 30 gauge injection 
needle connected by polyethylene tubing (PE-20) to a 10 µl Hamilton microsyringe 
driven by a minipump (KD Instruments, Varese, Italy). The injection needle 
protruded 1.5 mm beyond the tip of the cannula and a 0.5 µl injection 
volume/hemisphere was infused at a rate of 0.37 µl/min. The injection needles 
were retained within the cannulae for an additional 20 s after drug infusion to 
maximize diffusion and to prevent backflow of drug into the cannulae. The 
infusion volume for the hippocampus was based on findings that infusions of this 
volume administered into the dorsal hippocampus produce different effects on 
the two-phase inhibitory avoidance task (Malin and McGaugh, 2006). All drugs 
were purchased from Tocris Bioscience and freshly prepared before each 
experiment. 
Histology. The rats were anesthetized with an overdose of sodium pentobarbital 
(100 mg/kg, i.p.) and perfused intracardially with a 0.9% saline solution. The 
brains were then removed and immersed in a 4% formaldehyde solution. At least 
48-h before sectioning, the brains were transferred to a 20% sucrose solution in 
saline for cryoprotection. Coronal sections of 35 µm were cut on a cryostat, 
mounted on gelatin coated slides, and stained with cresyl violet. The sections 
were examined under a light microscope (Microscope Nikon 801, Florence, Italy), 
and the location of infusion needle tips in the hippocampus was made according 
to the standardized atlas plates of Paxinos and Watson (Paxinos et al, 2005) by an 
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observer blind to drug treatment condition. For all experiments, only rats with 
needle tips within the boundaries of the hippocampus were included in the data 
analysis. Approximately 14% of the animals were excluded from analysis because 
of either cannula misplacement or damage to the targeted tissue.  
Endocannabinoid extraction and analysis. AEA and 2-AG endocannabinoid levels in 
the hippocampus were measured 20 min after the two days of training and 
immediately after the probe on naïve rats trained (and tested) under different 
water temperatures (25°C or 19°C). After rapid decapitation, the hippocampus 
was dissected within 3 min and stored at -80°C. Brain samples were subjected to a 
lipid extraction process and the endocannabinoid content of the lipid extracts was 
determined using isotope-dilution, liquid chromatography−mass spectrometry as 
previously described (Hauer et al, 2011).  
Membrane preparation. Immediately after the probe trial, following rapid 
decapitation, the hippocampus was dissected from rats trained and tested under 
the high arousing or the low arousing conditions and from home-cage rats. Brain 
samples were stored at -80°C. Membranes were collected from hippocampi by 
the homogenization of frozen tissue in 10 volumes of TME buffer (50 mM Tris HCl, 
pH 5 7.4; 1 mM ethylenediaminetetraacetic acid [EDTA], and 3 mM MgCl2). 
Homogenates were then centrifuged at 18,000g for 20 min and the resulting 
crude membrane fraction-containing pellet was resuspended in 10 volumes of 
TME buffer. Protein concentrations were determined using the Bradford method 
(Bio-Rad, Hercules, CA). 
CB1 receptor radioligand-binding assay. CB1 receptor agonist binding parameters 
were determined using radioligand binding as previously described (Lee and Hill). 
Bmax (maximal binding site density) and Kd (binding affinity) values were 
determined by nonlinear curve fitting of specific binding data to the single site 
binding equation using GraphPad Prism (GraphPad, LaJolla, CA, USA). 
FAAH activity assay. FAAH activity from hippocampal membranes was measured 
by conversion of AEA labeled with [3H] in the ethanolamine portion of the 
molecule to [3H] ethanolamine preparations as reported earlier (Lee et al). The 
binding affinity of AEA for FAAH (Km) and maximal hydrolytic activity of FAAH 
(Vmax) values for this conversion were determined by fitting the data to the 
Michaelis–Menten equation using GraphPad Prism (GraphPad, LaJolla, CA, USA). 
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MAGL activity assay. MAGL activity was measured by conversion of 2-
oleoylglycerol labeled with [3H] ([3H] 2-OG) in the glycerol portion of the 
molecule to [3H] glycerol preparations. Membranes were incubated in a final 
volume of 0.5 ml TME buffer (50 mM Tris-HCl, 3.0 mM MgCl2, 1.0 mM EDTA, and 
300 nM URB597, pH 7.4) that contained 1.0 mg/ml fatty acid-free bovine serum 
albumin and 100,000 dpm [3H] 2-OG. Isotherms were constructed using six 
concentrations of 2-OG at concentrations between 10 µM and 500 µM. Incubation 
was carried out at 30°C and the enzymatic reaction was stopped by the addition 
of 2 ml of chloroform/methanol (1:2). After remaining in room temperature for 30 
min with frequent mixing, 0.67 ml of chloroform and 0.6 ml of water were added 
and aqueous and organic phases were separated by centrifugation at 1000 rpm 
for 10 min. The amount of [3H] in 0.5 ml each of the aqueous and organic phases 
was determined by liquid scintillation counting and conversion of [3H] 2-OG to 
[3H] glycerol was calculated. The Km and Vmax values for this conversion were 
determined by fitting the data to a single-site Michaelis–Menten equation using 
GraphPad Prism (GraphPad, LaJolla, CA, USA). 
Statistics. Water maze training data were analyzed with one or two-way ANOVAs 
with the 2 acquisition trainings as repeated measure. Water maze measurements 
on probe trial for vehicle treated rats were analyzed with unpaired t tests and 
two-way ANOVA. Water maze measurements on probe trial for all the other 
experimental groups were analyzed with one-, two-, or three-way ANOVAs. 
Endocannabinoid brain levels, CB1 binding, FAAH and MAGL activity parameters 
were analyzed with one-way ANOVAs. The source of the detected significances 
was determined by Tukey–Kramer post hoc tests. Data were expressed as mean ± 
SEM. P values of less than 0.05 were considered statistically significant. The 
number of rats per group is indicated in the figure legends. 
Results 
High arousal condition enhances spatial memory retention and retrieval in 
vehicle-treated rats 
We first analyzed possible behavioral differences in rats trained and tested under 
the two different water temperatures (25 °C and 19 °C) during the training days 
(before any drug treatment), and during the probe trial (after vehicle infusions).  
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A one-way ANOVA as repeated measures on the mean escape latencies to find the 
hidden platform during the two training days revealed a significant effect of 
training days (F(1,74) = 203.03, P < 0.0001), confirming that the two groups of 
animal progressively learned the spatial location of the platform across the 
training sessions. Interestingly, ANOVA also revealed a significant training days x 
water temperature effect (F(1,74) = 7.38, P = 0.0082). Post-hoc analysis indicated 
that rats trained under the high arousal conditions (19 °C-water temperature) 
presented lower mean escape latencies on the second day of training as 
compared with rats trained at 25 °C (P < 0.01; Fig. 1), thus indicating that high  
 
 
 
 
 
 
 
 
 
 
 
aroused rats had a better memory retention of the task. As shown in Fig. 2 the 
high arousal condition improved spatial memory retrieval in rats. Unpaired t-tests 
revealed that rats under the high arousal condition spent less time to initially 
cross the platform location (t74= -3.72; P = 0.0004; Fig. 2A) and performed a higher 
number of crossings through the platform location (t74= 2.97; P = 0.0041; Fig. 2B) 
as compared to low aroused rats. The pattern of effects for quadrant search times 
was similar to that for initial latency to cross the platform location and number of 
target crossings (Fig. 2C). A two-way ANOVA for time spent in searching the 
platform location revealed no water temperature effect (F(1,148) = 0.85, P = 0.36) 
but a significant quadrant (F(1,148) = 171.18, P < 0.0001) and water temperature x 
quadrant interaction effect (F(1,148) = 4.30, P = 0.039). Both groups of vehicle-
infused rats acquired correctly the behavioral task. Indeed they exhibited memory 
of the platform position during trainings, as indicated by significantly longer 
search times in the vicinity of the platform location (i.e., in the target quadrant) 
than in the opposite quadrant (P < 0.01; Fig. 2C). Interestingly, rats under the 
lower, high arousing, water temperature spent significantly less time in the   
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Figure 1. Effect of water temperature on training 
performances of vehicle treated rats.  Both rats 
trained at 25 °C and 19 °C acquired the behavioral 
task as indicated by a significant difference 
between mean escape latencies during training 1 
and training 2. Rats trained at 19 °C showed a 
better memory performance that rats at 25 °C 
during training 2. ** P < 0.01 vs training 1; , P < 
0.01 between mean escape latencies at 25 °C vs 
mean escape latencies at 19 °C. Results represent 
mean ± SEM (n = 36-40 per group).  
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opposite quadrant than rats under the higher water temperature (P < 0.01; Fig. 
2C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To examine possible differences in motor performance that may have been 
caused by the different water temperatures, the swimming distances during the 
probe trial of the different groups were compared. No significant differences were 
found between swimming distances of the two experimental groups (t74 = 0.35; P 
= 0.73; data not shown). 
Intra-hippocampal infusion of the CB receptor agonist WIN55,212–2 impairs 
spatial memory retrieval through the activation of the CB1 receptor under high 
arousal but not low arousal condition 
This experiment investigated whether intra-hippocampal infusions of the 
cannabinoid receptor agonist WIN55,212-2 60 min before the probe trial altered 
spatial memory retrieval and whether this WIN55,212-2 effect was influenced by 
the different water temperatures.  
25° C-water temperature. All rats learned to locate the platform position during 
the days of training before drug treatment, as indicated by decreasing mean 
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Figure 2. The high arousal condition (19 °C) 
enhanced spatial memory retrieval in rats. 
High aroused rats (19° C) spent less time to 
first cross the platform location (A) and 
performed a higher number of target 
crossings (B) during probe as compared 
with the low aroused group (25 °C). (C) 
Both experimental groups spent more time 
in the target quadrant than in the opposite 
quadrant in searching the platform 
location. High aroused rats spent less time 
in the opposite quadrant that low aroused 
rats. Representative probe trial swim paths 
of low aroused (D) and high aroused rats 
(E). **, P < 0.01 vs low aroused group; ##, 
P < 0.01 vs the correspondent opposite 
quadrant; §, P < 0.05 vs opposite quadrant 
time of low aroused group. All results 
represent mean ± SEM (n = 36-40 per 
group). 
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escape latencies as training progressed (F(1,32) = 95.96, P < 0.0001); data not 
shown). As shown in Fig. 3A-B-C, intra-hippocampal infusions of WIN55,212-2 60 
min before the probe trial did not induce any alteration on spatial memory 
retrieval in rats under the low arousal conditions. One-way ANOVAs for the initial 
latency to cross the platform location (i.e. crossing latencies) and for the number 
of crossings through the platform location (target crossings) did not reveal a 
significant WIN55,212-2 effect (F(2,32) = 0.50, P = 0.62; F(2,32) = 0.52, P = 0.60; 
respectively, Fig. 3A-B). A two-way ANOVA for quadrant search times during the 
probe trial showed a significant quadrant effect (F(1,64) = 59.30, P < 0.0001), but did 
not reveal a significant drug effect (F(2,64) = 0.13, P = 0.88), or an interaction 
between both factors (F(2,64) = 0.65, P = 0.52). Post-hoc analysis revealed that all 
the experimental groups spent longer search times in the target quadrant than in 
the opposite quadrant (P < 0.01; Fig 3C), thus indicating that animals exhibited 
memory of the platform position during training. To examine possible differences 
in motor performance that may have been caused by the different drug 
treatments, the total swim distances during the probe trial of the different groups 
were compared. No significant differences were found between total swim 
distances of the experimental groups (F(2,32) = 0.77; P = 0.47; data not shown).  
19° C-water temperature. All animals progressively learned the spatial location of 
the platform across the training sessions before drug treatment, as indicated by 
decreasing mean escape latencies as training progressed (F(1,31) = 140.88, P < 
0.0001; data not shown). Figures 3D-E-F show that intra-hippocampal infusions of 
WIN55,212-2 60 min before the probe trial impaired spatial memory retrieval in 
rats under the high arousal condition. One-way ANOVAs for crossing latencies and 
for target crossings during the probe trial revealed a significant WIN55,212-2 
effect (F(2,31) = 3.53, P = 0.041; F(2,31) = 5.78, P = 0.0074; respectively, Fig. 3D-E). The 
10 ng/0.5 μl dose of WIN55,212-2, but not the higher dose, significantly increased 
the crossing latencies (P < 0.05; Fig. 3D) and, conversely, decreased the number of 
crossings through the platform location (P < 0.01; Fig. 3E) of rats trained and 
tested at the lower temperature as compared with the respective control groups. 
A two-way ANOVA for quadrant search times during the probe trial showed a 
significant quadrant effect (F(1,62) = 109.23, P < 0.0001), no drug effect (F(2,62) = 
9.23, P = 0.56), and a significant interaction between both factors (F(2,62) = 7.37, P = 
0.0013). Post-hoc analysis revealed that all the experimental groups spent longer 
time swimming in the target quadrant than in the opposite quadrant (P < 0.01; 
Fig. 3F), thus indicating that animals exhibited memory of the platform position 
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during trainings. Further, time spent by rats administered with WIN55,212-2 (10-
30 ng/0.5 μL) in searching the platform location in the target quadrant was 
shorter than that of vehicle-treated group (P < 0.05; Fig. 3F). No significant 
differences were found between total swim distances of the three experimental 
groups during the probe trial (F(2,31) = 0.46; P = 0.63; data not shown), thus 
demonstrating that drug infusions did not alter locomotor activity in rats under 
the high arousal condition.  
To investigate whether hippocampal CB1 receptors might mediate the impairing 
effect of WIN55,212-2 treatment on retrieval of spatial memory, bilateral 
infusions of a non-impairing dose of the CB1 receptor antagonist AM251 (0.28 ng 
in 0.5 μl) were concurrently administered into the dorsal hippocampus 60 min 
before retention testing together with the effective dose of WIN55,212-2 (10 
ng/0.5 μl) or with vehicle. Repeated-measures ANOVA for mean escape latencies 
during trainings showed that all groups acquired the Morris water maze task as 
indicated by decreasing latencies to find the hidden platform between days (F(1,44) 
= 209.55; P < 0.0001; data not shown). As shown in Fig. 3G-H, two-way ANOVAs 
for crossing latencies and number of target crossings during testing for memory 
retrieval revealed a significant main effect of WIN55,212-2 (F(1,44) = 8.99; P = 
0.0044; F(1,44) = 5.37; P = 0.025; for crossing latencies and target crossings, 
respectively), no AM251 effect (F(1,44) = 3.43; P = 0.071; F(1,44) = 2.81; P = 0.10; for 
crossing latencies and target crossings, respectively) and a significant interaction 
effect between these two treatments (F(1,44) = 5.59; P = 0.023; F(1,44) = 7.22; P = 
0.010; for crossing latencies and target crossings, respectively). Tukey’s post hoc 
comparisons showed that intra-hippocampal infusions of WIN55,212-2 alone 
significantly increased the initial time to cross the platform location (P < 0.01; Fig. 
3G) and decreased the number of target crossings (P < 0.05; Fig. 3H) as compared 
with rats given vehicle. Initial crossing latencies of rats given WIN55,212-2 
together with AM251 were significantly shorter than those of rats given 
WIN55,212-2 alone (P < 0.05; Fig. 3G) and equivalent to those of rats given vehicle 
and AM251 alone. Consistently, the number of target crossings of rats given 
WIN55,212-2 with AM251 were significantly higher than those of rats given 
WIN55,212-2 alone (P < 0.05; Fig. 3H) and equivalent to those of rats given vehicle 
and AM251 alone.  
A three-way ANOVA for quadrant search times during the probe trial revealed no 
main effect of WIN55,212-2 (F(1,88) = 1.18; P = 0.28) but a significant AM251 (F(1,88) = 
4.95; P = 0.029), quadrant (F(1,88) = 191.75; P < 0.0001) and WIN55,212-2 x AM251  
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Figure 3. Intra-hippocampal infusions of the cannabinoid agonist WIN55,212-2 (WIN) did not affect 
spatial memory retrieval in the low arousal condition (25 °C), but did impair it in the high arousal 
condition (19 °C). The CB1 antagonist AM251 (0.28 ng/0.5 µl) blocked the memory impairing effect 
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induced by a concurrent administration with the effective dose of WIN (10 ng/0.5 µl; WIN 10) under 
the high arousal condition. Effects of WIN on the latency to first cross the platform location (A), the 
number of target crossings (B) and the time spent in the target and opposite quadrants (C) during 
the 1-min probe trial at 25 °C. Effects of WIN on the latency to first cross the platform location (D), 
the number of target crossings (E) and the time spent in the target and opposite quadrants (F) 
during the 1-min probe trial at 19 °C. Effects of WIN+AM251 administration on the latency to first 
cross the platform location (G), the number of target crossings (H) and the time spent in the target 
and opposite quadrants (I) during the 1-min probe trial at 19 °C. (J) Representative probe trial swim 
paths. *, P < 0.05, **, P < 0.01 vs the correspondent vehicle (veh) group; ##, P < 0.01 vs the 
correspondent opposite quadrant; , P < 0.05, , P < 0.01  vs target quadrant time of vehicle 
group; $, P < 0.05, $$, P < 0.01 vs the correspondent WIN+AM251 group. All results represent mean 
± SEM (n = 9-14 per group).  
 x quadrant interaction effect (F(1,88) = 4.20; P = 0.043; Fig. 3I). Control rats 
given vehicle infusions into the hippocampus spent significantly more time in 
the target quadrant than in the opposite quadrant (P < 0.01; Fig. 3I). As was 
found in the previous experiment, WIN55,212-2 infused into the hippocampus 
60 min before probe decreased time spent in the target quadrant (P < 0.01, 
compared with vehicle; Fig. 3I). Although pretest administration of AM251 into 
the hippocampus alone did not affect time spent in either the target or the 
opposite quadrants, AM251 blocked the changes induced by co-infusion with 
WIN55,212-2 into the hippocampus. Rats given combined infusions of AM251 
and WIN55,212-2 spent significantly more time in the target quadrant (P < 
0.01; Fig. 3I) than rats given WIN55,212-2 alone and on this measure did not 
differ significantly from control rats given either vehicle or AM251 infusions 
into the hippocampus. Two-way ANOVA for total swim distance did not reveal 
significant WIN55,212-2 (F(1,44) = 0.006; P = 0.94), AM251 (F(1,44) = 0.34; P = 
0.56), or WIN55,212-2 x AM251 interaction effects (F(1,44) = 0.13; P = 0.72; data 
not shown). 
Intra-hippocampal infusion of the AEA hydrolysis inhibitor URB597 does not 
affect spatial memory retrieval of rats neither in the low arousal nor in the 
high arousal conditions 
We next examined whether the endogenous cannabinoid AEA could modulate 
spatial memory retrieval. To this aim the FAAH inhibitor URB597 was 
bilaterally infused into the hippocampus 60 min before the probe trial in rats 
trained and tested under different water temperatures. 
25° C-water temperature. All rats learned to locate the platform position 
during the trainings before drug treatment, as indicated by decreasing mean 
escape latencies as training progressed (F(1,33) = 86.99, P < 0.0001); data not 
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shown). As shown in Fig. 4A-B-C, intra-hippocampal infusions of URB597 60 
min before the probe trial did not induce any alteration on spatial memory 
retrieval in rats under the low arousal condition. One-way ANOVAs for the 
initial latency to cross the platform location and for the number of crossings 
through the platform location did not reveal a significant URB597 effect (F(2,33) 
= 0.077, P = 0.93; F(2,33) = 0.69, P = 0.51; respectively, Fig. 4A-B). A two-way 
ANOVA for quadrant search times during the probe trial showed a significant 
quadrant effect (F(1,66) = 112.69, P < 0.0001), but did not reveal a significant 
drug effect (F(2,66) = 0.16, P = 0.86), or an interaction between both factors 
(F(2,66) = 2,35, P = 0.10). Post-hoc analysis revealed that all the experimental 
groups spent longer time in the target quadrant than in the opposite quadrant 
(P < 0.01; Fig. 4C), thus indicating that they exhibited memory of the platform 
position during trainings. No significant differences were found between total 
swim distances of the experimental groups (F(2,66) = 0.053; P = 0.95; data not 
shown).  
19° C-water temperature. A one-way ANOVA as repeated measures on the 
mean escape latencies to find the hidden platform on the two training days 
revealed a significant effect of training days (F (1,28) = 84.23, P < 0.0001 data not 
shown), confirming that rats progressively learned the spatial location of the 
platform across the training sessions. Figures 4D-E-F shows that intra-
hippocampal infusions of URB597 60 min before the probe trial did not alter 
spatial memory retrieval in rats under the high arousal conditions. One-way 
ANOVAs for crossing latencies and for target crossings during the probe trial 
did not reveal significant drug effects (F(2,28) = 0.36, P = 0.70; F(2,28) = 0.62, P = 
0.55; respectively, Fig. 4D-E). A two-way ANOVA for quadrant search times 
during the probe trial showed a significant quadrant effect (F(1,56) = 82.64, P < 
0.0001), but no drug (F(2,56) = 0.084, P = 0.92), or quadrant x drug effects (F (2,56) 
= 1.56, P = 0.22). Post-hoc analysis revealed that all the experimental groups 
spent longer time swimming in the target quadrant than in the opposite 
quadrant (P < 0.01; Fig. 4 F), thus indicating that animals exhibited memory of 
the platform position during training. No significant differences were found 
between total swim distances of the three experimental groups during the 
probe trial (F(2,28) = 0.52; P = 0.60; data not shown). 
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Figure 4. Intra-hippocampal infusions of the FAAH inhibitor URB597 (URB) did not affect spatial 
memory retrieval in either of the two different arousing conditions. Effects of URB on the latency to 
first cross the platform location (A), the number of target crossings (B) and the time spent in the 
target and opposite quadrants (C) during the 1-min probe trial at 25 °C. Effects of URB on the latency 
to first cross the platform location (D), the number of target crossings (E) and the time spent in the 
target and opposite quadrants (F) during the 1-min probe trial at 19 °C. ##, P < 0.01 vs the 
correspondent opposite quadrant. All results represent mean ± SEM (n = 9-13 per group).  
Intra-hippocampal infusion of the 2-AG hydrolysis inhibitor JZL184 impairs 
spatial memory retrieval through the activation of the CB1 receptor under high 
arousal but not low arousal conditions 
Given the previous results, we further examined whether the endogenous 
cannabinoid 2-AG could modulate spatial memory retrieval as well. To this aim 
the MAGL inhibitor JZL184 was bilaterally infused into the hippocampus 60 min 
before the probe trial in rats trained and tested under different water 
temperatures. 
25° C-water temperature. All the experimental groups learned to find the platform 
position during the two days of training, before drug treatment, as indicated by 
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decreasing mean escape latencies between training days (F(1,36) = 114.30, P < 
0.0001; data not shown). As shown in Fig. 5A-B-C, intra-hippocampal infusions of 
JZL184 60 min before the probe trial did not induce any alteration on spatial 
memory retrieval in rats under the low arousal conditions. Initial latencies to cross 
the platform location and the number of target crossings of rats in this 
experiment are presented in Fig. 5A-B. One-way ANOVAs did not reveal a 
significant JZL184 effect (F(2,36) = 0.24, P = 0.79; F(2,36) = 0.37, P = 0.69; for crossing 
latencies and target crossings, respectively, Fig. 5A-B). A two-way ANOVA for 
quadrant search times during the probe trial showed a significant quadrant effect 
(F(1,72) = 47.31, P < 0.0001), but did not reveal a significant drug effect (F(2,72) = 0.45, 
P = 0.64), or an interaction between both factors (F(2,72) = 0.19, P =0.83). Post-hoc 
analysis revealed that all the experimental groups spent longer search times in the 
vicinity of the platform location than in the opposite quadrant (P < 0.01; Fig. 5 C), 
thus indicating that animals exhibited memory of the platform position during 
trainings. To examine possible differences in motor performance that may have 
been caused by the different drug treatments, the total swim distance during the 
probe trial of the different groups were compared. No significant differences were 
found between total swim distances of the three experimental groups (F(2,36) = 
0.008; P = 0.99; data not shown).  
19° C-water temperature. All animals progressively learned the spatial location of 
the platform across the training sessions before drug treatment, as indicated by 
decreasing mean escape latencies as training progressed (F(1,26) = 119.11, P < 
0.0001; data not shown).  
Highly comparable with WIN55,212-2 effects, Fig. 5D-E-F shows that intra-
hippocampal infusions of JZL184 60 min before the probe trial impaired spatial 
memory retrieval in rats under the high arousal condition. One-way ANOVAs for 
crossing latencies and target crossings during the probe trial revealed a significant 
JZL184 effect (F(2,26) = 4.28, P = 0.025; F(2,26) = 5.99, P = 0.0073; for crossing 
latencies and target crossings, respectively, Fig. 5D-E). The 1 μg/0.5 μl dose of 
JZL184, but not the lower dose, significantly increased the crossing latencies (P < 
0.05; Fig. 5D) and, conversely, both doses of JZL184 (0.1-1 μg/0.5 μl) decreased 
the number of crossings through the platform location (P < 0.05; Fig. 5E) of rats 
trained and tested at the lower temperature as compared with the respective 
control groups. As shown in Fig. 5F, a two-way ANOVA for quadrant search times 
during the probe trial showed a significant quadrant effect (F(1,52) = 59.30, P < 
0.0001), no drug effect (F(2,52) = 0.17, P = 0.84), and a significant interaction 
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between both factors (F(2,52) = 7.05, P = 0.002). Post hoc analysis revealed that 
control rats given vehicle infusions into the hippocampus spent significantly more 
time in the target quadrant than in the opposite quadrant (P < 0.01; Fig. 5F), thus 
indicating that animals acquired the behavioral task. The 1 μg/0.5 μl dose of 
JZL184, but not the lower dose, infused into the hippocampus 60 min before 
retention testing decreased time spent in the target quadrant to a chance level 
and increased time spent in the opposite quadrant (P < 0.05 vs control group, for 
both comparisons; Fig. 5 F). No significant differences were found between total 
swim distances of the three experimental groups during the probe trial (F(2,26) = 
2.44; P = 0.11; data not shown), thus demonstrating that drug infusion did not 
alter locomotor activity in rats under the high arousal condition.  
This experiment examined whether CB1 receptor activation in the hippocampus 
may be essential in enabling JZL184 effects on memory retrieval. To this aim the 
CB1 receptor antagonist AM251 (0.28 ng/0.5 μl) was concurrently infused 
bilaterally into the dorsal hippocampus 60 min before retention testing together 
with the effective dose of JZL184 (1 µg/0.5 μl) or with vehicle.  
All groups acquired the Morris water maze task as indicated by decreasing 
latencies to find the hidden platform between days (F(1,41) = 123.48; P < 0.0001; 
data not shown).  Figures 5G-H-I shows the effect of intra-hippocampal infusions 
of AM251 (0.28 ng/0.5 μL) on probe trial retrieval impairment induced by intra-
hippocampal infusion of JZL184. Two-way ANOVAs for crossing latencies and 
number of target crossings during testing for memory retrieval revealed 
significant JZL184 (F(1,41) = 9.56; P = 0.0036; F(1,41) = 5.90; P = 0.02; for crossing 
latencies and target crossings, respectively), AM251 (F(1,41) = 8.24; P = 0.0065; F(1,41) 
= 4.28; P = 0.045; for crossing latencies and target crossings, respectively) and 
JZL184 x AM251 interaction effects (F(1,41) = 9.79; P = 0.0032; F(1,41) = 10.55; P = 
0.0023; for crossing latencies and target crossings, respectively). Intra-
hippocampal infusion of JZL184 alone significantly increased the initial time to 
cross the platform location (P < 0.01; Fig. 5G) and decreased the number of target 
crossings (P < 0.01; Fig. 5H) as compared with rats given vehicle. Initial crossing 
latencies of rats given JZL184 together with AM251 were significantly shorter than 
those of rats given JZL184 alone (P < 0.01; Fig. 5G) and equivalent to those of rats 
given vehicle and AM251 alone. Consistently, the number of target crossings of 
rats given JZL184 with AM251 were significantly higher than those of rats given 
JZL184 alone (P < 0.01; Fig. 5H) and equivalent to those of rats given vehicle and 
AM251 alone. A three-way ANOVA for time spent in the target quadrant revealed   
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Figure 5. Intra-hippocampal infusions of the MAGL inhibitor JZL184 (JZL) did not affect spatial 
memory retrieval in the low arousal condition (25 °C), but did impair it in the high arousal condition 
(19 °C). The CB1 antagonist AM251 (0.28 ng/0.5 µl) blocked the memory impairing effect induced by 
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a concurrent administration with the effective dose of JZL (1 µg/0.5 µl; JZL 1) under the high arousal 
condition. Effects of JZL on the latency to first cross the platform location (A), the number of target 
crossings (B) and the time spent in the target and opposite quadrants (C) during the 1-min probe 
trial at 25 °C. Effects of JZL on the latency to first cross the platform location (D), the number of 
target crossings (E) and the time spent in the target and opposite quadrants (F) during the 1-min 
probe trial at 19 °C.  Effects of JZL+AM251 administration on the latency to first cross the platform 
location (G), the number of target crossings (H) and the time spent in the target and opposite 
quadrants (I) during the 1-min probe trial at 19 °C. (J) Representative probe trial swim paths. *, P < 
0.05, **, P < 0.01 vs the correspondent vehicle (veh) group; ##, P < 0.01 vs the correspondent 
opposite quadrant; , P < 0.05, vs target quadrant time of vehicle group; §, P < 0.05 vs opposite 
quadrant time of vehicle group; $$, P < 0.01 vs the correspondent JZL+AM251 group. All results 
represent mean ± SEM (n = 8-14 per group).  
no main effects of JZL184 (F(1,82) = 0.76; P = 0.39) or AM251 (F(1,82) = 1.52; P = 0.22) 
on quadrant search times during the probe trial (Fig. 5I). However, there was a 
significant quadrant (F(1,82) = 141.89; P < 0.0001) and JZL184 x AM251 x quadrant 
interaction effect (F(1,82) = 7.18; P = 0.0089). Control rats given vehicle infusions 
into the hippocampus spent significantly more time in the target quadrant than in 
the opposite quadrant (P < 0.01; Fig. 5I). As was found in the previous experiment, 
JZL184 infused into the hippocampus 60 min before probe decreased time spent 
in the target quadrant (P < 0.05, compared with vehicle; Fig 5I). Although pretest 
administration of AM251 into the hippocampus alone did not affect time spent in 
either the target or the opposite quadrant, AM251 blocked the changes induced 
by coadministration of JZL184 into the hippocampus. Rats concurrently infused 
with AM251 and JZL184 spent significantly more time in the target quadrant (P < 
0.01; Fig. 5I) than rats given JZL184 alone without significantly differing from 
control rats given either vehicle or AM251 alone. Two-way ANOVA for total swim 
distance did not reveal significant JZL184 (F(1,41) = 0.008; P = 0.93), AM251 (F(1,41) = 
1.69; P = 0.20), or JZL184 x AM251 interaction effects (F(1,41) = 1.21; P = 0.28; data 
not shown). 
High arousal but not low arousal condition increases hippocampal 2-AG levels 
during spatial memory consolidation and retrieval of the Morris water maze 
task 
Previous findings have shown that rats, 20 min after a Morris water maze training 
at 19 °C water temperature, performed better and presented higher levels of 
plasma corticosterone than rats trained at 25 °C (Akirav et al, 2004). Therefore we 
investigated whether such increase in stress hormone levels could alter 
endocannabinoid hippocampal levels and, thus, modulate spatial memory 
processes. To this aim parallel groups of rats were trained at 19 °C or 25 °C water 
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temperature and sacrified 20 min after the two days of training for brain tissue 
dissection and subsequent endocannabinoid measurements in the hippocampus. 
To assess whether the possible alteration in endocannabinoid hippocampal levels 
might underlie the different effects in memory retrieval observed in the previous 
experiments, other groups of rats were sacrified immediately after the 1-min 
probe trial. Control rats (home cage) were only handled and sacrified at the same 
time points. We did not found any alteration in hippocampal AEA levels in any of 
the experimental groups. One-way ANOVAs for hippocampal AEA levels did not 
reveal any experimental condition effect (F(2,22) = 1.03; P = 0.37; F(2,23) = 1.46; P = 
0.25; F(2,25) = 0.94; P = 0.40, for training 1, training 2 and probe, respectively; Table 
1). However, as shown in Table 1, one-way ANOVAs for hippocampal 2-AG levels  
Table 1. Hippocampal endocannabinoid concentration of low aroused (25 °C), high 
aroused (19 °C) and home cage rats. 
Time point 
Anandamide  
(pmol/g tissue) 
2-Arachidonoylglycerol 
 (nmol/g tissue) 
Home 
cage  
19 °C 25 °C 
Home 
cage 
19 °C 25 °C 
20 min after 
training 1 
5.8 ± 0.4 7.1 ± 0.5 7.3 ± 1.5 4.3 ± 0.4 6.7 ± 1.0*
,#
 3.6 ± 0.3 
20 min after 
training 2 
8.7 ± 1.7 6.7 ± 0.9 5.9 ± 0.8 3.5 ± 0.3 5.3 ± 0.4**
#
, 3.9 ± 0.3 
Immediately 
after probe 
7.8 ± 1.3 7.0 ± 0.9 6.1 ± 0.4 4.7 ±  0.7  7.8 ± 1.1*
,#
 4.7 ± 0.5 
*, P < 0.05, **, P < 0.01 vs the corresponding home cage group, 
#
, P < 0.05 vs the corresponding 25 
°C group. Data are expressed as mean ± SEM (n = 7 – 10 per group). 
after trainings 1, training 2 and probe, revealed a significant experimental 
condition effect (F(2,19) = 6.14; P = 0.0088; F(2,23) = 7.91; P = 0.0024; F(2,24) = 4.68; P = 
0.019, respectively). Rats trained at 19 °C presented higher levels of 2-AG than 
both rats in the 25 °C group and home cage rats as assessed 20 min after training 
1 (P < 0.05; for both comparisons; Table 1), training 2 (P < 0.05 vs low aroused 
group; P < 0.01 vs home cage group; Table 1) and immediately after probe (P < 
0.05; for both comparisons; Table 1). Thus, our findings that high arousal 
conditions elevates 2-AG levels in the hippocampus, suggest that hippocampal 
endocannabinoid signaling is critically involved in mediating the stress effects on 
retrieval of contextual fear memory. 
High arousal and low arousal conditions modulates hippocampal CB1 receptor 
binding during spatial memory retrieval  
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This experiment investigates whether the level of stress associated to the 
different water temperatures might induce any alteration on hippocampal CB1 
receptor binding during memory retrieval. Three different groups of rats (high 
aroused, low aroused and home cage) were sacrified immediately after the 1-min 
probe trial for hippocampal tissue dissection. As shown in Table 2, one-way 
ANOVA for CB1 receptor Bmax revealed a significant experimental condition 
effect (F(2,15) = 8.24; P = 0.0039). Interestingly, both rats in the high arousal and low 
arousal conditions exhibited lower levels of the CB1 receptor binding site densities 
relative to home cage animals (P < 0.01; for both comparisons; Table 2), thus 
suggesting that the degree of emotional arousal associated to the behavioral task 
per se, independently from the different water temperatures, might induce such 
alterations. No main experimental condition effect was found for CB1 receptor 
binding affinity (F(2,15) = 1.64; P = 0.23; Table 2). 
Table 2. Bmax and Kd values for CB1 receptor radioligand binding assay and Vmax and Km 
values for FAAH and MAGL activity assay in low aroused (25 °C), high aroused (19 °C) and 
home cage rats. 
Parameter 
CB1 binding assay 
Home cage 19 °C 25 °C 
Bmax (pmol/mg protein) 1.6 ± 0.04 1.3 ± 0.05** 1.3 ± 0.1** 
Kd (nM) 1.6 ± 0.3 1.3 ± 0.1 1.2 ± 0.1 
 FAAH activity assay 
 Home cage 19 ° C 25 °C 
Vmax (pmol/mg protein/min) 1961.3 ± 178.6 1710.0 ± 115.6 1889.8 ± 118.2 
Km (nM) 0.84 ± 0.1 0.86 ± 0.1 0.85 ± 0.1 
 MAGL activity assay 
 Home cage 19 ° C 25 °C 
Vmax (nmol/mg protein/min) 61.5 ± 4.5 71.3 ± 7.7 62.8 ± 2.3 
Km (nM) 40.5 ± 5.5 61.8 ± 4.9*
,#
 36.1 ± 4.1 
*, P < 0.05, **, P < 0.01 vs the corresponding home cage group, #, P < 005 vs the corresponding 25 
°C group. Data are expressed as mean ± SEM (n = 3- 6 per group). 
High arousal but not low arousal condition modulates hippocampal MAGL 
activity during spatial memory retrieval, without altering the activity of FAAH 
These experiments investigate whether the level of stress associated to the 
different water temperatures might induce any alteration on hippocampal FAAH 
and MAGL activity during memory retrieval. Three different groups of rats (high 
aroused, low aroused and home cage) were sacrified immediately after the 1-min 
probe trial for hippocampal tissue dissection.  
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As shown in Table 2, one-way ANOVAs for Vmax and Km of FAAH did not reveal 
any significant experimental condition effect (F(2,15) = 0.85; P = 0.45; F(2,15) = 0.28; P 
= 0.76; for Vmax and Km, respectively). Interestingly, one-way ANOVAs for Km, 
but not for Vmax, of MAGL did exhibit a significant experimental condition effect 
(F(2,8) = 7.04; P = 0.017; F(2,8) = 1.12; P = 0.37; for Km and Vmax, respectively; Table 
2). Post hoc comparisons, indicated that the behavioral task performed at 19 °C 
water temperature increased the MAGL Km value as compared to those of home 
cage and low aroused rats (P < 0.05, for both comparisons; Table 2).  
Discussion 
In the present study we demonstrate that a pharmacologically-induced increase 
of hippocampal 2-AG levels mediates the impairment of spatial memory retrieval 
for a high emotionally arousing, but not a low emotionally arousing version of a 
Morris water maze task. Furthermore our findings indicate that the high 
emotionally arousing version of this behavioral task induce molecular changes in 
the endocannabinoid system components that mediate a better memory 
consolidation and retrieval in naïve animals. 
We first evaluated spatial memory performance in naïve rats and, accordingly 
with previous findings (Akirav et al, 2001; Salehi et al, 2010; Sandi et al, 1997), we 
found that rats trained and tested under moderate level of stress (19°C water 
temperature) presented a better memory consolidation and retrieval than rats 
under the low arousing condition (25°C water temperature).  
Bilateral intra-hippocampal infusions of the cannabinoid agonist WIN55,212-2, 
given 60 min before testing rats for memory retrieval, impaired such memory 
process only in animals trained under the high arousing condition. Furthermore 
we found that such effect was mediated by the activation of CB1 receptors, since 
a concurrent infusion of a non-impairing dose of the CB1 antagonist AM251 
blocked the memory impairing effects of WIN55,212-2. In a second set of 
experiments, by employing the same experimental protocol, we examined 
whether the endogenous cannabinoids AEA and/or 2-AG could modulate spatial 
memory retrieval as well. To this aim the AEA hydrolysis inhibitor URB597 or the 
2-AG hydrolysis inhibitor JZL184 were infused bilaterally into the hippocampus 60 
min before the probe trial. We found that URB597 did not alter spatial memory 
retrieval performances in any of the two experimental conditions. Interestingly, 
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highly comparable with WIN55,212-2 effects, JZL184 impaired spatial memory 
retrieval only in rats trained at the lower, high-arousing, temperature via the 
activation of CB1 receptors. This experimental protocol also produced different 
biochemical effects on the cannabinoid system. The higher stressful experimental 
conditions induced an increase in hippocampal 2-AG levels, without altering 
hippocampal AEA levels, after the training and probe sessions. Consistently, 
immediately after testing rats for memory retrieval, we found an alteration in the 
binding affinity for MAGL in animals under the high arousing condition without 
observing any alteration in the hippocampal FAAH activity. Hippocampal CB1 
receptors functionality analysis showed a decrease in maximal binding site density 
for both high aroused and low aroused rats.  
Previous findings demonstrated that rats trained in a Morris water maze at 19 °C 
exhibited both better memory consolidation and retrieval than rats trained at 25 
°C (Akirav et al, 2004; Akirav et al, 2001; Sandi et al, 1997). A more recent study 
reported that animals trained in a radial arm water maze task showed an inverted 
U-shape memory function according with the stressfulness of the experimental 
conditions employed (Salehi et al, 2010). Performance of rats trained at 19 °C was 
more accurate than that of animals trained at either higher (16 °C) or lower (25 
°C) stress conditions (Salehi et al, 2010). It has also been shown that rats trained 
at 19 °C presented higher levels of corticosterone than rats trained at 16° C and 
lower than animals trained at 25 °C (Akirav et al, 2004; Akirav et al, 2001; Salehi et 
al, 2010; Sandi et al, 1997). Accordingly, our results showed a stronger memory 
consolidation, as indicated by shorter latencies to find the hidden platform during 
the second day of training, in rats in the high arousal conditions relative to low 
aroused animals. It is possible that the experimental conditions have elicited a 
different release of corticosterone depending on the level of stress induced by the 
two water temperatures and, subsequently, such hormone may have affected 
differentially memory consolidation mechanisms of the two groups of rats. 
Importantly, our results strongly support the current view that stress (and 
glucocorticoids) facilitates memory consolidation (de Quervain et al, 2009; Oitzl 
and de Kloet, 1992; Roozendaal et al, 2008; Roozendaal et al, 1999; Sandi et al, 
2007; Sandi and Rose, 1994). Our findings fall in line with the proposed inverted 
U-shaped dose-response relationship between stress and memory performance 
(Lupien et al, 1997). Extreme low and high levels of stress and glucocorticoids 
impair consolidation, whereas moderate activation seems to be a prerequisite for 
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the long-term storage of information (Conrad et al, 1997; Diamond et al, 1992; 
Diamond et al, 1999; Flood et al, 1978; Liu et al, 1999; Oitzl et al, 1994). The 
differential behavioral performances exhibited by rats trained at different water 
temperatures might account for the first raising part of the inverted U-shaped 
curve. Consistently, high aroused rats, also showed a better memory retrieval of a 
strongly consolidated training, relative to low aroused rats.  
Extensive cognitive and neurobiological research on animals, healthy human 
subjects, and amnesic patients indicates that the hippocampus is an important 
brain region involved in memory retrieval (Brun et al, 2002; Cabeza and Nyberg, 
2000; Eldridge et al, 2000; Hirsch, 1974; Holt and Maren, 1999; Matus-Amat et al, 
2004; Moser and Moser, 1998; Riedel et al, 1999; Schacter and Wagner, 1999; 
Squire et al, 2001) and is also a primary target of stress hormones (Reul and de 
Kloet, 1985). CB1 receptors are also abundantly expressed on hippocampal 
GABAergic terminals and, to a minor extent, glutamatergic terminals (Katona et al, 
1999). Findings of several studies indicates that stress and glucocorticoids 
typically impair memory retrieval in both animal and human subjects (de Quervain 
et al, 2009; de Quervain et al, 1998; Roozendaal, 2000; Roozendaal et al, 2004a). 
We have recently shown that blockade of hippocampal CB1 receptors with local 
infusions of AM251 prevented the glucocorticoid-induced impairment of 
contextual fear memory retrieval thus indicating that endocannabinoid signaling 
plays an important role in regulating stress effects on this memory phase (Atsak et 
al, 2012). Moreover, we also found that intra-hippocampal infusions of 
WIN55,212–2 impaired the retrieval of contextual fear memory (Atsak et al, 
2012). Here we showed that cannabinoid impairing effects on memory retrieval 
are strictly dependent on the level of emotional arousal associated to the 
experimental condition. Indeed we found that intra-hippocampal infusions of 
WIN55,212–2 in high aroused rats impaired spatial memory retrieval and such 
effect was mediated by the activation of CB1 receptors, since hippocampal 
infusion of AM251 blocked the WIN55,212–2 impairing effect. Conversely, the 
same pharmacological manipulation did not induce any effect on memory in low 
aroused rats. Accordingly with our findings, intra-hippocampal infusions of 
WIN55,212–2 have been reported to impair memory retrieval of high arousing 
test situations (Piri et al, 2011; Segev et al, 2011). We further found that intra-
hippocampal infusions of the FAAH inhibitor URB597 did not alter memory 
performance in any of the two experimental conditions. Interestingly, highly 
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comparable with WIN55,212–2 effects, intra-hippocampal infusions of the 2-AG 
hydrolysis inhibitor JZL184 impaired memory retrieval via an indirect activation of 
CB1 receptors, only in high aroused rats. Taken together these findings 
demonstrated that hippocampal 2-AG, but not AEA, mediates memory retrieval 
impairment under high arousing situations. In accordance with these results, we 
previously showed that impairing effects on contextual fear memory retrieval 
induced by pretest corticosterone administration are mediated by an increase of 
hippocampal 2-AG (Atsak et al, 2012).  
Furthermore, we found that the high stressful experimental condition, in not-
treated rats, also induced an increase in hippocampal 2-AG, without altering AEA 
levels, 20 min after the training sessions and immediately after probe. These 
findings are consistent with previous evidence that stress and glucocorticoids 
rapidly alter endocannabinoid signaling in a variety of stress-responsive brain 
regions, including the hippocampus (Hill et al, 2010a; Hill and McEwen, 2010b). 
Although some controversy exists in the literature, stress has been shown to 
mobilize 2-AG while concurrently decreasing AEA levels in the hippocampus (Hill 
et al, 2010b; Patel and Hillard, 2008). Consistently with the increase in 2-AG levels, 
we also found that the high arousing training procedure at 19 °C did not alter 
FAAH activity but induced a decrease in MAGL affinity for its substrate 2-AG. CB1 
receptor maximal binding site density decreased in both experimental groups. It is 
likely that the stress associated to the behavioral procedure per se, regardless of 
its level, had induced this change in hippocampal CB1 receptors. Although not 
fully in accordance with our results, it has previously been shown that chronic 
corticosterone administration in drinking water decreases CB1 receptor binding 
site density in the hippocampus, reduced AEA content, increased FAAH activity 
and significantly increased 2-AG concentrations within the hippocampus (Bowles 
et al, 2012). However, we employed a completely different experimental 
procedure associated to lower level of stress that might have induced only some 
of these previously reported alterations.  
As previously highlighted, stress effects on memory follow an inverted U-shaped 
pattern, we therefore can speculate that the higher stressful conditions during 
trainings at 19 °C might have increased hippocampal 2-AG to optimal levels to 
ensure a stronger consolidation, thus promoting a better retrieval of spatial 
memory. In contrast to the consolidation phase, it is unlikely that glucocorticoids 
might have influenced a 1-min memory retrieval performance in vehicle treated 
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rats. However, it is more plausible that the arousal-induced noradrenergic activity, 
in concert with optimal levels of 2-AG, might have induced an enhancement in 
memory retrieval. Indeed, the hippocampus receives a dense input of 
noradrenergic terminals (Schroeter et al, 2000), and during emotionally arousing 
conditions norepinephrine is rapidly released in the brain (Gold and van Buskirk, 
1978; McIntyre et al, 2002) typically returning to baseline levels within 10 min, 
but the glucocorticoid response is much slower (De Boer et al, 1990). 
Corroborating our findings, a recent clinical study showed that retrieval 
performance under stress is positively correlated with autonomic arousal, 
expressed as change in blood pressure, but unaffected by cortisol. Conversely, 
retrieval performance 25 min post stress was negatively correlated with the 
cortisol response to the stressor (Schonfeld et al, 2013). 
Detrimental effects of glucocorticoids on memory retrieval of emotionally 
arousing experiences depend crucially on an interaction with arousal-induced 
noradrenergic activity (de Quervain et al, 2007; Roozendaal et al, 2003; 
Roozendaal et al, 2004b; Schutsky et al, 2011) and are mediated by hippocampal 
2-AG (Atsak et al, 2012). We have recently shown that systemic injection of 
WIN55,212-2 increases corticosterone plasma levels when injected in rats trained 
in an object recognition task and never habituated to experimental arena (high 
aroused), while the same compound decreases plasma corticosterone levels in 
rats which were in a less aroused state because of an extensive prior habituation 
to the training context (Campolongo et al, 2013). In the present study, on the one 
hand, intra-hippocampal WIN55,212-2 administration may have induced the same 
increasing effects on plasma corticosterone levels and, further, by directly 
stimulating CB1 receptors, and interacting with the arousal-induced noradrenergic 
activity, may have impaired spatial memory retrieval only in high aroused rats. On 
the other hand, intra-hippocampal JZL184 administration, by further increasing 2-
AG levels may have mimicked corticosterone increasing effects on hippocampal 2-
AG (Atsak et al, 2012) which interacts with concurrent arousal-dependent 
increases in noradrenergic activity (Atsak et al, 2012), thus inducing detrimental 
effects on spatial memory retrieval observed only in rats trained and tested under 
the lower, high arousing, water temperature.  
Collectively, the present findings indicate that the hippocampal endocannabinoid 
system plays a key role in mediating emotional arousal effects on spatial memory 
retrieval, shedding light on the neurobiological mechanism involved in the 
differential impact of stress on memory processes. Thus, the findings of the 
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present study may be relevant to develop new therapeutic strategies for 
psychiatric pathologies characterized by cognitive disturbances, such as post-
traumatic stress disorder.  
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Abstract 
Extensive evidence indicates that endocannabinoids modulate cognitive processes 
in animal models and human subjects. However, the results of endocannabinoid 
system manipulations on cognition have been contradictory. As for anxiety 
behavior, a duality has indeed emerged with regard to cannabinoid effects on 
memory for emotional experiences. Here we summarize findings describing 
cannabinoid effects on memory acquisition, consolidation, retrieval and 
extinction. Additionally, we review findings showing how the endocannabinoid 
system modulates memory function differentially, depending on the level of 
stress and arousal associated with the experimental context. Based on the 
evidence reviewed here, we propose that the endocannabinoid system is an 
emotional buffer that moderates the effects of environmental context and stress 
on cognitive processes. 
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Introduction 
Emerging evidence indicates that cannabinoid drugs can induce distinct and often 
opposite effects on anxiety, cognition, and several other behaviors, depending on 
stress level and the aversiveness of the context (Campolongo et al, 2012; Haller et 
al, 2009; Szuster et al, 1988; Zanettini et al, 2011). Although cannabinoid signaling 
has been demonstrated to influence memory processing (Campolongo et al, 
2009b; Marsicano et al, 2002), it is difficult to define its exact role because, 
regardless of the pharmacodynamic properties of the drug, both impairing and 
enhancing effects have been reported with cannabinoid drug administration. 
Although such discrepancies are not unusual in memory research, the factors 
contributing to these conflicting findings remain poorly understood.  
In this review, we begin with a summary of the differing memory modulatory 
effects of endocannabinoids reported in the literature. We then discuss in detail 
the biphasic/opposite effects induced by cannabinoid drugs, including evidence 
that such effects may be strongly dependent on the aversiveness of 
environmental context and on the level of stress at the time of drug 
administration and/or training. Finally, with the ultimate aim of developing an 
explanation of the apparent discrepancies among studies of cannabinoid effects 
on memory function, we propose hypotheses to explain the observed 
dual/opposing effects of cannabinoids on emotional memory functions. 
The endocannabinoid system  
The discovery of the main psychoactive constituent of marijuana, Δ9-
tetrahydrocannabinol (Δ9-THC), led to the identification of the endogenous 
endocannabinoid system (Gaoni and Mechoulam, 1964). The endocannabinoid 
system is a lipid signaling system in the brain that begins to exhibit functional 
activity early in brain development by way of modulating neurotransmitter 
release, pre- and postnatally (Campolongo et al, 2009c; Campolongo et al, 2011; 
Fernandez-Ruiz et al, 2000; Fride, 2004; Harkany et al, 2007; Trezza et al, 2008; 
Trezza et al, 2012). Although many molecular targets of the endocannabinoid 
system have been described, the primary targets of cannabinoid compounds are 
the type 1 and type 2 cannabinoid receptors (CB1 and CB2, respectively) (Devane 
et al, 1988; Herkenham et al, 1990; Matsuda et al, 1990).  
The two major endogenous ligands for the CB1 and CB2 receptors are N-
arachidonoyl ethanolamine (anandamide, AEA) (Devane et al, 1992) and 2-
arachidonoyl glycerol (2-AG) (Sugiura et al, 1995). AEA acts as a partial agonist of 
CB1 and CB2 receptors (Pertwee, 2010), whereas 2-AG is full agonist of these 
receptors (Stella et al, 1997). Unlike classical neurotransmitters, 
endocannabinoids are not stored in presynaptic vesicles, but rather are 
synthesized postsynaptically from lipid membrane precursor molecules in an 
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activity-dependent manner (Kano et al, 2009). Once released from the 
postsynaptic membrane into the synaptic cleft, they travel backward to bind 
cannabinoid receptors expressed on presynaptic terminals. Activation of CB1 
receptors inhibits neurotransmitter release by modulating several ion channels 
and kinases (Kano et al, 2009; Turu and Hunyady, 2010). Following receptor 
activation, AEA and 2-AG are deactivated by a still poorly defined uptake process 
involving a transporter mechanism (Fu et al, 2011; Hillard et al, 1997). 
Subsequently, they are metabolized mainly by their respective degradative 
enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) 
(Kano et al, 2009).  
CB1 receptors represent the most abundant class of G-protein-coupled 
receptors in the central nervous system, and are also present in a variety of 
peripheral tissues. They couple with both Gi and Go proteins, which inhibit 
adenylyl cyclase activity, activate potassium channels, and inhibit voltage-gated 
calcium channels (Howlett et al, 2002). CB1 receptors are expressed abundantly in 
major structures of the limbic system, including the hippocampus and basolateral 
complex of the amygdala (BLA), as well as in the prefrontal cortex (PFC), which is 
closely linked with limbic structures (McPartland et al, 2007); low levels of CB1 
mRNA have also been detected in the central nucleus of the amygdala (CeA) 
(Kamprath et al, 2010; Marsicano and Lutz, 1999; Matsuda et al, 1993). Within 
these limbic regions, the CB1 receptor is expressed at very high levels in 
cholecystokinin-positive GABAergic interneurons (Azad et al, 2008; Marsicano et 
al, 1999; Morozov et al, 2009) and at moderate levels in glutamatergic terminals 
(Kano et al, 2009; Kawamura et al, 2006; Monory et al, 2006). The CB1 receptor 
has also been detected on serotonergic, noradrenergic, and dopaminergic 
terminals (Haring et al, 2007; Hermann et al, 2002; Oropeza et al, 2007).  
The CB2 receptor is a Gi/o protein-coupled receptor (Howlett et al, 2002). CB2 
receptors are located mostly in the periphery on immunological tissues. They 
were confirmed only recently by immunohistochemical analyses to be expressed 
by neurons and glia in diverse rat brain areas, including the cerebellum and 
hippocampus (Onaivi et al, 2006; Van Sickle et al, 2005).  
Studies examining the functions of endocannabinoid signaling in the limbic 
system have shown that CB1 receptors play a key role in modulating synaptic 
transmission (Katona et al, 2001; Tan et al, 2011) and neuronal firing (Pistis et al, 
2004). Furthermore, growing evidence indicates that endocannabinoids play a key 
role in modulating emotional memory processes (Atsak et al, 2012b; Campolongo 
et al, 2009b; Ganon-Elazar and Akirav, 2009; Marsicano and Lafenetre, 2009; 
Marsicano et al, 2002; Tan et al, 2011; Wotjak, 2005). In the succeeding sections, 
we provide a review of findings from studies that examined cannabinoid effects 
on emotional memory function, focusing especially on the functional relationship 
between endocannabinoids and glucocorticoids in modulating cognitive 
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processes. Subsequently, we discuss how stress and arousal state may modulate 
endocannabinoid effects on memory. 
Modulation of memory for emotional experiences 
Emotional learning is extremely important for the survival of an individual; indeed 
life events of positive and negative valence typically leave lasting and vivid 
memories due to arousal and stress hormone effects on memory consolidation 
(McGaugh, 2000). Emotionality describes a highly complex repertoire of behaviors 
triggered by various environmental stimuli. The regulation of emotional responses 
under different environmental conditions is essential for mental health and 
requires fine-tuned neurotransmitter release processes as well as functional 
neuronal circuits (Gold, 2004; McEwen, 2012; McGaugh, 2000). During 
emotionally arousing situations, stress hormones are released from the adrenal 
medulla (epinephrine) and cortex (corticosterone [CORT] in rats, cortisol in 
humans) into the bloodstream. These systemic stress hormones stimulate the 
vagus nerve in the periphery, thereby activating the nucleus of tractus solitarius 
(NTS) in the brainstem, which releases memory modulatory norepinephrine into 
limbic brain structures (McGaugh and Roozendaal, 2002).  
Additionally, glucocorticoid hormones, which are highly lipophilic, readily enter 
the brain where they bind mineralocorticoid receptors (MRs) with high affinity 
and glucocorticoid receptors (GRs) with low affinity. Thus, under basal conditions, 
only MRs are occupied, but during and immediately after a stressful experience, 
both MRs and GRs are bound by glucocorticoids (Reul and de Kloet, 1985). 
Extensive evidence indicates that stress hormones, in concert with several other 
stress-activated systems, mediate the selective enhancement of consolidation of 
memory for emotionally significant experiences (de Kloet et al, 1999; Joels and 
Baram, 2009; Oitzl and de Kloet, 1992; Roozendaal, 2000; Sandi and Rose, 1994). 
Conversely, glucocorticoids typically impair memory retrieval and working 
memory during emotionally arousing test situations (de Quervain et al, 2009; de 
Quervain et al, 1998; Roozendaal, 2000; Roozendaal et al, 2004). 
The neural circuitry underlying emotionality is considerably complex, but 
broadly consists of subcortical limbic structures, such as the amygdala, 
hippocampus, ventral striatum, and thalamus, as well as cortical structures, 
including the anterior cingulate cortex and medial and orbital regions of the PFC 
(Price and Drevets, 2010). This corticolimbic circuit interacts with visceral 
autonomic centers in the hypothalamus and brain stem to regulate emotional 
expression and to modulate the activity of the hypothalamic-pituitary-adrenal 
(HPA) axis (Price et al, 2010). In this assembly, the amygdala represents a key 
region for the association of environmental information with emotional 
significance. Although the acquisition of emotional salience by external stimuli has 
been studied most extensively in relation to fear and anxiety responses, the 
145 
 
amygdala has also been shown to be important for the processing of positive 
emotions, such as in stimulus-reward learning (Aggleton, 1993; Baxter and 
Murray, 2002; Davis et al, 1994; Pape and Pare, 2010).  
In particular, considerable evidence indicates not only that stressors increase 
neuronal activity in the BLA (Pelletier et al, 2005), but also that emotional 
memory modulation requires activation of the BLA specifically. For example, 
lesions of the BLA, but not the CeA, block the memory enhancing effects of 
systemic GR activation on inhibitory avoidance retention (Roozendaal and 
McGaugh, 1996). Furthermore, posttraining infusion of norepinephrine or a β-
adrenoceptor agonist into the BLA enhances memory of training on several 
learning tasks (Ferry and McGaugh, 1999; Hatfield et al, 1999; LaLumiere et al, 
2003; Roozendaal et al, 2008). In contrast, attenuation of noradrenergic signaling 
by infusion of a β-adrenoceptor antagonist (propranolol or atenolol) into the BLA, 
but not into the neighboring CeA, has been shown to block the memory 
enhancement induced by systemic or intra-BLA administration of a GR agonist 
(Quirarte et al, 1997; Roozendaal et al, 2002). Considerable evidence developed in 
rodent studies indicates that glucocorticoid-induced enhancement of memory 
consolidation depends upon an interaction with noradrenergic activation within 
the BLA (Roozendaal et al, 2009). Importantly, a recent clinical study corroborated 
this model by showing that the amygdala is also an important locus of 
glucocorticoid-norepinephrine interactions in the enhancement of memory for 
emotionally salient information in humans (van Stegeren et al, 2010). Indeed, a 
convergence of five decades of research now points to the amygdala, especially 
the BLA, as a critical structure in the acquisition and retention of lasting memories 
of emotional experiences (McGaugh, 2000; Roozendaal et al, 2009). 
Cannabinoid modulation of memory for emotional experiences 
Recent evidence suggests that endocannabinoid signaling may be a key system in 
the regulation of synaptic efficacy within and between amygdaloid subnuclei 
(Ramikie and Patel, 2012). Notably, glucocorticoids regulate the endocannabinoid 
response, which in turn, modulates glucocorticoid secretion through both local 
and distal regulation of HPA axis activity (Hill and McEwen, 2010b; Hill et al, 
2010c; Steiner and Wotjak, 2008b). Indeed, endocannabinoid activity is necessary 
for some central effects of glucocorticoids (Barna et al, 2004; Weidenfeld et al, 
1994).  
It has been demonstrated that an increase in glucocorticoid levels leads to a 
concomitant increase in endocannabinoid levels in the hypothalamus (Di et al, 
2003). Endocannabinoids then act retrogradely to inhibit glutamate release in the 
paraventricular nucleus and suppress HPA axis activity (Di et al, 2003; Di et al, 
2005). Conversely, endocannabinoid content in limbic brain regions, which can 
augment or terminate stress responses, can itself be modulated by stress or 
146 
 
exogenous glucocorticoid administration (Hill et al, 2010b). Additionally, Morrish 
and colleagues found that the endocannabinoid system mediates stress responses 
and emotional homeostasis by targeting noradrenergic circuits (Morrish et al, 
2009).  
The supposition that the endocannabinoid system may mediate a 
noradregeneric-modulatory role is supported by anatomic and physiological 
evidence. Autoradiography and immunohistochemistry experiments have 
demonstrated moderate CB1 receptor expression in the principal noradrenergic 
nuclei, namely the locus coeruleus (LC) and the NTS, and reverse transcription 
polymerase chain reaction experiments have confirmed local CB1 transcription in 
these regions (Derbenev et al, 2004; Herkenham et al, 1991; Jelsing et al, 2008; 
Mailleux and Vanderhaeghen, 1992; Matsuda et al, 1993). Systemic 
administration of the synthetic cannabinoid receptor agonist WIN55212-2 (WIN) 
increases noradrenergic release in the PFC (Oropeza et al, 2005), and intravenous 
injection of WIN or Δ9-THC, increases the firing rate of LC noradrenergic neurons 
in a manner that is dose dependent and can be blocked by the cannabinoid 
receptor antagonist rimonabant (Muntoni et al, 2006). These findings suggest a 
role for the cannabinoid system in at least basic brain activities regulated by 
norepinephrine, such as arousal and wakefulness (Berridge et al, 2012). 
More recent evidence suggests that the cannabinoid system may also play a 
key role in higher level noradrenergic functions, such as regulation of emotional 
states and memory processes (Akirav, 2011; Campolongo et al, 2009b; Kano et al, 
2009; Marsicano et al, 2009; Wotjak, 2005). However, the literature regarding 
cannabinoid effects on cognition remains contradictory. Human cannabis users 
have been reported to show impairments in aspects of executive functioning such 
as planning, working memory, and mental flexibility (Verdejo-Garcia et al, 2006). 
Cannabis abusers also show short-term memory deficits (Ranganathan and 
D'Souza, 2006; Riedel and Davies, 2005). However, Fisk and Montgomery (2008) 
found no evidence of cannabis-related deficits in executive component processes 
or associative learning. Moreover, the acute effects of cannabis need to be 
distinguished from the effects of chronic use. Acutely, cannabis has well-known 
psychoactive effects, can impair coordination, and may produce feelings of 
anxiety or paranoia. Meanwhile, chronic use of cannabis has been reported to 
induce mood disturbances, exacerbate psychiatric disorders in vulnerable people, 
impair cognition, and to increase the risk of cardiovascular and respiratory 
diseases (for a detailed review see (Karila et al, 2013)). Although new evidence 
continues to become available, it would be premature to draw any strong 
conclusions from clinical studies of cannabis users/abusers now due to the widely 
differing methodologies and participant selection strategies used, especially in 
terms of poly-drug abuse and pre-existing cognitive and emotional criteria 
(Ranganathan et al, 2006). Therefore, animal studies remain critical to elucidating 
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the neural underpinnings of cannabinoid effects on cognition, particularly with 
respect to cannabinoid effects on memory for emotional experiences. 
Cannabinoid effects on different memory phases 
As will become clear, even basic research studies in this field are producing some 
controversial and difficult to resolve outcomes. In the following paragraphs, we 
summarize some basic research findings of cannabinoid effects on different 
phases of memory processes with the intent of disentangling which effects 
involve influences on particular stages of memory processing. Cannabinoid effects 
on memory acquisition, consolidation, retrieval, and extinction are summarized in 
Tables 1–4, respectively.  
Cannabinoid effects on memory acquisition 
There is general agreement about the observation that activation of the 
endocannabinoid system impairs memory acquisition (Table 1). Notably, systemic 
administration of a cannabinoid receptor agonist (i.e. Δ9-THC or WIN) before 
training impairs acquisition of water maze, contextual fear, and object recognition 
tasks in rodents (Da and Takahashi, 2002; Lichtman et al, 1995; Pamplona and 
Takahashi, 2006b). Similarly, indirect cannabinoid receptor agonism impairs 
memory acquisition in a recognition memory task (Campolongo et al., 2012) and 
in the inhibitory avoidance task (Campolongo et al, 2012; Mazzola et al, 2009). 
However, as highlighted in Table 1, systemic administration of the cannabinoid 
receptor antagonist rimonabant has also been reported to impair acquisition in a 
spatial memory task (Robinson et al, 2008).  
Local infusions of cannabinoid compounds within the same brain region have 
provided more consistent results, though comparing the results across brain areas 
remains difficult to explain. For example, pretraining activation of CB1 receptors 
in the hippocampus has consistently been shown to impair spatial learning (Abush 
and Akirav, 2010; Egashira et al, 2002; Lichtman et al, 1995; Wegener et al, 2008), 
although pretraining blockade of CB1 receptor transmission in the BLA also 
impaired olfactory fear conditioning (Tan et al, 2011). Drawing conclusions from 
studies involving pretraining drug administration is extremely challenging given 
that such treatments necessarily affect diverse processes (McGaugh, 1966). 
Moreover, since cannabinoid compounds affect motivational and sensorimotor 
processes (Economidou et al, 2007; Solinas and Goldberg, 2005; Steiner et al, 
1999; Zimmer et al, 1999), it is difficult to discriminate between purely cognitive 
effects and confounding variables (e.g. alteration in pain sensitivity and/or 
locomotor activity and/or motivation) following pretraining cannabinoid 
administration. Therefore, it remains to be resolved whether cannabinoids affect 
cognition per se during learning rather than other non-specific factors. 
148 
 
Cannabinoid effects on memory consolidation 
Conflicting data have been reported regarding cannabinoid effects on memory 
consolidation (Table 2). Drugs can be administered after a learning event to 
isolate the consolidation phase of memory and exclude influences on acquisition 
or any sensory, motor, or motivational processes that may influence learning 
indirectly (McGaugh, 1966). Systemic posttraining administration of cannabinoid 
receptor agonists impairs memory consolidation (Mackowiak et al, 2009; Yim et 
al, 2008), while systemic posttraining injection of cannabinoid receptor 
antagonists improves it (Wise et al, 2008; Wolff and Leander, 2003). However, 
there are concerns related to non-specificity in experiments using systemic 
agonist manipulations. Drugs that inhibit endocannabinoid degradation can be 
employed to avoid such potentially confounding effects. For example, when 
Busquets-Garcia and colleagues tested the effects of systemic posttraining 
administration of the FAAH inhibitor URB597, which increases AEA levels only in 
those brain regions where it is released endogenously, they observed impaired 
memory consolidation in an object recognition task (Busquets-Garcia et al, 2011).  
Conflicting data have been reported concerning the effects on memory 
consolidation of infusing cannabinoid drugs locally into discrete brain regions. 
Posttraining intra-hippocampal administration of the synthetic cannabinoid 
receptor agonist WIN (0.25-10 µg/rat) has been reported to impair memory 
consolidation of several behavioral tasks (i.e. step-through inhibitory avoidance, 
Morris water maze) (Jamali-Raeufy et al, 2011; Yim et al, 2008; Zarrindast et al, 
2011). However, other authors reported enhancing effects of AEA in the 
hippocampus (0.17 ng/side) (De Oliveira Alvares et al, 2008) and of WIN in the 
BLA (50 ng/side) (Campolongo et al, 2009b). Moreover, cannabinoid receptor 
antagonists have been found to yield memory impairing effects similar to those 
induced by cannabinoid receptor antagonism described above (Jamali-Raeufy et 
al, 2011; Yim et al, 2008; Zarrindast et al, 2011). In particular, it has been shown 
that intra-hippocampal (de Oliveira Alvares et al, 2005) administration of the CB1 
receptor antagonist AM251 impairs memory consolidation in an aversive 
hippocampus-dependent task (de Oliveira Alvares et al, 2005). Differences in 
handling procedures, experimental conditions, behavioral task, doses, and the 
drug administered may account for the diversity of findings reported (Table 2). 
Indeed WIN is less selective than the endogenous ligand AEA (Howlett et al, 2002) 
and, when administered at high doses in discrete brain regions, could induce 
broader effects, complicating interpretation. However, there are other intriguing 
possibilities that should be explored. In particular, given the robust effects of 
glucocorticoids, norepinephrine, and other neurotransmitters including 
acetylcholine and dopamine in limbic structures on memory consolidation 
(McGaugh, 2000), it could be that factors related to arousal, stress, and emotional 
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state at the time of training may influence cannabinoid effects on memory. This 
issue is discussed further in section 5. 
Table 1. Cannabinoid effects on memory acquisistion in rodents. 
Drug 
Dose Administration Animals Paradigm Effect Reference 
CB1/CB2 receptor agonists 
WIN 2.5-5 
mg/kg 
i.p. Wistar rats CFC Impairing 
(Pamplona et al, 
2006b) 
1.2 
mg/kg 
i.p. 
Sprague-
Dawley rats 
Object 
recognition 
Impairing (Schneider et al, 2008) 
5 µg/side Intra-CA1 
Sprague-
Dawley rats 
MWM Impairing (Abush et al, 2010) 
Δ
9
-THC 10 
mg/kg 
i.p. 
FAAH -/-, 
+/+  mice 
MWM Impairing (Wise et al, 2012) 
20 
µg/side 
Intra- DH-VH-
DMT 
Wistar rats 
Eight-arm 
radial maze 
Impairing (Egashira et al, 2002) 
CB1 antagonists (and inverse agonists) 
AM251 
50–500 
ng/side 
Intra-BLA 
Sprague-
Dawley rats 
Olfactory 
fear 
conditioning 
Impairing (Tan et al, 2011) 
Rimonabant 
3 mg/kg i.p 
Sprague-
Dawley rats 
Radial arm 
maze 
Enhancing (Lichtman, 2000) 
3 mg/kg i.p. 
Lister 
Hooded 
rats 
MWM Impairing (Robinson et al, 2008) 
AM281 2.5 
mg/kg 
i.p. 
C57BL/6J 
mice 
CFC Enhancing (Lin et al, 2011) 
0.05 
µg/rat 
Intra-CA1 
C57BL/6J 
mice 
CFC Enhancing (Lin et al, 2011) 
Indirect agonists 
AM404 (AEA 
uptake 
inhibitor) 
0.5–1 
mg/kg 
i.p. Wistar rats 
Spatial open 
field 
Impairing 
(Campolongo et al, 
2012) 
1 µg/rat Intra-CA1 
C57BL/6J 
mice 
CFC Impairing (Lin et al, 2011) 
URB597 (FAAH 
inhibitor) 
0.1–1.0 
mg/kg 
i.p. 
Sprague-
Dawley rats 
IA Impairing (Mazzola et al, 2009) 
JZL195 (FAAH 
and MAGL 
inhibitor) 
20 
mg/kg 
i.p. 
FAAH -/- 
mice 
MWM Impairing (Wise et al, 2012) 
20 
mg/kg 
i.p. 
FAAH +/+ 
mice 
MWM Impairing (Wise et al, 2012) 
JZL184 (MAGL 
inhibitor) 
20–40 
mg/kg 
i.p. 
FAAH -/- 
mice 
MWM Impairing (Wise et al, 2012) 
40 
mg/kg 
i.p. 
FAAH +/+ 
mice 
MWM Impairing (Wise et al, 2012) 
AEA, anandamide; i.p., intraperitoneal; FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol 
lipase; CFC, contextual fear conditioning; MWM, Morris water maze; IA, step-through inhibitory 
avoidance; BLA, basolateral complex of the amygdala; CeA, central amygdala; DH, dorsal 
hippocampus; VH, ventral hippocampus; DMT, dorsomedial thalamus nucleus.  
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Table 2. Cannabinoid effects on memory consolidation in rodents. 
Drug Dose Administration Animals Paradigm Effect Reference 
CB1/CB2 receptor agonists 
AEA 
0.17 ng/side Intra-CA1 Wistar rats IA Enhancing 
(De Oliveira Alvares 
et al, 2008) 
HU-210 
0.1 mg/kg i.p. Wistar rats CFC Impairing 
(Mackowiak et al, 
2009) 
WIN 
1-3 mg/kg i.p. 
Long-Evans 
rats 
MWM Impairing (Yim et al, 2008) 
 
0.3 mg/kg i.p. 
Sprague-
Dawley rats 
HA-object 
recognition 
Enhancing 
(Campolongo et al, 
2013) 
 
50 ng/side Intra-BLA 
Sprague-
Dawley rats 
IA Enhancing 
(Campolongo et al, 
2009b) 
 0.1–0.25 
µg/rat 
Intra-CeA Wistar rats 
IA 
Impairing 
(Zarrindast et al, 
2012) 
 0.25–0.5 
µg/rat 
Intra-CA1 Wistar rats 
IA 
Impairing 
(Moshfegh et al, 
2011) 
 0.1–0.5 
µg/rat 
Intra-CA1 
Wistar rats 
IA 
Impairing (Nasehi et al, 2009) 
 0.25-0.5 
µg/rat 
Intra-CA1 
Wistar rats 
IA 
Impairing 
(Jamali-Raeufy et al, 
2011) 
 10 
nmol/side 
Intra-CA1 Wistar rats 
Object 
recognition 
Impairing (Clarke et al, 2008) 
CB1 antagonists (and inverse agonists) 
AM251 0.28  
ng/side 
Intra-BLA 
Sprague-
Dawley rats 
IA Impairing 
(Campolongo et al, 
2009b) 
 0.28  
ng/side 
Intra-BLA Wistar rats CFC Impairing 
(Bucherelli et al, 
2006) 
 
5.5 ng/side Intra-CA1 Wistar rats IA Impairing 
(de Oliveira Alvares 
et al, 2005) 
Rimonaban
t 1 mg/kg i.p. 
Sprague-
Dawley rats 
Eight-arm 
radial maze 
Enhancing (Wolff et al, 2003) 
 
1 mg/kg i.p. 
Swiss albino 
mice 
Elevated T- 
maze 
Enhancing 
(Takahashi et al, 
2005) 
CE 
0.1 mg/kg i.p. 
Sprague-
Dawley rats 
Radial-arm 
maze 
Enhancing (Wise et al, 2008) 
Indirect agonist 
URB597 (FAAH 
inhibitor) 
0.3–1 
mg/kg 
i.p. 
Swiss albino 
mice 
Object 
recognition 
Impairing 
(Busquets-Garcia et 
al, 2011) 
1 mg/kg i.p. 
Swiss albino 
mice 
Context 
recognition 
Impairing 
(Busquets-Garcia et 
al, 2011) 
AEA, anandamide; i.p., intraperitoneal; FAAH, fatty acid amide hydrolase; CFC, contextual fear 
conditioning; MWM, Morris water maze; IA, step-through inhibitory avoidance; HA, high arousal; 
BLA, basolateral complex of the amygdala; CeA, central amygdala.  
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Cannabinoid effects on memory retrieval 
Although the literature related to cannabinoid effects on retrieval is fairly limited, 
no controversy exists with regards to cannabinoid effects on memory retrieval 
(Table 3). Detrimental effects of cannabinoid receptor agonism on memory  
Table 3. Cannabinoid effects on memory retrieval in rodents. 
Drug Dose Administration Animals Paradigm Effect Reference 
CB1/CB2 receptor agonists 
WIN 
0.3 mg/kg i.p. 
Sprague-
Dawley rats 
HA-object 
recognition 
Impairing 
(Campolongo et al, 
2013) 
 
0.3 mg/kg i.p. 
Sprague-
Dawley rats 
LA-object 
recognition 
Enhancing 
(Campolongo et al, 
2013) 
 10–30 
ng/side 
Intra-CA1 
Sprague-
Dawley rats 
CFC Impairing (Atsak et al, 2012a) 
 0.25–0.5 
µg/rat 
Intra-CA1 Wistar rats IA Impairing (Piri et al, 2011) 
 
5 µg/side Intra-VSub 
Sprague-
Dawley rats 
CFC Impairing (Segev et al, 2011) 
Δ
9
-THC 
5.6 mg/kg i.p 
Sprague-
Dawley rats 
Radial arm 
maze 
Impairing (Wise et al, 2009) 
 
6 mg/kg i.p. Wistar rats 
Eight-arm 
radial maze 
Impairing (Mishima et al, 2001) 
 
10 mg/kg i.p. 
C57BL/6J 
mice 
MWM Impairing 
(Niyuhire et al, 
2007a) 
 
10 mg/kg i.p. Wistar rats IA Impairing (Mishima et al, 2001) 
I.p., intraperitoneal; CFC, contextual fear conditioning; MWM, Morris water maze; IA, step-through 
inhibitory avoidance; VSub, ventral subiculum; HA, highly arousal; LA, low arousal. 
retrieval have been documented when administered either systemically (Mishima 
et al, 2001; Niyuhire et al, 2007a) or in discrete brain areas (Atsak et al, 2012a; Piri 
and Zarrindast, 2011; Segev and Akirav, 2011). In particular, it has been 
demonstrated that systemic administration of Δ9-THC impairs memory retrieval in 
a Morris water maze task (Niyuhire et al, 2007a) and a step-through inhibitory 
avoidance task (Mishima et al, 2001). In line with these findings, cannabinoid 
agonists infused directly into the hippocampus impair aversive memory retrieval 
(Atsak et al, 2012a; Piri et al, 2011; Segev et al, 2011). Interestingly, intra-BLA 
infusions of the same drugs did not affect memory retrieval (Segev et al, 2011). 
Taken together, the preclinical evidence reported above, although still sparse, 
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suggests that cannabinoids induce impairing effects on memory retrieval, at least 
under the experimental conditions investigated thus far (Table 3). 
Cannabinoid effects on memory extinction 
There is a strong consensus in the memory extinction literature that the 
endocannabinoid system is a key modulator in the facilitation of memory 
extinction (Table 4). Inhibition of endocannabinoid transmission robustly inhibits 
extinction of fear conditioning (Marsicano et al, 2002; Pamplona et al, 2006a; 
Suzuki et al, 2004). Conversely, stimulation of endocannabinoid signaling  
Table 4. Cannabinoid effects on memory extinction in rodents. 
Drug Dose Administration Animals Paradigm Effect Reference 
CB1/CB2 receptor agonists 
WIN 0.25 
mg/kg 
i.p. Wistar rats CFC Enhancing 
(Pamplona et 
al, 2006a) 
 
5 µg/side Intra-CA1 
Sprague-
Dawley rats 
IA Enhancing 
(Abush et al, 
2010) 
CB1 antagonists (and inverse agonists) 
Rimonabant 1.5–5 
mg/kg 
i.p 
Sprague-
Dawley rats 
FPS Impairing 
(Chhatwal et al, 
2005) 
 
3 mg/kg i.p. 
C57BL/6J 
mice 
Auditory fear 
conditioning 
Impairing 
(Marsicano et 
al, 2002) 
3–10 
mg/kg 
i.p. 
C57BL/6J 
mice 
CFC Impairing 
(Suzuki et al, 
2004) 
 
3 mg/kg i.p. 
C57BL/6J 
mice 
MWM Impairing 
(Varvel et al, 
2005) 
3 mg/kg i.p. 
C57BL/6J 
mice 
IA Impairing 
(Niyuhire et al, 
2007b) 
Indirect agonists 
AM404 (AEA 
uptake 
inhibitor) 
10 mg/kg i.p 
Sprague-
Dawley rats 
FPS Enhancing 
(Chhatwal et al, 
2005) 
1 µg/rat i.c.v. Wistar rats CFC Enhancing 
(Bitencourt et 
al, 2008) 
OL-135 
(FAAH 
inhibitor) 
30 mg/kg i.p. 
C57BL/6J 
mice 
MWM Enhancing 
(Varvel et al, 
2007) 
I.p., intraperitoneal; i.c.v., intracerebroventricular; FAAH, fatty acid amide hydrolase; CFC, contextual 
fear conditioning; MWM, Morris water maze; IA, step-through inhibitory avoidance; FPS, fear-
potentiaed startle. 
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accelerates fear extinction (Barad et al, 2006; Chhatwal et al, 2005; Pamplona et 
al, 2006a; Suzuki et al, 2004). Similarly, in a Morris water maze task, Varvel et al. 
(2005; 2007) found that the inverse CB1 receptor agonist rimonabant or genetic 
CB1 receptor disruption impaired extinction, whereas Δ9-THC did not affect 
extinction (Varvel et al, 2005; Varvel et al, 2007). Interestingly, Niyuhire and co-
workers (2007b) reported that rimonabant administration disrupted extinction 
significantly in two different aversively motivated behavioral tasks (e.g., 
conditioned freezing and inhibitory avoidance) but failed to affect extinction in an 
appetitively motivated operant conditioning task (Niyuhire et al, 2007b). Thus, the 
evidence obtained to date suggests that activation of the cannabinoid system 
facilitates aversive memory extinction.  
Role of emotional arousal in influencing cannabinoid effects on memory  
Discrepant findings have been reported concerning the role of the 
endocannabinoid system in the modulation of cognitive processes, especially with 
regard to memory acquisition and consolidation. Such reports are very 
reminiscent of the dual effects on emotionality reported by cannabis users. That 
is, although cannabis consumption is commonly associated with euphoria and 
contentment (Velez and Ungemack, 1989), some people report experiencing 
anxiety, dysphoria, and a depressive mood with cannabis consumption (Reilly et 
al, 1998). Clinical studies have indicated that the context of cannabinoid 
consumption—that is, the nature of both one’s physical state and social setting—
has a direct influence on emotionality (Del Porto and Masur, 1984; Zinberg, 1984), 
even though clinical studies are less controlled in terms of dosage, poli-drug 
abuse, and context. Biphasic effects of cannabinoid consumption on anxiety-
related behavior have also been reported in preclinical studies (for a detailed 
review see (Micale et al, 2013). The indirect cannabinoid receptor agonists 
URB597 and AM404, which increase AEA levels in the synaptic cleft, have been 
reported to exert both anxiolytic- and antidepressant-like effects in rodents 
(Bortolato et al, 2006; Gobbi et al, 2005; Kathuria et al, 2003). Haller and co-
workers (2009) showed that URB597 does not reduce anxiety when a behavioral 
task (i.e. elevated plus maze) is performed under mildly aversive conditions (e.g., 
in a familiar room or under low light) (Haller et al, 2009). Sciolino et al. (2011) 
found that an increase in 2-AG levels, induced by administration of the MAGL 
inhibitor JZL184, induced an anxiolytic-like effect in the same behavioral task 
under highly aversive conditions (i.e. bright light), but had no detectable effect on 
anxiety under low-stress conditions (Sciolino et al, 2011). Likewise, Campos et al. 
(2010) reported that the cannabinoid uptake inhibitor AM404 was anxiolytic in 
the elevated plus maze test in rats previously exposed to a 2-h restraint stress, but 
anxiogenic in rats that were not previously stressed (Campos et al, 2010). Thus, it 
may be that stress conditions during the test, as well as housing and handling 
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procedures prior to the test, influence cannabinoid effects on emotionality. A 
similar scenario is now emerging with regards to cannabinoid effects on memory. 
(Herkenham et al, 1991; Tsou et al, 1998). In the following sections, we describe 
evidence demonstrating how cannabinoid effects on memory may depend on the 
level of stress associated with an experimental context (i.e. footshock intensity in 
the inhibitory avoidance task), previous stress experiences completely unrelated 
to the task, and/or a combination of these two factors.  
Context-induced stress shapes cannabinoid modulation of memory 
The cannabinoid system may have a particularly important role in the control of 
neuronal responses to environmental challenges. This notion is consistent with 
the observation that CB1 receptors are expressed abundantly in limbic structures. 
It is possible to speculate that the endocannabinoid system may shape how 
environmental stimuli affect emotional responses, rather than producing an 
overall aspecific effect on memory. This putative context-dependence may help to 
explain apparently conflicting data obtained with different training and drug 
administration paradigms. 
To investigate the importance of emotionality in cannabinoid effects on 
memory function, we compared the effects of cannabinoid receptor activation on 
novel object recognition in high arousal (HA) versus low-arousal (LA) conditions. 
Briefly, in the HA condition, the rats were not handled and the task was 
performed under bright light in an empty arena. In the LA condition, the rats were 
habituated to the experimenter through daily handling (1 min per day for 1 week) 
and the task was performed under dim red light in an arena in which the ground 
was covered with familiar bedding. Animals were administered the 
endocannabinoid transport inhibitor AM404 30 min before commencing the novel 
object recognition task. The behavioral paradigm consisted of six consecutive 5-
min sessions, separated by 3-min intervals, wherein one familiar object was 
replaced with a new object in the last session, which served as the test trial. We 
found that exogenous enhancement of endocannabinoid signaling impaired novel 
object recognition in rats tested in the HA condition, but had no effect in rats 
tested in the LA condition (Campolongo et al, 2012). This study demonstrated for 
the first time that acute effects of cannabinoid agonism on memory function are 
influenced by the stress state of the subject. Because this experiment employed a 
pretraining drug administration, we cannot exclude the possibility that the 
memory performance effect observed could have been due, even in part, to 
confounding variables associated with a pretraining manipulation.  
In a subsequent study, we employed a previously validated, modified version 
of the object recognition task that enabled us to administer the drug immediately 
after training to isolate the effect of the drug on memory consolidation. We 
followed a previously described procedure to induce two different levels of 
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arousal during the object recognition task (Okuda et al, 2004). One group of rats 
received extensive prior habituation to the training apparatus (in the absence of 
any objects), while a second group was not exposed to the experimental 
apparatus until training. Animals were injected with the cannabinoid receptor 
agonist WIN immediately after a single 3-min training trial and then tested for 
memory retention 1 h or 24 h later. As shown in Figure 1A and B, WIN, 
administered immediately after object recognition training, impaired short-term 
(1-h) retention performance in rats not habituated to the experimental context. 
The same dose of WIN enhanced short-term memory in rats that had been 
habituated to the experimental context (Campolongo et al, 2013). Meanwhile, 
WIN enhanced long-term (24-h) retention in non-habituated rats, but had no 
effect on long-term memory in habituated rats (Fig. 1C and D). This experience-
dependent cannabinoid effect on memory is highly comparable to the 
glucocorticoid effects described by Okuda et al. (2004) and Roozendaal et al. 
(2006). That is, glucocorticoid compounds administered after object recognition 
training enhanced memory consolidation in non-habituated rats (a relatively 
higher stress condition) but not in habituated rats (a relatively lower stress 
condition (Okuda et al, 2004; Roozendaal et al, 2006b). Moreover, posttraining 
exposure to an out-of-context stressor (i.e. elevated platform) after object 
recognition training has been reported to enhance long-term memory only in rats 
not previously habituated to the experimental apparatus (Maroun and Akirav, 
2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effects of the CB receptor agonist WIN on short- and long-term retention of 
object recognition training are influenced by the level of training-associated emotional 
arousal. Rats were either habituated for 7 d (WITH) or not habituated (WITHOUT) to the 
training context. On day 8, they were given a 3-min training trial during which they could 
freely explore two identical objects, training was followed by a systemic administration of 
WIN (0.1, 0.3 or 1 mg/kg, i.p.). Retention was tested 1 h or 24 h later. Data represent 
discrimination index (%) at the retention trial, expressed as mean ± SEM. The 
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
A
0.1Veh 0.3 1.0
WITHOUT WITH
*
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
0.3
1.00.1
B
Veh
WIN (mg/kg) WIN (mg/kg)
  
*
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
0.3 1.00.1
B
Veh
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
A
0.1
0.3
1.0
*
Veh
WITHOUT WITH
WIN (mg/kg) WIN (mg/kg)
  
*
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
0.3 1.00.1
B
Veh
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
A
0.1
0.3
1.0
*
Veh
WITHOU WITH
WIN (mg/kg) WIN (mg/kg)
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
A
0.1Veh 0.3 1.0
WITHOUT WITH
*
D
is
c
ri
m
in
a
ti
o
n
 i
n
d
e
x
 (
%
)
-30
-15
0
15
30
45
60
75
0.3
1.00.1
B
Veh
WIN (mg/kg) WIN (mg/kg)
1 hr 
WITHOUT 
1 hr 
WITH 
24 hr 
WITHOUT 
24 hr 
WITHOUT 
 B C D 
156 
 
discrimination index was calculated as the difference in the time spent exploring the novel 
and the familiar object, expressed as a ratio of the total time spent exploring both objects. 
Posttraining WIN impaired 1-h object recognition performance of non-habituated rats (A) 
but enhanced performance of habituated rats (B). In contrast, posttraining administration 
of WIN, at a dose that impaired 1-h retention, enhanced 24-h object recognition 
performance of non-habituated rats (C) but not of habituated rats (D). *P < 0.05 vs. 
vehicle. Adapted from (Campolongo et al, 2013). 
Given the close relationship between the cannabinoid system and HPA axis activity 
(Armario, 2010; Atsak et al, 2012a; Barna et al, 2004; Hill et al, 2010a; Hill et al, 
2010b), we proceeded to explore the possibility that the conditionally divergent 
effects of systemic WIN on object recognition memory could be related to differential 
effects of WIN on training-induced glucocorticoid levels. We found that WIN elevated 
plasma CORT levels in non-habituated rats, but decreased CORT levels in habituated 
rats. Most importantly, as shown in Figure 2, we demonstrated that adrenocortical 
suppression with the CORT-synthesis inhibitor metyrapone altered the effects of 
posttraining WIN administration on non-habituated rats’ short- and long-term 
recognition memory in such a way that their cognitive performance became similar to 
that seen in habituated animals (Campolongo et al, 2013). Thus, our findings suggest 
that differential effects of cannabinoid receptor agonism on memory may be related 
to the ability of cannabinoids to interact with the HPA axis, depending on the stress 
state of the animal in relation to the aversiveness of the environmental conditions. A 
WIN-induced increase in CORT levels likely affected short-term memory performance 
(1-h test) in the HA condition by influencing retrieval (Atsak et al, 2012a). In the long-
term memory experiment (24-h test), however, increased CORT levels could only 
have influenced consolidation. Since habituation attenuates training-induced surges 
in noradrenergic activity, glucocorticoids might not modulate recognition memory in 
habituated rats due to their relatively low levels of norepinephrine (Roozendaal et al, 
2006b). Together, these aforementioned findings provide strong support for the view 
that cannabinoid-mediated regulation of glucocorticoid secretion may play an 
important role in determining the pattern of cannabinoid effects on memory. 
Although the administration of direct cannabinoid receptor agonists mimics cannabis 
consumption, the use of indirect agonists or antagonists can provide more focal 
specificity and may be particularly useful for elucidating the physiological role of the 
endogenous “on-demand” endocannabinoid system. Indeed, de Oliveira Alvares and 
co-workers (2010) reported that the hippocampal endocannabinoid system is 
recruited to enhance memory consolidation of contextual fear conditioning only 
under HA conditions. Specifically, they found that blockade of cannabinoid receptors 
induced by immediate posttraining infusion of the cannabinoid receptor antagonist 
AM251 into the dorsal hippocampus impaired 24-h memory retention of conditioning 
with a 0.7-mA footshock, but did not affect memory when a less aversive 0.3 mA 
footshock was used (de Oliveira Alvares et al, 2010). Hence, the hippocampal  
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Figure 2. Effects of the CB receptor agonist WIN on short- and long-term retention of 
object recognition in rats trained under HA conditions and pretreated with the CORT 
synthesis inhibitor metyrapone (Mety). Metyrapone (35 mg/kg, i.p.) administered to non-
habituated rats 40 min before training reverted the impairing effect of posttraining WIN 
(0.3 mg/kg, i.p.) on 1-h retention performance (A) and the enhancing effect of WIN (0.3 
mg/kg, i.p.) on 24-h retention performance (B) in such a way that their performances 
became similar to that seen in habituated animals (compare panel C to panel A). Data are 
expressed as means ± SEM. *P < 0.05; **P < 0.01 vs. the corresponding vehicle group; 
##
P 
< 0.01 vs. WIN alone group. Adapted from (Campolongo et al, 2013). 
endocannabinoid system may modulate memory consolidation only when there is 
some threshold level of aversiveness involved. Intriguingly however, Jacob and co-
workers (2012) reported that CB1 knockout mice required a higher intensity 
footshock than wild-type mice to exhibit enhanced fear conditioning memory and 
generalized contextual fear (Jacob et al, 2012). However, with mice lacking CB1 
receptors, it is not possible to discriminate which memory phase has been 
affected. Furthermore when a receptor is genetically deleted, other 
compensatory mechanisms may occur (Fraser and Wahlestedt, 1997; Giros et al, 
1996).  
Interestingly, clinical research has shown that the nature of the social setting in 
which a drug is taken has a direct influence on the probability of particular drug 
effects occurring (Porto and Masur, 1984; Zinberg, 1984). Researchers have also 
found that past experiences dictate the content and structure of future drug-
taking experiences (Smith, 1978) and that cannabinoid drugs modulate memory 
for emotionally arousing experiences preferentially, without modulating memory 
for mundane experiences (Ballard et al, 2012). 
Together, the preclinical and clinical findings reviewed above indicate that 
some degree of training-associated arousal or stress is required for 
glucocorticoids to affect memory consolidation and that endocannabinoids may 
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act as a buffer system in this regard. This interaction between stress hormones 
and the cannabinoid system provides support for the notion that differential 
sensitivity to cannabinoids may be related to the level of activation of stress 
pathways (Carvalho and Van Bockstaele, 2012; Oropeza et al, 2005; Page et al, 
2007; Patel and Hillard, 2003). Taken together, these findings provide evidence in 
support of the view that the endocannabinoid system may play a key role in 
mediating the effects of arousal and stress on memory. 
Out-of-context stress shapes cannabinoid modulation of memory 
Intra-cerebroventricular administration of a CB1 receptor antagonist has been 
demonstrated to activate the HPA axis (Manzanares et al, 1999), thus indicating a 
central site of action despite the presence of CB1 receptors in the pituitary and 
adrenal glands (Cota et al, 2007; Ziegler et al, 2010). Conversely, both stress and 
glucocorticoids alter endocannabinoid levels in healthy volunteers subjected to 
stressful conditions (Feuerecker et al, 2012), in patients with stress-related 
disorders (Hauer et al, 2013; Hauer et al, 2012; Neumeister et al, 2013), and in 
limbic regions of CORT-injected rats (Hill et al, 2010b). This glucocorticoid-
cannabinoid interaction may serve to maintain homeostatic balance. Collectively, 
these and other data (Hill and Tasker, 2012)—together with the broad expression 
of cannabinoid receptors in cortico-limbic and hypothalamic circuitry where they 
seem to dampen HPA axis activation (Gonzalez et al, 2004; Hill et al, 2009b; 
Manzanares et al, 1999; Newsom et al, 2012; Patel et al, 2004; Steiner et al, 
2008a)—suggest that the endocannabinoid system could play a critical role in 
mediating response to stress as well as the effects of stress on memory processes.  
Few studies have investigated the effects of out-of-context and non-
pharmacologically induced stress and its interaction with the endocannabinoid 
system in modulating cognitive functions. Ganon-Elazar and Akirav (2009) have 
shown that infusion of the cannabinoid receptor agonist WIN into the BLA inhibits 
the increase in plasma CORT in rats exposed to an elevated platform stress for 30 
min. Pretraining intra-BLA infusion of WIN did not induce any effect by itself, but 
prevented the enhancing effects of elevated platform stress on inhibitory 
avoidance memory and prevented the impairment of extinction induced by pre-
extinction stress exposure (Ganon-Elazar et al, 2009). Likewise, in a food-reward-
reduction straight-alley maze task, intra-BLA WIN (5 µg/side) infusions had no 
effect on memory consolidation alone, but blocked the memory enhancing effects 
of stress exposure (i.e. elevated platform for 30 min)(Ramot and Akirav, 2012). 
These findings appear, at least superficially, to be at odds with our observation 
that intra-BLA infusions of WIN (50 ng/side) immediately after inhibitory 
avoidance training enhanced memory consolidation (Campolongo et al, 2009b). 
These differential outcomes could be due to the different doses used or 
differences in the nature of the behavioral tasks employed. The inhibitory 
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avoidance task is an aversive, fear-motivated task, whereas the alley-maze task 
has a strong reward component and the reduction of a reward has been 
associated with a state of frustration (Spence, 1956). Interestingly, de Oliveira 
Alvares et al. (2010) showed that intra-hippocampal infusions of the cannabinoid 
receptor antagonist AM251 reverted the stress-induced facilitatory effect on 
memory consolidation. In this experiment, rats were trained in a contextual fear 
conditioning paradigm (0.3-mA footshock intensity) and tested 24 h later. AM251 
had no effect per se on memory consolidation, but yielded a reversion to the 
memory enhancing effects of a preconditioning stressor (two 0.1-mA footshocks 
in a different context) (de Oliveira Alvares et al, 2010). Although it is possible that 
preconditioning stress might have influenced task acquisition, this finding 
provides further evidence that stress hormones interact with endocannabinoids in 
enhancing memory consolidation of aversive experiences. In light of the findings 
of these still limited and sometimes seemingly contradictory studies, it is 
becoming increasingly evident how the endocannabinoid system, by modulating 
stress responses (and vice versa), could affect memory functions differently 
depending on the aversiveness of the experimental conditions.  
The endocannabinoid system as an emotional buffer: a possible explanation for 
variable cannabinoid effects on memory 
It is difficult to pinpoint the exact role exerted by cannabinoid compounds on 
memory function given that they can induce biphasic behavioral effects that may 
arise from different factors and may alter sensorimotor and motivational 
processes (Economidou et al, 2007; Solinas et al, 2005; Steiner et al, 1999; 
Zimmer et al, 1999). However, growing evidence suggests that apparently 
conflicting findings with cannabinoid manipulations across studies may be due, 
perhaps in large part, to variations in the stressfulness of experimental conditions. 
This evidence has led us to hypothesize that the interaction of cannabinoids with 
stress hormones is of crucial importance in determining their modulatory effects 
on memory processes.  
Stress effects on both consolidation and retrieval of emotionally arousing 
experiences require concurrent glucocorticoid and noradrenergic activity 
(McGaugh et al, 2002; Roozendaal, 2002). Stress hormone effects on memory 
typically follow an inverted-U shaped (rather than linear) dose-response 
relationship, in which modulatory effects are seen most prominently with doses in 
the mid-range of the inverted-U curve (Mendl, 1999; Yerkes, 1908). Although this 
stress-memory relationship seems not to apply to all cases with respect to several 
factors (i.e. stress duration, intensity, and timing in relation to memory phase) 
(Sandi and Pinelo-Nava, 2007), it is plausible that, depending on stress hormone 
levels, the subsequent interplay between endocannabinoids and glucocorticoids 
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and/or norepinephrine could produce opposing effects of cannabinoids on 
memory performance.  
Cannabinoid administration can both activate and inhibit the HPA axis (Cota et 
al, 2007; Ganon-Elazar et al, 2009); and systemically administered CORT can 
produce rapid elevation of endocannabinoid levels in the amygdala (Hill et al, 
2010a). Noradrenergic signaling within the BLA plays an important role in the 
modulation of memory for emotionally arousing experiences, a process highly 
dependent on the integrity of the BLA (McGaugh, 2000; Quirarte et al, 1997; 
Roozendaal, 2002; Roozendaal et al, 2004; Roozendaal et al, 2006a). The BLA 
appears to orchestrate the use of various memory systems during periods of 
emotional arousal, rather than serving as a substrate of long-term memory 
storage (Packard and Wingard, 2004). There are multiple ways in which the BLA 
may modulate memory processes. First, aversive tasks can augment autonomic 
and humoral stress responses and activate the amygdala (Roozendaal, 2002; 
Roozendaal et al, 1992). These augmented stress responses may in turn interact 
differentially with cannabinoids and affect cognitive functions in other brain 
regions such as the hippocampus and PFC. Second, the BLA can modulate 
cognitive functions through direct or indirect neural connections to other limbic 
structures. The BLA has efferents projecting to the medial PFC, nucleus 
accumbens, and hippocampus (Krettek and Price, 1978; Pape et al, 2010). Most of 
the amygdalo-hippocampal projections reach the ventral hippocampus, which 
appears to have limited involvement in learning and memory (Moser et al, 1993). 
Thus, the BLA may influence dorsal hippocampal memory processes indirectly via 
projections through the nucleus accumbens and entorhinal cortex. Therefore, 
cannabinoids could influence memory processes by modulating BLA activity and, 
thus, BLA efferents to other brain regions. Within the BLA, CB1 receptors are 
expressed abundantly by GABAergic interneurons (Katona et al, 2001) and 
activation of CB1 receptors has consistently been shown to suppress GABA 
release (Katona et al, 2001; Katona et al, 1999; Ohno-Shosaku et al, 2001) via 
rapid inhibition of calcium entry into the terminals (Hoffman and Lupica, 2000; 
Wilson and Nicoll, 2001). Moreover, the amygdalar GABAergic system modulates 
memory storage (McGaugh, 2000) and inhibition of GABAergic activity within the 
BLA enhances memory consolidation by increasing the release of norepinephrine 
(Hatfield et al, 1999). We demonstrated recently that endocannabinoids in the 
BLA enhance memory consolidation for an emotionally salient event by 
interacting with glucocorticoids (Campolongo et al, 2009b). Indeed, we found that 
intra-BLA administration of the CB1 receptor antagonist AM251 blocked the 
ability of systemically administered CORT to facilitate memory consolidation of 
inhibitory avoidance training (Campolongo et al, 2009b). These findings showed, 
for the first time in vivo, that glucocorticoids recruit endocannabinoid signaling in 
the BLA while modulating aversive memory consolidation (Hill and McEwen, 
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2009a; Hill et al, 2010c). Moreover, de Oliveira Alvares and co-workers 
demonstrated that intra-hippocampal AM251 infusion impaired memory in rats 
that had received a synthetic glucocorticoid (dexamethasone) injection 
immediately after, but not 30 min before training. Their study demonstrated that, 
in the context of modulation of aversive memory consolidation, hippocampal 
endocannabinoid transmission is activated in a time-dependent manner and 
interacts with glucocorticoids (de Oliveira Alvares et al, 2010).  
An interaction between glucocorticoids and endocannabinoids in modulating 
memory retrieval has also been examined recently. Infusion of the cannabinoid 
receptor antagonist AM251 into the dorsal hippocampus blocked the retrieval 
impairing effects of systemic CORT, which were dependent upon elevation of 
hippocampal 2-AG levels (Atsak et al, 2012a). Moreover, the β-adrenoceptor 
antagonist propranolol blocked the impairing effect of WIN on memory retrieval 
and, conversely, infusion of the CB1 receptor antagonist AM251 into 
hippocampus together with an impairing dose of norepinephrine failed to abolish 
the impairing effect of norepinephrine on memory retrieval (Atsak et al, 2012a). 
Collectively, these findings indicate that endocannabinoids interact with 
glucocorticoids and may modulate memory functions differentially depending on 
the activation state of the noradrenergic system.  
In view of this evidence, we have proposed a model in which CORT binds to 
membrane bound receptors in the BLA that activate a G-protein signaling cascade 
to stimulate the synthesis of endocannabinoids. Once in the synaptic cleft, 
endocannabinoids may inhibit GABA release from presynaptic terminals, which in 
turn may lead to disinhibition of norepinephrine release and increased 
noradrenergic activation of postsynaptic β-adrenoceptors, enhancing the 
consolidation of emotionally aversive memories (Fig. 3) (Atsak et al, 2012b; 
Campolongo et al, 2009b; Hill and McEwen, 2009). There are several 
characteristics of the endocannabinoid system that should be considered and 
might be involved in the dual cannabinoid effects on memory. First, 
endocannabinoids are synthesized and released on-demand and, as a result, they 
are released only in those brain regions where and when there is active 
endocannabinoid signaling. Brain endocannabinoid responses, and the relative 
activation of the endocannabinoid system in discrete brain areas, may vary 
depending on the nature and intensity of environmental stimuli. Interestingly, 
pharmacological manipulations with indirect cannabinoid receptor agonists or 
antagonists increase and block, respectively, the endocannabinoid response only 
in those brain areas where signaling was concurrently active. Conversely, direct 
agonists bind all cannabinoid receptors in the brain and the periphery, regardless 
of their involvement in a particular process.  
Second, CB1 receptors are widely expressed in brain regions that play key 
roles in responding to stressful stimuli. It is possible that CB1 receptors produce  
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Figure 3. Model of endocannabinoid role in the modulation of memory consolidation 
within the BLA. Stress hormones (i.e. CORT and epinephrine) are released into the 
bloodstream during training. CORT binds metabotropic GRs within the BLA, activating the 
Gs–cAMP/PKA pathway to induce endocannabinoid (eCB) synthesis. Endocannabinoids are 
released into the synaptic cleft where they bind CB1 receptors on GABAergic terminals, 
thereby inhibiting GABA release. Suppression of GABAergic transmission results in the 
disinhibition of noradrenergic neurons and increases noradrenergic activation of 
postsynaptic β-adrenoreceptors, enhancing the consolidation of emotionally aversive 
memories. Adapted from (Hill and McEwen, 2009). 
opposite behavioral effects, depending on their anatomical location. Since CB1 
receptors are expressed presynaptically, they can suppress the release of 
neurotransmitters such as GABA and glutamate (Azad et al, 2008; Kano et al, 
2009; Marsicano et al, 1999; Monory et al, 2006), which often act in opposition to 
each other in the control of neurophysiological processes related to memory and 
emotional responses (Chevaleyre et al, 2006; Metna-Laurent et al, 2012; Millan, 
2003; Myhrer, 2003). Furthermore, the densities of the molecular 
endocannabinoid system components differ between synapse types in general 
(i.e. glutamatergic vs. GABAergic) and among the great variety of individual 
synapses expressing cannabinoid receptors (Katona and Freund, 2012). For 
instance, the highest density of CB1 receptors is found on cholecystokinin-positive 
GABAergic synapses in the hippocampus (Katona et al, 2000; Katona et al, 1999), 
and much lower levels of CB1 receptors are found on glutamatergic synapses 
(Katona et al, 2006; Kawamura et al, 2006). Hence, cannabinoid influences on 
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behavior may differ qualitatively depending on the synapses activated and 
neuronal circuits recruited in a particular situation. CB1 receptors might shape the 
environmental impact on memory functions by balancing inhibitory and excitatory 
neuronal activity. The functional interaction of the endocannabinoid system with 
these inhibitory or excitatory neurotransmitters may consequently be particularly 
relevant for the dual effects of cannabinoids in learning and memory processes. A 
small change in the environment might recruit new neurons in a different circuit, 
changing the location and the neurochemical nature of the cannabinoid-
modulated synapses that were activated. This unique characteristic makes the 
endocannabinoid system well suited to serve as a buffer system to balance 
emotional reactivity and ensure an appropriate stress response.  
Furthermore, the capacity of endocannabinoids to activate receptors other 
than CB1 should be considered. CB2 receptors were also proposed to be relevant 
for emotional responses (Onaivi et al, 2006). Moreover, endocannabinoids also 
activate the peroxisome proliferator-activated nuclear receptor (O'Sullivan, 2007), 
which modulates both aversive memory consolidation (Campolongo et al, 2009a) 
and acquisition (Mazzola et al, 2009), and the transient receptor potential 
vanilloid type 1 (Starowicz et al, 2007) which has been shown to mediate 
opposing effects on emotional responses with respect to CB1 (Maione et al, 
2006).  
Conclusions 
The findings reviewed here shed light on the divergent effects of cannabinoids on 
memory processes reported in the literature, indicating that environmental 
events characterized by different levels of stress can shape responses to the 
cognitive effects of cannabinoids. Given its modulatory role, we propose that the 
endocannabinoid system may moderate environmental impacts on emotional 
memory and attenuate excessive behavioral responses to stress. As a key 
modulator of environmental and stress influences on memory, the 
endocannabinoid system should be explored as a possible therapeutic target for 
neuropsychiatric illness involving memory dysfunction, such as post-traumatic 
stress disorder. 
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Conclusion 
This thesis explored the role of the endocannabinoid system in the modulation of 
cognitive function and its interaction with stress and emotional arousal in 
determining modulatory effects on memory processes. 
First, we investigated the neurobiological mechanisms underlying memory 
consolidation for emotionally arousing experiences and demonstrated that the 
endocannabinoid system within the basolateral complex of the amygdala plays an 
important role in regulating aversive memory formation.  
We, then, examined the interaction between the endocannabinoid system and 
stress hormones in the modulation of emotional memory processes, 
demonstrating that, depending on the availability of stress hormones, the 
subsequent interplay between endocannabinoids and glucocorticoids and/or 
norepinephrine results in opposing effects on memory processes. We pointed out 
that the endocannabinoid system shapes stress effects on memory to prepare the 
organism for similar challenges in the future. 
The concept of emotion regulation is considered critical to healthy emotional 
functioning and is disrupted in a variety of different types of psychopathology. 
Intensely emotional events or exposure to stressful experiences can create 
traumatic memories and even result in the development of mood and anxiety 
disorders, including post-traumatic stress disorder and major depressive illness. It 
is of considerable importance to better understand the brain mechanisms related 
to cognitive processes to shed light on the neural underpinnings of several 
cognitive disorders that are not yet well understood and current therapeutic tools 
are not always successful to treat such disorders. Therefore, to study the role of 
the endocannabinoid system in cognitive processes would help to provide new 
therapeutic approaches for the treatment of stress-induced psychopathological 
alterations associated with cognitive disturbances.  
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